[
  {
    "paper_id": "pubmed:30888929",
    "source": "pubmed",
    "source_id": "30888929",
    "title": "PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.",
    "year": 2019,
    "authors": [
      "Jiang Yongshuai",
      "Chen Ming",
      "Nie Hong",
      "Yuan Yuanyang"
    ],
    "abstract": "Programmed death-1 (PD-1) is a cell surface receptor that functions as a T cell checkpoint and plays a central role in regulating T cell exhaustion. Binding of PD-1 to its ligand, programmed death-ligand 1 (PD-L1), activates downstream signaling pathways and inhibits T cell activation. Moreover abnormally high PD-L1 expression on tumor cells and antigen-presenting cells in the tumor microenvironment mediates tumor immune escape, and the development of anti-PD-1/PD-L1 antibodies has recently become a hot topic in cancer immunotherapy. Here, we review the structure of PD-1 and PD-L1, the function of the PD-1/PD-L1 signaling pathway, the application of PD-1 or PD-L1 monoclonal antibodies and future directions for anti-PD-1/PD-L1 antibodies with combination therapies. Cancer immunotherapy using PD-1/PD-L1 immune checkpoint blockade may require more studies, and this approach may be curative for patients with many types of cancer in the future.",
    "journal": "Human vaccines & immunotherapeutics",
    "pub_date": "2019",
    "doi": "10.1080/21645515.2019.1571892",
    "pmid": "30888929",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Antibodies, Monoclonal",
      "Antineoplastic Agents, Immunological",
      "B7-H1 Antigen",
      "Clinical Trials as Topic",
      "Combined Modality Therapy",
      "Humans",
      "Immunotherapy",
      "Neoplasms",
      "Programmed Cell Death 1 Receptor",
      "Signal Transduction",
      "T-Lymphocytes",
      "Tumor Microenvironment"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/30888929/",
    "summary_ja": "PD-1はT細胞のチェックポイント受容体で、PD-L1との結合により下流シグナルが活性化されT細胞活性が抑制され、疲弊の制御に関与する。腫瘍細胞や腫瘍微小環境の抗原提示細胞でのPD-L1高発現は免疫逃避を促し、抗PD-1/PD-L1抗体の開発ががん免疫療法で注目されている。本稿はPD-1/PD-L1の構造とシグナル経路、抗体療法の応用、併用療法を含む今後の方向性を概説する。免疫チェックポイント阻害は多くのがん種で将来的に治癒的となり得るが、さらなる研究が必要だと述べている。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:39068460",
    "source": "pubmed",
    "source_id": "39068460",
    "title": "Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer.",
    "year": 2024,
    "authors": [
      "Cheng Weishi",
      "Kang Kai",
      "Zhao Ailin",
      "Wu Yijun"
    ],
    "abstract": "Cancer immunotherapies, represented by immune checkpoint inhibitors (ICIs), have reshaped the treatment paradigm for both advanced non-small cell lung cancer and small cell lung cancer. Programmed death receptor-1/programmed death receptor ligand-1 (PD-1/PD-L1) and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) are some of the most common and promising targets in ICIs. Compared to ICI monotherapy, which occasionally demonstrates treatment resistance and limited efficacy, the dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 operates at different stages of T cell activation with synergistically enhancing immune responses against cancer cells. This emerging dual therapy heralds a new direction for cancer immunotherapy, which, however, may increase the risk of drug-related adverse reactions while improving efficacy. Previous clinical trials have explored combination therapy strategy of anti-PD-1/PD-L1 and anti-CTLA-4 agents in lung cancer, yet its efficacy remains to be unclear with the inevitable incidence of immune-related adverse events. The recent advent of bispecific antibodies has made this sort of dual targeting more feasible, aiming to alleviate toxicity without compromising efficacy. Thus, this review highlights the role of dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in treating lung cancer, and further elucidates its pre-clinical mechanisms and current advancements in clinical trials. Besides, we also provide novel insights into the potential combinations of dual blockade therapies with other strategies to optimize the future treatment mode for lung cancer.",
    "journal": "Journal of hematology & oncology",
    "pub_date": "2024-Jul",
    "doi": "10.1186/s13045-024-01581-2",
    "pmid": "39068460",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Animals",
      "Humans",
      "B7-H1 Antigen",
      "Carcinoma, Non-Small-Cell Lung",
      "CTLA-4 Antigen",
      "Immune Checkpoint Inhibitors",
      "Immunotherapy",
      "Lung Neoplasms",
      "Programmed Cell Death 1 Receptor"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/39068460/",
    "summary_ja": "免疫チェックポイント阻害薬において、PD-1/PD-L1とCTLA-4を同時に標的とするデュアルブロッケードは、T細胞活性化の異なる段階に作用して相乗的に抗腫瘍免疫を高め、肺がん治療の新たな方向性として期待される。単剤療法では抵抗性や効果の限界がみられる一方、併用は有効性向上と引き換えに免疫関連有害事象など毒性リスクが増える可能性がある。これまで臨床試験で検討されてきたが、有効性はなお不明確で有害事象の発生は避けがたいとされる。近年は二重特異性抗体により二重標的化が現実的となり、効果を保ちつつ毒性軽減を目指すアプローチが紹介されている。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:34538007",
    "source": "pubmed",
    "source_id": "34538007",
    "title": "PD-1/PD-L1 blockade: Prospectives for immunotherapy in cancer and autoimmunity.",
    "year": 2021,
    "authors": [
      "Hosseinzadeh Ramin",
      "Feizisani Fahimeh",
      "Shomali Navid",
      "Abdelbasset Walid Kamal",
      "Hemmatzadeh Maryam",
      "Gholizadeh Navashenaq Jamshid",
      "Jadidi-Niaragh Farhad",
      "Bokov Dmitry O",
      "Janebifam Morteza",
      "Mohammadi Hamed"
    ],
    "abstract": "Immune checkpoint blockade therapy (ICBT) has become a successful cancer treatment approach in the field of cancer immunotherapy. Blockade of programmed death 1 (PD-1) and programmed death-ligand 1 (PD-L1) with monoclonal antibodies have been known as successful examples of cancer immunotherapy in recent years. Although ICBT has been shown to be beneficial in cancers, such benefits have only been seen in a portion of cancer patients. In this regard, enhancing the therapeutic effects of inhibiting PD-1 and PD-L1 and reducing the side effects of this approach can be considered as a potential approach in a successful ICBT. In this review, we have highlighted new viewpoints regarding improving the therapeutic effect of PD-1 and PD-L1 blockades in cancer therapy. Besides, their expression levels as a biomarker with prognostic value, their role in intestinal microbiota modulation, combination therapy, and immune-related side effects (irAEs) have been discussed.",
    "journal": "IUBMB life",
    "pub_date": "2021-Nov",
    "doi": "10.1002/iub.2558",
    "pmid": "34538007",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Antineoplastic Combined Chemotherapy Protocols",
      "Arthritis, Rheumatoid",
      "Autoimmunity",
      "B7-H1 Antigen",
      "Biomarkers, Tumor",
      "Diabetes Mellitus, Type 1",
      "Gastrointestinal Microbiome",
      "Humans",
      "Immune Checkpoint Inhibitors",
      "Immunotherapy",
      "Lupus Erythematosus, Systemic",
      "Neoplasms",
      "Polymorphism, Single Nucleotide",
      "Prognosis",
      "Programmed Cell Death 1 Receptor"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/34538007/",
    "summary_ja": "本総説は、がん免疫療法として成功している免疫チェックポイント阻害療法のうち、PD-1/PD-L1を標的とする抗体治療の現状と課題を概説している。臨床的有益性は示されている一方で、奏効は一部患者に限られるため、効果増強と副作用低減が重要な改善点として論じられている。治療効果向上に向けて、バイオマーカーとしてのPD-1/PD-L1発現、腸内細菌叢との関連、併用療法の可能性が取り上げられている。さらに、免疫関連有害事象（irAEs）についても整理し、今後の最適化の方向性を提示している。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:30635237",
    "source": "pubmed",
    "source_id": "30635237",
    "title": "Intratumoral Tcf1",
    "year": 2019,
    "authors": [
      "Siddiqui Imran",
      "Schaeuble Karin",
      "Chennupati Vijaykumar",
      "Fuertes Marraco Silvia A",
      "Calderon-Copete Sandra",
      "Pais Ferreira Daniela",
      "Carmona Santiago J",
      "Scarpellino Leonardo",
      "Gfeller David",
      "Pradervand Sylvain",
      "Luther Sanjiv A",
      "Speiser Daniel E",
      "Held Werner"
    ],
    "abstract": "Checkpoint blockade mediates a proliferative response of tumor-infiltrating CD8",
    "journal": "Immunity",
    "pub_date": "2019-Jan",
    "doi": "10.1016/j.immuni.2018.12.021",
    "pmid": "30635237",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Animals",
      "Antibodies, Monoclonal",
      "CD8-Positive T-Lymphocytes",
      "Cell Differentiation",
      "Cell Proliferation",
      "Hepatitis A Virus Cellular Receptor 2",
      "Hepatocyte Nuclear Factor 1-alpha",
      "Humans",
      "Immunotherapy",
      "Lymphocytes, Tumor-Infiltrating",
      "Melanoma",
      "Melanoma, Experimental",
      "Mice",
      "Mice, Inbred C57BL",
      "Programmed Cell Death 1 Receptor",
      "Stem Cells",
      "T-Lymphocyte Subsets"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/30635237/",
    "summary_ja": "提示されたアブストラクトは途中までで情報が不完全ですが、チェックポイント阻害療法が腫瘍浸潤CD8 T細胞の増殖反応を誘導することを示唆しています。タイトルからは、腫瘍内のTcf1（T細胞の分化・幹細胞様性に関与する転写因子）がこの反応や抗腫瘍免疫の維持に関係する可能性が考えられます。全体として、チェックポイント阻害下での腫瘍局所T細胞状態（特にTcf1関連）の機序解明を目的とした研究である可能性が高いです。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:32839551",
    "source": "pubmed",
    "source_id": "32839551",
    "title": "Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy.",
    "year": 2020,
    "authors": [
      "Gao Yang",
      "Nihira Naoe Taira",
      "Bu Xia",
      "Chu Chen",
      "Zhang Jinfang",
      "Kolodziejczyk Aleksandra",
      "Fan Yizeng",
      "Chan Ngai Ting",
      "Ma Leina",
      "Liu Jing",
      "Wang Dong",
      "Dai Xiaoming",
      "Liu Huadong",
      "Ono Masaya",
      "Nakanishi Akira",
      "Inuzuka Hiroyuki",
      "North Brian J",
      "Huang Yu-Han",
      "Sharma Samanta",
      "Geng Yan",
      "Xu Wei",
      "Liu X Shirley",
      "Li Lei",
      "Miki Yoshio",
      "Sicinski Piotr",
      "Freeman Gordon J",
      "Wei Wenyi"
    ],
    "abstract": "Immunotherapies that target programmed cell death protein 1 (PD-1) and its ligand PD-L1 as well as cytotoxic T-lymphocyte-associated protein 4 (CTLA4) have shown impressive clinical outcomes for multiple tumours. However, only a subset of patients achieves durable responses, suggesting that the mechanisms of the immune checkpoint pathways are not completely understood. Here, we report that PD-L1 translocates from the plasma membrane into the nucleus through interactions with components of the endocytosis and nucleocytoplasmic transport pathways, regulated by p300-mediated acetylation and HDAC2-dependent deacetylation of PD-L1. Moreover, PD-L1 deficiency leads to compromised expression of multiple immune-response-related genes. Genetically or pharmacologically modulating PD-L1 acetylation blocks its nuclear translocation, reprograms the expression of immune-response-related genes and, as a consequence, enhances the anti-tumour response to PD-1 blockade. Thus, our results reveal an acetylation-dependent regulation of PD-L1 nuclear localization that governs immune-response gene expression, and thereby advocate targeting PD-L1 translocation to enhance the efficacy of PD-1/PD-L1 blockade.",
    "journal": "Nature cell biology",
    "pub_date": "2020-Sep",
    "doi": "10.1038/s41556-020-0562-4",
    "pmid": "32839551",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Acetylation",
      "Animals",
      "B7-H1 Antigen",
      "Cell Line",
      "Cell Line, Tumor",
      "Cell Nucleus",
      "E1A-Associated p300 Protein",
      "Gene Expression",
      "HEK293 Cells",
      "Humans",
      "Immunotherapy",
      "MCF-7 Cells",
      "Mice",
      "Neoplasms",
      "Programmed Cell Death 1 Receptor",
      "Protein Processing, Post-Translational",
      "RAW 264.7 Cells"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/32839551/",
    "summary_ja": "PD-1/PD-L1やCTLA4を標的とする免疫療法は有効例がある一方で、持続的奏効は一部に限られ、その機序の未解明部分が課題である。本研究は、PD-L1がエンドサイトーシスおよび核-細胞質輸送経路の因子と相互作用して膜から核へ移行し、その過程がp300によるアセチル化とHDAC2による脱アセチル化で制御されることを示した。PD-L1欠損は免疫応答関連遺伝子の発現低下と関連し、PD-L1のアセチル化を遺伝学的・薬理学的に調節して核移行を阻害すると遺伝子発現が再プログラムされ、PD-1阻害の抗腫瘍効果が増強された。これらより、PD-L1の核移行制御を標的化することが免疫チェックポイント阻害療法の有効性向上につながる可能性が示唆される。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:38660299",
    "source": "pubmed",
    "source_id": "38660299",
    "title": "Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges.",
    "year": 2024,
    "authors": [
      "Javed Sadique A",
      "Najmi Asim",
      "Ahsan Waquar",
      "Zoghebi Khalid"
    ],
    "abstract": "The programmed death-1 receptor (PD-1) acts as a T-cell brake, and its interaction with ligand-1 (PD-L-1) interferes with signal transduction of the T-cell receptor. This leads to suppression of T-cell survival, proliferation, and activity in the tumor microenvironment resulting in compromised anticancer immunity. PD-1/PD-L-1 interaction blockade shown remarkable clinical success in various cancer immunotherapies. To date, most PD-1/PD-L-1 blockers approved for clinical use are monoclonal antibodies (mAbs); however, their therapeutic use are limited owing to poor clinical responses in a proportion of patients. mAbs also displayed low tumor penetration, steep production costs, and incidences of immune-related side effects. This strongly indicates the importance of developing novel inhibitors as cancer immunotherapeutic agents. Recently, advancements in the small molecule-based inhibitors (SMIs) that directly block the PD-1/PD-L-1 axis gained attention from the scientific community involved in cancer research. SMIs demonstrated certain advantages over mAbs, including longer half-lives, low cost, greater cell penetration, and possibility of oral administration. Currently, several SMIs are in development pipeline as potential therapeutics for cancer immunotherapy. To develop new SMIs, a wide range of structural scaffolds have been explored with excellent outcomes; biphenyl-based scaffolds are most studied. In this review, we analyzed the development of mAbs and SMIs targeting PD-1/PD-L-1 axis for cancer treatment. Altogether, the present review delves into the problems related to mAbs use and a detailed discussion on the development and current status of SMIs. This article may provide a comprehensive guide to medicinal chemists regarding the potential structural scaffolds required for PD-1/PD-L-1 interaction inhibition.",
    "journal": "Frontiers in immunology",
    "pub_date": "2024",
    "doi": "10.3389/fimmu.2024.1383456",
    "pmid": "38660299",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Humans",
      "Neoplasms",
      "Programmed Cell Death 1 Receptor",
      "Immune Checkpoint Inhibitors",
      "Immunotherapy",
      "B7-H1 Antigen",
      "Animals",
      "Tumor Microenvironment",
      "Antibodies, Monoclonal"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/38660299/",
    "summary_ja": "PD-1はT細胞応答を抑制する受容体で、PD-L1との結合により腫瘍微小環境でT細胞の生存・増殖・活性が低下し、抗腫瘍免疫が損なわれる。PD-1/PD-L1阻害は多くのがんで臨床的成功を示してきたが、主流であるモノクローナル抗体は一部患者で反応不良があり、腫瘍浸透性、製造コスト、免疫関連有害事象などの課題がある。著者らはこれらの制約を踏まえ、PD-1/PD-L1軸を直接阻害する低分子阻害薬（SMI）の開発動向と利点（経口投与可能性、細胞浸透性、コスト等）を概説し、特にビフェニル骨格などの構造スキャフォールドを中心に整理している。本総説は抗体薬と低分子薬の現状・課題を俯瞰し、新規SMI設計の指針を提供することを目的としている。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:30918149",
    "source": "pubmed",
    "source_id": "30918149",
    "title": "Development of Cancer Immunotherapy Targeting the PD-1 Pathway.",
    "year": 2019,
    "authors": [
      "Kamimura Naomi",
      "Wolf Alexander M",
      "Iwai Yoshiko"
    ],
    "abstract": "Immune checkpoint inhibitors are causing a paradigm shift in cancer treatment. Immune checkpoint molecules such as programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) dampen T cell activation to avoid autoimmunity and the destructive effects of an excessive inflammatory response. Immune checkpoint signaling can be exploited by tumors to escape host immune surveillance, and immune checkpoint inhibitors enhance antitumor immunity by releasing the brakes on the immune system. PD-1 was identified in 1992 by Honjo and colleagues at Kyoto University. Studies in animal models revealed that PD-1 blockade can inhibit tumorigenesis and tumor metastasis. In addition, PD-1 blockade showed fewer adverse effects than CTLA-4 blockade. Based on these findings, a humanized monoclonal antibody against human PD-1 called nivolumab was developed. Since PD-1 blockade targets lymphocytes rather than tumor cells, the therapeutic effects last longer, even if mutations occur during tumorigenesis. Furthermore, because it does not depend on specific tumor antigens, PD-1 blockade can be applied to various kinds of tumors.",
    "journal": "Journal of Nippon Medical School = Nippon Ika Daigaku zasshi",
    "pub_date": "2019",
    "doi": "10.1272/jnms.JNMS.2019_86-2",
    "pmid": "30918149",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Animals",
      "Antineoplastic Agents, Immunological",
      "CTLA-4 Antigen",
      "Carcinogenesis",
      "Humans",
      "Immunotherapy",
      "Molecular Targeted Therapy",
      "Neoplasms",
      "Nivolumab",
      "Programmed Cell Death 1 Receptor",
      "T-Lymphocytes"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/30918149/",
    "summary_ja": "免疫チェックポイント分子であるPD-1やCTLA-4は自己免疫や過剰炎症を避けるためにT細胞活性化を抑制するが、腫瘍はこの仕組みを利用して免疫監視から逃避する。免疫チェックポイント阻害薬はこの抑制（ブレーキ）を解除し、抗腫瘍免疫を増強することでがん治療を変革しつつある。PD-1は1992年に同定され、動物モデルでPD-1遮断が腫瘍形成・転移を抑え、CTLA-4遮断より有害事象が少ないことが示された。これらを基にヒト化抗PD-1抗体ニボルマブが開発され、リンパ球を標的とするため効果が持続しやすく、特定抗原に依存しないことから多様ながん種へ応用可能と述べている。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:38861924",
    "source": "pubmed",
    "source_id": "38861924",
    "title": "Interruption of the intratumor CD8",
    "year": 2024,
    "authors": [
      "Geels Shannon N",
      "Moshensky Alexander",
      "Sousa Rachel S",
      "Murat Claire",
      "Bustos Matias A",
      "Walker Benjamin L",
      "Singh Rima",
      "Harbour Stacey N",
      "Gutierrez Giselle",
      "Hwang Michael",
      "Mempel Thorsten R",
      "Weaver Casey T",
      "Nie Qing",
      "Hoon Dave S B",
      "Ganesan Anand K",
      "Othy Shivashankar",
      "Marangoni Francesco"
    ],
    "abstract": "PD-1 blockade unleashes potent antitumor activity in CD8",
    "journal": "Cancer cell",
    "pub_date": "2024-Jun",
    "doi": "10.1016/j.ccell.2024.05.013",
    "pmid": "38861924",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Animals",
      "CD8-Positive T-Lymphocytes",
      "T-Lymphocytes, Regulatory",
      "Humans",
      "Mice",
      "Programmed Cell Death 1 Receptor",
      "Melanoma",
      "Inducible T-Cell Co-Stimulator Protein",
      "Immunotherapy",
      "Immune Checkpoint Inhibitors",
      "Interleukin-2",
      "Mice, Inbred C57BL",
      "Signal Transduction",
      "Melanoma, Experimental",
      "Cell Line, Tumor"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/38861924/",
    "summary_ja": "提示されたアブストラクトは断片的ですが、PD-1阻害（ブロッケード）がCD8 T細胞における強力な抗腫瘍活性を解放することを示唆しています。タイトルからは、腫瘍内（intratumor）のCD8に関する何らかの「中断」や制御が主題である可能性があります。ただし研究デザイン（臨床・動物・細胞）、対象、評価項目が不明なため、効果の大きさや臨床的有用性を判断できません。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:30784085",
    "source": "pubmed",
    "source_id": "30784085",
    "title": "PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy.",
    "year": 2019,
    "authors": [
      "Salmaninejad Arash",
      "Valilou Saeed Farajzadeh",
      "Shabgah Arezoo Gowhari",
      "Aslani Saeed",
      "Alimardani Malihe",
      "Pasdar Alireza",
      "Sahebkar Amirhossein"
    ],
    "abstract": "Over the course of past few years, cancer immunotherapy has been accompanied with promising results. However, preliminary investigations with respect to immunotherapy concentrated mostly on targeting the immune checkpoints, nowadays, emerge as the most efficient strategy to raise beneficial antitumor immune responses. Programmed cell death protein 1 (PD-1) plays an important role in subsiding immune responses and promoting self-tolerance through suppressing the activity of T cells and promoting differentiation of regulatory T cells. PD-1 is considered as an immune checkpoint and protects against autoimmune responses through both induction of apoptosis in antigen-specific T cells and inhibiting apoptosis in regulatory T cells. Several clinical trials exerting PD-1 monoclonal antibodies as well as other immune-checkpoint blockades have had prosperous outcomes and opened new horizons in tumor immunotherapy. Nonetheless, a bulk of patients have failed to respond to these newly emerging immune-based approach and the survival rate was not satisfying. Additional strategies, especially combination therapies, has been initiated and been further promising. Attempts to identify novel and well-suited predictive biomarkers are also sensed. In this review, the promotion of cancer immunotherapy targeting PD-1 immunoinhibitory pathway is discussed.",
    "journal": "Journal of cellular physiology",
    "pub_date": "2019-Aug",
    "doi": "10.1002/jcp.28358",
    "pmid": "30784085",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "B7-H1 Antigen",
      "Gene Expression Regulation, Neoplastic",
      "Humans",
      "Immunotherapy",
      "Neoplasms",
      "Programmed Cell Death 1 Receptor"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/30784085/",
    "summary_ja": "本総説は、がん免疫療法における免疫チェックポイント、とくにPD-1/PD-L1経路の基礎生物学と治療標的としての意義を概説している。PD-1はT細胞活性の抑制や制御性T細胞の分化促進を通じて免疫応答を鎮静化し、自己寛容の維持に寄与する。PD-1阻害抗体などの免疫チェックポイント阻害は臨床試験で有望な成果を示した一方、無効例が多く生存改善が十分でない点が課題として述べられる。著者らは、併用療法の開発や予測バイオマーカー探索など追加戦略の必要性を強調している。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:33079077",
    "source": "pubmed",
    "source_id": "33079077",
    "title": "Anti-PD-1 And Anti-PD-L1 Antibodies as Immunotherapy Against Cancer: A Structural Perspective.",
    "year": 2020,
    "authors": [
      "Córdova-Bahena Luis",
      "Velasco-Velázquez Marco A"
    ],
    "abstract": "Programmed cell death protein 1 (PD-1) and its ligand, programmed death-ligand-1 (PD-L1), play key roles in the suppression of the cytotoxic activity of T cells. PD-L1 is overexpressed on various types of cancer cells, leading to immune evasion. In the past decade, therapeutic antibodies that target the PD-1/PD-L1 axis have been developed to inhibit the immune suppression triggered by these two proteins. At present, five antibodies (two anti-PD-1 and three anti-PD-L1) have received approval by regulatory agencies in the US and Europe. In this work, we aimed to review their clinical applications and adverse effects. Furthermore, using their reported crystal structures, we discuss the similarities and differences between the PD-1/PD-L1 interface and the epitopes that are recognized by the antibodies. Detailed analyses of the contact residues involved in the ligand-receptor and target-antibody interactions have shown partial overlap. Altogether, the data presented here demonstrate that: (1) in contrast to other therapeutic antibodies, anti-PD-1/PD-L1 has a wide range of clinical applications; (2) these targeted therapies are not exempt from adverse effects; and (3) the characterization of the structural domains that are recognized by the antibodies can guide the development of new PD-1- and PD-L1-blocking agents.",
    "journal": "Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion",
    "pub_date": "2020-Oct",
    "doi": "10.24875/RIC.20000341",
    "pmid": "33079077",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Antibodies",
      "B7-H1 Antigen",
      "Humans",
      "Immunotherapy",
      "Neoplasms",
      "Programmed Cell Death 1 Receptor"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/33079077/",
    "summary_ja": "PD-1/PD-L1経路はT細胞の細胞傷害活性を抑制し、がん細胞でPD-L1が過剰発現すると免疫逃避に寄与する。本論文は、PD-1/PD-L1を標的とする承認済み抗体（抗PD-1×2、抗PD-L1×3）の臨床応用と有害事象を概説する。さらに結晶構造情報に基づき、PD-1/PD-L1界面と各抗体エピトープの共通点・相違点や接触残基の部分的重複を解析し、構造的知見が新規阻害薬設計に有用であると論じている。総じて、適応範囲の広さと副作用リスクを踏まえつつ、構造ベースの開発指針を提示するレビューである。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:30635236",
    "source": "pubmed",
    "source_id": "30635236",
    "title": "Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1",
    "year": 2019,
    "authors": [
      "Kurtulus Sema",
      "Madi Asaf",
      "Escobar Giulia",
      "Klapholz Max",
      "Nyman Jackson",
      "Christian Elena",
      "Pawlak Mathias",
      "Dionne Danielle",
      "Xia Junrong",
      "Rozenblatt-Rosen Orit",
      "Kuchroo Vijay K",
      "Regev Aviv",
      "Anderson Ana C"
    ],
    "abstract": "An improved understanding of the anti-tumor CD8",
    "journal": "Immunity",
    "pub_date": "2019-Jan",
    "doi": "10.1016/j.immuni.2018.11.014",
    "pmid": "30635236",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Animals",
      "Antibodies, Monoclonal",
      "Antigens, Neoplasm",
      "CD8-Positive T-Lymphocytes",
      "Cell Proliferation",
      "Hepatitis A Virus Cellular Receptor 2",
      "Hepatocyte Nuclear Factor 1-alpha",
      "Humans",
      "Immunologic Memory",
      "Immunotherapy",
      "Lymphocytes, Tumor-Infiltrating",
      "Melanoma, Experimental",
      "Mice",
      "Mice, Inbred C57BL",
      "Neoplasms, Experimental",
      "Programmed Cell Death 1 Receptor",
      "T-Lymphocyte Subsets",
      "Transcriptome"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/30635236/",
    "summary_ja": "提示されたアブストラクトが「An improved understanding of the anti-tumor CD8」以降で途切れており、研究デザイン・対象（ヒト/動物）・介入・主要評価項目・結果が不明です。タイトルからは、チェックポイント阻害免疫療法によりPD-1の発現/状態が動的に変化することを扱う研究である可能性が示唆されます。正確な要約とエビデンスレベル推定のため、アブストラクト全文（可能なら方法・結果の記載を含む）を提示してください。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:39941004",
    "source": "pubmed",
    "source_id": "39941004",
    "title": "Glycoscience in Advancing PD-1/PD-L1-Axis-Targeted Tumor Immunotherapy.",
    "year": 2025,
    "authors": [
      "Sun Qiyue",
      "Hong Senlian"
    ],
    "abstract": "Immune checkpoint blockade therapy, represented by anti-PD-1/PD-L1 monoclonal antibodies, has significantly changed the immunotherapy landscape. However, the treatment is still limited by unsatisfactory response rates, immune-related adverse effects, and drug resistance. Current studies have established that glycosylation, a common post-translational modification, is crucial in promoting cancer progression and immune invasion. Targeting aberrant glycosylation in cancers presents precision medicine regimens for monitoring cancer progression and developing personalized medicine. Notably, the immune checkpoints PD-1 and PD-L1 are highly glycosylated, which affects PD-1/PD-L1 interaction and the binding of anti-PD-1/PD-L1 monoclonal antibodies. Recent achievements in glycoscience to enhance patient outcomes, referred to as glycotherapy, have underscored their high potency in advancing PD-1/PD-L1 blockade therapies, i.e., glycoengineered antibodies with improved binding toward PD-1/PD-L1, pharmaceutic inhibitors for core fucosylation and sialylation, and synergistic treatment with the antibody-sialidase conjugate. This review briefly introduces the PD-1/PD-L1 axis and glycosylation and highlights the fundamental and applied advances in glycoscience that improve PD-1/PD-L1 immunoblockade therapies.",
    "journal": "International journal of molecular sciences",
    "pub_date": "2025-Jan",
    "doi": "10.3390/ijms26031238",
    "pmid": "39941004",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Humans",
      "Neoplasms",
      "Programmed Cell Death 1 Receptor",
      "Immunotherapy",
      "Glycosylation",
      "B7-H1 Antigen",
      "Animals",
      "Immune Checkpoint Inhibitors",
      "Antibodies, Monoclonal"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/39941004/",
    "summary_ja": "本総説は、抗PD-1/PD-L1抗体による免疫チェックポイント阻害療法の有効性が一方で、奏効率の限界、有害事象、薬剤耐性といった課題に直面している点を概説する。がんにおける糖鎖修飾（糖タンパク質の糖鎖付加）は腫瘍進展や免疫回避に関与し、異常糖鎖を標的とすることが精密医療・個別化医療の観点から有望である。PD-1およびPD-L1自体が高度に糖鎖修飾されており、その修飾がPD-1/PD-L1相互作用や抗体の結合性に影響しうることを強調する。さらに、糖鎖工学的に改変した抗体、フコシル化・シアル化阻害薬、抗体-シアリダーゼ複合体など、糖鎖科学（glycotherapy）によるPD-1/PD-L1阻害療法の増強戦略を整理して紹介する。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:30417781",
    "source": "pubmed",
    "source_id": "30417781",
    "title": "Small Molecules as PD-1/PD-L1 Pathway Modulators for Cancer Immunotherapy.",
    "year": 2018,
    "authors": [
      "Jiao Peifu",
      "Geng Qiaohong",
      "Jin Peng",
      "Su Gaoxing",
      "Teng Houyun",
      "Dong Jinlong",
      "Yan Bing"
    ],
    "abstract": "Blockade of PD-1/PD-L1 interactions using PD-1/PD-L1 pathway modulators has shown unprecedented clinical efficacy in various cancer models. Current PD-1/PD-L1 modulators approved by FDA are exclusively dominated by therapeutic antibodies. Nevertheless, therapeutic antibodies also exhibit several disadvantages such as low tumor penetration, difficulty in crossing physiological barriers, lacking oral bioavailability, high manufacturing costs, inaccessible to intracellular targets, immunogenicity, immune-related adverse events (irAEs). Modulation of PD-1/PD-L1 pathway using small molecules may be an alternative approach to mobilize immune system to fight against cancers. In this review, we focus on summarizing the recently disclosed chemical structures and preliminary structure-activity relationships (SARs) of small molecules as PD-1/PD-L1 modulators for cancer immunotherapy.",
    "journal": "Current pharmaceutical design",
    "pub_date": "2018",
    "doi": "10.2174/1381612824666181112114958",
    "pmid": "30417781",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Humans",
      "Immunotherapy",
      "Neoplasms",
      "Programmed Cell Death 1 Receptor",
      "Small Molecule Libraries"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/30417781/",
    "summary_ja": "PD-1/PD-L1相互作用の阻害は多様ながんモデルで高い治療効果を示す一方、FDA承認薬は主に抗体製剤に限られている。抗体は腫瘍浸透性の低さ、経口投与困難、高コスト、細胞内標的への到達不能、免疫原性やirAEsなどの課題を抱える。そこで小分子によるPD-1/PD-L1経路の調節が代替戦略となり得る。本レビューは、最近報告された小分子モジュレーターの化学構造と予備的な構造活性相関（SAR）を概説する。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:39179486",
    "source": "pubmed",
    "source_id": "39179486",
    "title": "Targeting PD-1/PD-L1 in tumor immunotherapy: Mechanisms and interactions with host growth regulatory pathways.",
    "year": 2024,
    "authors": [
      "Shen Songyu",
      "Hong Yihan",
      "Huang Jiajun",
      "Qu Xiaosheng",
      "Sooranna Suren Rao",
      "Lu Sheng",
      "Li Tian",
      "Niu Bing"
    ],
    "abstract": "Tumor immunotherapy has garnered considerable attention, emerging as a new standard of care in cancer treatment. The conventional targets, such as VEGF and EGFR, have been extended to others including BRAF and PD-1/PD-L1, which have shown significant potential in recent cancer treatments. This review aims to succinctly overview the impact and mechanisms of therapies that modulate PD-1/PD-L1 expression by targeting VEGF, EGFR, LAG-3, CTLA-4 and BRAF. We investigated how modulation of PD-1/PD-L1 expression impacts growth factor signaling, shedding light on the interplay between immunomodulatory pathways and growth factor networks within the tumor microenvironment. By elucidating these interactions, we aim to provide insights into novel potential synergistic therapeutic strategies for cancer immunotherapy.",
    "journal": "Cytokine & growth factor reviews",
    "pub_date": "2024-Oct",
    "doi": "10.1016/j.cytogfr.2024.08.001",
    "pmid": "39179486",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Humans",
      "B7-H1 Antigen",
      "Neoplasms",
      "Programmed Cell Death 1 Receptor",
      "Immunotherapy",
      "Tumor Microenvironment",
      "Signal Transduction",
      "Animals",
      "Vascular Endothelial Growth Factor A",
      "Immune Checkpoint Inhibitors",
      "ErbB Receptors",
      "Proto-Oncogene Proteins B-raf",
      "CTLA-4 Antigen"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/39179486/",
    "summary_ja": "本総説は、がん免疫療法の主要標的であるPD-1/PD-L1経路について、VEGF、EGFR、LAG-3、CTLA-4、BRAFなどを標的とする治療がPD-1/PD-L1発現をどのように調節し得るか、その機序を概説する。さらに、PD-1/PD-L1の変調が増殖因子シグナル伝達に与える影響を整理し、腫瘍微小環境における免疫調節経路と増殖因子ネットワークの相互作用を論じる。これらの相互作用を明らかにすることで、免疫療法の相乗効果を狙った新規併用戦略の可能性を示唆している。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:31337439",
    "source": "pubmed",
    "source_id": "31337439",
    "title": "Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma.",
    "year": 2019,
    "authors": [
      "Zheng Yi",
      "Wang Tingting",
      "Tu Xiaoxuan",
      "Huang Yun",
      "Zhang Hangyu",
      "Tan Di",
      "Jiang Weiqin",
      "Cai Shunfeng",
      "Zhao Peng",
      "Song Ruixue",
      "Li Peilu",
      "Qin Nan",
      "Fang Weijia"
    ],
    "abstract": "BACKGROUND: Checkpoint-blockade immunotherapy targeting programmed cell death protein 1 (PD-1) has recently shown promising efficacy in hepatocellular carcinoma (HCC). However, the factors affecting and predicting the response to anti-PD-1 immunotherapy in HCC are still unclear. Herein, we report the dynamic variation characteristics and specificities of the gut microbiome during anti-PD-1 immunotherapy in HCC using metagenomic sequencing. RESULTS: Fecal samples from patients responding to immunotherapy showed higher taxa richness and more gene counts than those of non-responders. For dynamic analysis during anti-PD-1 immunotherapy, the dissimilarity of beta diversity became prominent across patients as early as Week 6. In non-responders, Proteobacteria increased from Week 3, and became predominant at Week 12. Twenty responder-enriched species, including Akkermansia muciniphila and Ruminococcaceae spp., were further identified. The related functional genes and metabolic pathway analysis, such as carbohydrate metabolism and methanogenesis, verified the potential bioactivities of responder-enriched species. CONCLUSIONS: Gut microbiome may have a critical impact on the responses of HCC patients treated with anti-PD-1 immunotherapy. The dynamic variation characteristics of the gut microbiome may provide early predictions of the outcomes of immunotherapy in HCC, which is critical for disease-monitoring and treatment decision-making.",
    "journal": "Journal for immunotherapy of cancer",
    "pub_date": "2019-Jul",
    "doi": "10.1186/s40425-019-0650-9",
    "pmid": "31337439",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Antibodies, Monoclonal, Humanized",
      "Bacteria",
      "Carcinoma, Hepatocellular",
      "Clinical Decision-Making",
      "Gastrointestinal Microbiome",
      "Humans",
      "Immunotherapy",
      "Liver Neoplasms",
      "Metabolic Networks and Pathways",
      "Metagenomics",
      "Phylogeny",
      "Programmed Cell Death 1 Receptor",
      "Sequence Analysis, DNA",
      "Treatment Outcome"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/31337439/",
    "summary_ja": "本研究は、肝細胞癌患者に対する抗PD-1免疫療法中の腸内細菌叢をメタゲノム解析し、治療反応性との関連を検討した。奏効例では非奏効例よりも細菌タクサの豊富さと遺伝子数が高く、治療開始後早期（6週）から患者間のβ多様性の差が顕在化した。非奏効例ではProteobacteriaが3週から増加し、12週で優勢となった。Akkermansia muciniphilaやRuminococcaceae属など奏効例に富む菌種と、それに関連する代謝経路が同定され、腸内細菌叢の動的変化が治療効果予測に資する可能性が示唆された。",
    "evidence_level": "2b"
  },
  {
    "paper_id": "pubmed:32622347",
    "source": "pubmed",
    "source_id": "32622347",
    "title": "Immune metabolism in PD-1 blockade-based cancer immunotherapy.",
    "year": 2021,
    "authors": [
      "Kumar Alok",
      "Chamoto Kenji"
    ],
    "abstract": "Energy metabolism plays an important role in proliferating cells. Recent reports indicate that metabolic regulation or metabolic products can control immune cell differentiation, fate and reactions. Cancer immunotherapy based on blockade of programmed cell death protein 1 (PD-1) has been used worldwide, but a significant fraction of patients remain unresponsive. Therefore, clarifying the mechanisms and overcoming the unresponsiveness are urgent issues. Because cancer immunity consists of interactions between the cancer and host immune cells, there has recently been a focus on the metabolic interactions and/or competition between the tumor and the immune system to address these issues. Cancer cells render their microenvironment immunosuppressive, driving T-cell dysfunction or exhaustion, which is advantageous for cancer cell survival. However, accumulating mechanistic evidence of T-cell and cancer cell metabolism has gradually revealed that controlling the metabolic pathways of either type of cell can overcome T-cell dysfunction and reprogram the metabolic balance in the tumor microenvironment. Here, we summarize the role of immune metabolism in T-cell-based immune surveillance and cancer immune escape. This new concept has boosted the development of combination therapy and predictive biomarkers in cancer immunotherapy with immune checkpoint inhibitors.",
    "journal": "International immunology",
    "pub_date": "2021-Jan",
    "doi": "10.1093/intimm/dxaa046",
    "pmid": "32622347",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Cell Differentiation",
      "Combined Modality Therapy",
      "Energy Metabolism",
      "Humans",
      "Immune Checkpoint Inhibitors",
      "Immunotherapy",
      "Neoplasms",
      "Programmed Cell Death 1 Receptor",
      "T-Lymphocytes",
      "Tumor Escape",
      "Tumor Microenvironment"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/32622347/",
    "summary_ja": "エネルギー代謝は免疫細胞の分化や機能に深く関与し、PD-1阻害によるがん免疫療法の反応性にも影響する可能性がある。PD-1阻害療法は広く用いられる一方で無反応例が多く、その機序解明と克服が課題である。腫瘍は微小環境を免疫抑制的にし、T細胞の機能不全・疲弊を誘導するが、T細胞およびがん細胞の代謝経路を制御することでこの状態を改善し得ることが示唆される。本稿は免疫監視と免疫逃避における免疫代謝の役割を概説し、チェックポイント阻害薬の併用療法や予測バイオマーカー開発につながる概念を提示している。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:28774337",
    "source": "pubmed",
    "source_id": "28774337",
    "title": "PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy.",
    "year": 2017,
    "authors": [
      "Long Junyu",
      "Lin Jianzhen",
      "Wang Anqiang",
      "Wu Liangcai",
      "Zheng Yongchang",
      "Yang Xiaobo",
      "Wan Xueshuai",
      "Xu Haifeng",
      "Chen Shuguang",
      "Zhao Haitao"
    ],
    "abstract": "Gastrointestinal (GI) malignancies are the most prevalent tumors worldwide, with increasing incidence and mortality. Although surgical resection, chemotherapy, radiotherapy, and molecular targeted therapy have led to significant advances in the treatment of GI cancer patients, overall survival is still low. Therefore, alternative strategies must be identified to improve patient outcomes. In the tumor microenvironment, tumor cells can escape the host immune response through the interaction of PD-1 and PD-L, which inhibits the function of T cells and tumor-infiltrating lymphocytes while increasing the function of immunosuppressive T regulatory cells. The use of an anti-PD-1/PD-L blockade enables reprogramming of the immune system to efficiently identify and kill tumor cells. In recent years, the efficacy of PD-1/PD-L blockade has been demonstrated in many tumors, and this treatment is expected to be a pan-immunotherapy for tumors. Here, we review the signaling pathway underlying the dysregulation of PD-1/PD-L in tumors, summarize the current clinical data for PD-1/PD-L inhibitors in GI malignancies, and discuss road toward precision immunotherapy in relation to PD-1/PD-L blockade. The preliminary data for PD-1/PD-L inhibitors are encouraging, and the precision immunotherapy of PD-1/PD-L inhibitors will be a viable and pivotal clinical strategy for GI cancer therapy.",
    "journal": "Journal of hematology & oncology",
    "pub_date": "2017-Aug",
    "doi": "10.1186/s13045-017-0511-2",
    "pmid": "28774337",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Gastrointestinal Neoplasms",
      "Humans",
      "Immunotherapy",
      "Precision Medicine",
      "Programmed Cell Death 1 Receptor",
      "Tumor Microenvironment"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/28774337/",
    "summary_ja": "消化管がんは世界的に罹患率・死亡率が高く、既存治療の進歩にもかかわらず全生存の改善には限界があるため、新たな治療戦略が求められる。腫瘍微小環境ではPD-1/PD-L相互作用がT細胞や腫瘍浸潤リンパ球の機能を抑制し、免疫抑制性Tregの働きを高めることで免疫逃避が起こる。PD-1/PD-L阻害はこの抑制を解除して抗腫瘍免疫を再活性化し、腫瘍細胞の認識・殺傷を促進しうる。本稿はPD-1/PD-Lのシグナル異常の機序、消化管がんにおける阻害薬の臨床データを概説し、精密免疫療法へ向けた課題と展望を論じている。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:39364736",
    "source": "pubmed",
    "source_id": "39364736",
    "title": "Current progress of anti‑PD‑1/PDL1 immunotherapy for glioblastoma (Review).",
    "year": 2024,
    "authors": [
      "Wu Jianheng",
      "Wang Nannan"
    ],
    "abstract": "Glioblastoma (GBM) is the most common central nervous system malignancy in adults. GBM may be classified as grade IV diffuse astrocytoma according to the 2021 World Health Organization revised classification of central nervous system tumors, which means it is the most aggressive, invasive, undifferentiated type of tumor. Immune checkpoint blockade (ICB), particularly anti‑programmed cell death protein‑1 (PD‑1)/PD‑1 ligand‑1 immunotherapy, has been confirmed to be successful across several tumor types. However, in GBM, this treatment is still uncommon and the efficacy is unpredictable, and <10% of patients show long‑term responses. Recently, numerous studies have been conducted to explore what factors may indicate or affect the ICB response rate in GBM, including molecular alterations, immune expression signatures and immune infiltration. The present review aimed to summarize the current progress to improve the understanding of immunotherapy for GBM.",
    "journal": "Molecular medicine reports",
    "pub_date": "2024-Dec",
    "doi": "10.3892/mmr.2024.13344",
    "pmid": "39364736",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Humans",
      "Glioblastoma",
      "Immunotherapy",
      "B7-H1 Antigen",
      "Immune Checkpoint Inhibitors",
      "Programmed Cell Death 1 Receptor",
      "Brain Neoplasms"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/39364736/",
    "summary_ja": "膠芽腫（GBM）は成人の中枢神経系で最も一般的な悪性腫瘍で、2021年WHO分類ではグレードIVのびまん性星細胞腫に相当する極めて侵襲性の高い腫瘍である。免疫チェックポイント阻害、特に抗PD-1/PD-L1療法は他のがん種で有効性が示されている一方、GBMでは適用がまだ一般的ではなく効果の予測も難しく、長期奏効は10%未満にとどまる。近年、分子異常、免疫発現シグネチャ、免疫細胞浸潤など、ICB反応率に関連し得る因子の解明に向けた研究が進んでいる。本レビューはGBMに対する免疫療法の現状の進歩を整理し、理解を深めることを目的としている。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:30191996",
    "source": "pubmed",
    "source_id": "30191996",
    "title": "PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.",
    "year": 2019,
    "authors": [
      "Dermani Fatemeh K",
      "Samadi Pouria",
      "Rahmani Golebagh",
      "Kohlan Alisa K",
      "Najafi Rezvan"
    ],
    "abstract": "Recent studies show that cancer cells are sometimes able to evade the host immunity in the tumor microenvironment. Cancer cells can express high levels of immune inhibitory signaling proteins. One of the most critical checkpoint pathways in this system is a tumor-induced immune suppression (immune checkpoint) mediated by the programmed cell death protein 1 (PD-1) and its ligand, programmed death ligand 1 (PD-L1). PD-1 is highly expressed by activated T cells, B cells, dendritic cells, and natural killer cells, whereas PD-L1 is expressed on several types of tumor cells. Many studies have shown that blocking the interaction between PD-1 and PD-L1 enhances the T-cell response and mediates antitumor activity. In this review, we highlight a brief overview of the molecular and biochemical events that are regulated by the PD-1 and PD-L1 interaction in various cancers.",
    "journal": "Journal of cellular physiology",
    "pub_date": "2019-Feb",
    "doi": "10.1002/jcp.27172",
    "pmid": "30191996",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Animals",
      "Antineoplastic Agents, Immunological",
      "B7-H1 Antigen",
      "Humans",
      "Immunotherapy",
      "Molecular Targeted Therapy",
      "Neoplasms",
      "Programmed Cell Death 1 Receptor",
      "Signal Transduction",
      "Treatment Outcome",
      "Tumor Escape",
      "Tumor Microenvironment"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/30191996/",
    "summary_ja": "がん細胞は腫瘍微小環境で宿主免疫を回避し、免疫抑制性シグナル分子を高発現することがある。PD-1（主に活性化T細胞などに発現）とPD-L1（複数の腫瘍細胞に発現）による免疫チェックポイントは、腫瘍誘導性の免疫抑制に重要な役割を担う。PD-1/PD-L1相互作用を阻害するとT細胞応答が増強され、抗腫瘍活性が得られることが多くの研究で示されている。本レビューは、さまざまながんにおけるPD-1/PD-L1相互作用が制御する分子・生化学的イベントを概説する。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:31241380",
    "source": "pubmed",
    "source_id": "31241380",
    "title": "Cancer immunotherapy using anti-TIM3/PD-1 bispecific antibody: a patent evaluation of EP3356411A1.",
    "year": 2019,
    "authors": [
      "Herrera-Camacho Irma",
      "Anaya-Ruiz Maricruz",
      "Perez-Santos Martin",
      "Millán-Pérez Peña Lourdes",
      "Bandala Cindy",
      "Landeta Gerardo"
    ],
    "abstract": "",
    "journal": "Expert opinion on therapeutic patents",
    "pub_date": "2019-Aug",
    "doi": "10.1080/13543776.2019.1637422",
    "pmid": "31241380",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Animals",
      "Antibodies, Bispecific",
      "Hepatitis A Virus Cellular Receptor 2",
      "Humans",
      "Immunotherapy",
      "Neoplasms",
      "Patents as Topic",
      "Programmed Cell Death 1 Receptor"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/31241380/",
    "summary_ja": "（アブストラクト未取得: Cancer immunotherapy using anti-TIM3/PD-1 bispecific antibody: a patent evaluation of EP3356411A1.）",
    "evidence_level": "N/A"
  },
  {
    "paper_id": "pubmed:38403027",
    "source": "pubmed",
    "source_id": "38403027",
    "title": "CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma.",
    "year": 2024,
    "authors": [
      "Xie Peiyi",
      "Yu Mincheng",
      "Zhang Bo",
      "Yu Qiang",
      "Zhao Yufei",
      "Wu Mengyuan",
      "Jin Lei",
      "Yan Jiuliang",
      "Zhou Binghai",
      "Liu Shuang",
      "Li Xiaoqiang",
      "Zhou Chenhao",
      "Zhu Xiaodong",
      "Huang Cheng",
      "Xu Yongfeng",
      "Xiao Yongsheng",
      "Zhou Jian",
      "Fan Jia",
      "Hung Mien-Chie",
      "Ye Qinghai",
      "Guo Lei",
      "Li Hui"
    ],
    "abstract": "BACKGROUND & AIMS: The effectiveness of immune checkpoint inhibitor (ICI) therapy for hepatocellular carcinoma (HCC) is limited by treatment resistance. However, the mechanisms underlying immunotherapy resistance remain elusive. We aimed to identify the role of CT10 regulator of kinase-like (CRKL) in resistance to anti-PD-1 therapy in HCC. METHODS: Gene expression in HCC specimens from 10 patients receiving anti-PD-1 therapy was identified by RNA-sequencing. A total of 404 HCC samples from tissue microarrays were analyzed by immunohistochemistry. Transgenic mice (Alb-Cre/Trp53 RESULTS: CRKL was identified as a candidate anti-PD-1-resistance gene using a pooled genetic screen. CRKL overexpression nullifies anti-PD-1 treatment efficacy by mobilizing tumor-associated neutrophils (TANs), which block the infiltration and function of CD8 CONCLUSIONS: Activation of the CRKL/β-catenin/VEGFα and CXCL1 axis is a critical obstacle to successful anti-PD-1 therapy. Therefore, CRKL inhibitors combined with anti-PD-1 could be useful for the treatment of HCC. IMPACT AND IMPLICATIONS: Here, we found that CRKL was overexpressed in anti-PD-1-resistant hepatocellular carcinoma (HCC) and that CRKL upregulation promotes anti-PD-1 resistance in HCC. We identified that upregulation of the CRKL/β-catenin/VEGFα and CXCL1 axis contributes to anti-PD-1 tolerance by promoting infiltration of tumor-associated neutrophils. These findings support the strategy of bevacizumab-based immune checkpoint inhibitor combination therapy, and CRKL inhibitors combined with anti-PD-1 therapy may be developed for the treatment of HCC.",
    "journal": "Journal of hepatology",
    "pub_date": "2024-Jul",
    "doi": "10.1016/j.jhep.2024.02.009",
    "pmid": "38403027",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Carcinoma, Hepatocellular",
      "Liver Neoplasms",
      "Animals",
      "Humans",
      "Mice",
      "Drug Resistance, Neoplasm",
      "Immune Checkpoint Inhibitors",
      "Adaptor Proteins, Signal Transducing",
      "Neutrophil Infiltration",
      "Programmed Cell Death 1 Receptor",
      "Mice, Transgenic",
      "CD8-Positive T-Lymphocytes",
      "Cell Line, Tumor",
      "Male",
      "Chemokine CXCL1"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/38403027/",
    "summary_ja": "肝細胞癌における抗PD-1療法の抵抗性機序として、CRKLの役割を解析した研究である。抗PD-1治療を受けた患者検体のRNA-seqや多数例の免疫染色解析、さらに遺伝学的スクリーニングとマウスモデルを用いて、CRKL高発現が治療効果を低下させることを示した。CRKLは腫瘍関連好中球の浸潤を促進し、CD8陽性T細胞の腫瘍内浸潤・機能を阻害することで免疫抵抗性に関与すると結論づけている。CRKL/β-カテニン/VEGFαおよびCXCL1経路が障壁となり、抗PD-1との併用（例：抗VEGF療法やCRKL阻害）による克服可能性が示唆された。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:30309915",
    "source": "pubmed",
    "source_id": "30309915",
    "title": "Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.",
    "year": 2018,
    "authors": [
      "Cristescu Razvan",
      "Mogg Robin",
      "Ayers Mark",
      "Albright Andrew",
      "Murphy Erin",
      "Yearley Jennifer",
      "Sher Xinwei",
      "Liu Xiao Qiao",
      "Lu Hongchao",
      "Nebozhyn Michael",
      "Zhang Chunsheng",
      "Lunceford Jared K",
      "Joe Andrew",
      "Cheng Jonathan",
      "Webber Andrea L",
      "Ibrahim Nageatte",
      "Plimack Elizabeth R",
      "Ott Patrick A",
      "Seiwert Tanguy Y",
      "Ribas Antoni",
      "McClanahan Terrill K",
      "Tomassini Joanne E",
      "Loboda Andrey",
      "Kaufman David"
    ],
    "abstract": "Programmed cell death protein-1 (PD-1) and programmed cell death ligand-1 (PD-L1) checkpoint blockade immunotherapy elicits durable antitumor effects in multiple cancers, yet not all patients respond. We report the evaluation of >300 patient samples across 22 tumor types from four KEYNOTE clinical trials. Tumor mutational burden (TMB) and a T cell-inflamed gene expression profile (GEP) exhibited joint predictive utility in identifying responders and nonresponders to the PD-1 antibody pembrolizumab. TMB and GEP were independently predictive of response and demonstrated low correlation, suggesting that they capture distinct features of neoantigenicity and T cell activation. Analysis of The Cancer Genome Atlas database showed TMB and GEP to have a low correlation, and analysis by joint stratification revealed biomarker-defined patterns of targetable-resistance biology. These biomarkers may have utility in clinical trial design by guiding rational selection of anti-PD-1 monotherapy and combination immunotherapy regimens.",
    "journal": "Science (New York, N.Y.)",
    "pub_date": "2018-Oct",
    "doi": "10.1126/science.aar3593",
    "pmid": "30309915",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Antibodies, Monoclonal, Humanized",
      "Antineoplastic Agents, Immunological",
      "Biomarkers, Tumor",
      "Cell Cycle Checkpoints",
      "Genetic Markers",
      "Humans",
      "Immunotherapy",
      "Inflammation",
      "Molecular Targeted Therapy",
      "Mutation",
      "Neoplasms",
      "Programmed Cell Death 1 Receptor",
      "T-Lymphocytes",
      "Transcriptome",
      "Tumor Burden"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/30309915/",
    "summary_ja": "PD-1/PD-L1阻害療法は複数のがん種で持続的効果を示す一方、反応しない患者も多い。著者らは4つのKEYNOTE試験に由来する22腫瘍種・300例超の検体を解析し、腫瘍変異量（TMB）とT細胞炎症性遺伝子発現プロファイル（GEP）がペムブロリズマブ反応性の予測に有用であることを示した。TMBとGEPはそれぞれ独立に反応と関連し相関が低く、ネオ抗原性とT細胞活性化という異なる生物学的側面を捉える可能性が示唆された。TCGA解析でも両者の低相関が確認され、両指標の層別化により抵抗性に関わる生物学的パターンが示され、試験設計や単剤/併用選択に資する可能性がある。",
    "evidence_level": "2b"
  },
  {
    "paper_id": "pubmed:39663448",
    "source": "pubmed",
    "source_id": "39663448",
    "title": "Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.",
    "year": 2025,
    "authors": [
      "Melero Ignacio",
      "de Miguel Luken Maria",
      "de Velasco Guillermo",
      "Garralda Elena",
      "Martín-Liberal Juan",
      "Joerger Markus",
      "Alonso Guzman",
      "Goebeler Maria-Elisabeth",
      "Schuler Martin",
      "König David",
      "Dummer Reinhard",
      "Reig Maria",
      "Rodriguez Ruiz Maria-Esperanza",
      "Calvo Emiliano",
      "Esteban-Villarrubia Jorge",
      "Oberoi Arjun",
      "Sabat Paula",
      "Soto-Castillo Juan José",
      "Koster Kira-Lee",
      "Saavedra Omar",
      "Sayehli Cyrus",
      "Gromke Tanja",
      "Läubli Heinz",
      "Ramelyte Egle",
      "Fortuny Marta",
      "Landa-Magdalena Ana",
      "Moreno Irene",
      "Torres-Jiménez Javier",
      "Hernando-Calvo Alberto",
      "Hess Dagmar",
      "Racca Fabricio",
      "Richly Heike",
      "Schmitt Andreas M",
      "Eggenschwiler Corinne",
      "Sanduzzi-Zamparelli Marco",
      "Vilalta-Lacarra Anna",
      "Trojan Jörg",
      "Koch Christine",
      "Galle Peter R",
      "Foerster Friedrich",
      "Trajanoski Zlatko",
      "Hackl Hubert",
      "Gogolla Falk",
      "Koll Florestan J",
      "Wild Peter",
      "Chun Felix Kyoung Hwan",
      "Reis Henning",
      "Lloyd Peter",
      "Machacek Matthias",
      "Gajewski Thomas F",
      "Fridman Wolf H",
      "Eggermont Alexander M M",
      "Bargou Ralf",
      "Schöniger Sandra",
      "Rüschoff Josef",
      "Tereshchenko Anastasiia",
      "Zink Carina",
      "da Silva Antonio",
      "Lichtenegger Felix S",
      "Akdemir Julia",
      "Rüdiger Manfred",
      "L'Huillier Phil",
      "Dutta Aradhana",
      "Haake Markus",
      "Auckenthaler Alexandra",
      "Gjorgjioska Ana",
      "Rössler Bernhard",
      "Hermann Frank",
      "Liebig Mara",
      "Reichhardt Daniela",
      "Schuberth-Wagner Christine",
      "Wischhusen Jörg",
      "Fettes Petra",
      "Auer Marlene",
      "Klar Kathrin",
      "Leo Eugen"
    ],
    "abstract": "Cancer immunotherapies with antibodies blocking immune checkpoint molecules are clinically active across multiple cancer entities and have markedly improved cancer treatment",
    "journal": "Nature",
    "pub_date": "2025-Jan",
    "doi": "10.1038/s41586-024-08305-z",
    "pmid": "39663448",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Humans",
      "Growth Differentiation Factor 15",
      "Programmed Cell Death 1 Receptor",
      "Drug Resistance, Neoplasm",
      "B7-H1 Antigen",
      "Female",
      "Antibodies, Neutralizing",
      "Nivolumab",
      "Male",
      "Immune Checkpoint Inhibitors",
      "Neoplasms",
      "Tumor Microenvironment",
      "Middle Aged",
      "Lung Neoplasms"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/39663448/",
    "summary_ja": "提示されたアブストラクトが途中で途切れているため、研究デザイン・対象・主要結果・結論を特定できず、内容の要約は確定できません。全文（少なくとも方法と結果を含むアブストラクト全体）を共有してください。現時点で言えるのは、固形腫瘍における抗PD-1/PD-L1抵抗性をGDF-15中和で克服できる可能性を扱うテーマである、という点のみです。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:33855973",
    "source": "pubmed",
    "source_id": "33855973",
    "title": "TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis.",
    "year": 2021,
    "authors": [
      "Jiang Zhou",
      "Lim Seung-Oe",
      "Yan Meisi",
      "Hsu Jennifer L",
      "Yao Jun",
      "Wei Yongkun",
      "Chang Shih-Shin",
      "Yamaguchi Hirohito",
      "Lee Heng-Huan",
      "Ke Baozhen",
      "Hsu Jung-Mao",
      "Chan Li-Chuan",
      "Hortobagyi Gabriel N",
      "Yang Liuqing",
      "Lin Chunru",
      "Yu Dihua",
      "Hung Mien-Chie"
    ],
    "abstract": "Immune checkpoint blockade therapy has demonstrated promising clinical outcomes for multiple cancer types. However, the emergence of resistance as well as inadequate biomarkers for patient stratification have largely limited the clinical benefits. Here, we showed that tumors with high TYRO3 expression exhibited anti-programmed cell death protein 1/programmed death ligand 1 (anti-PD-1/PD-L1) resistance in a syngeneic mouse model and in patients who received anti-PD-1/PD-L1 therapy. Mechanistically, TYRO3 inhibited tumor cell ferroptosis triggered by anti-PD-1/PD-L1 and facilitated the development of a protumor microenvironment by reducing the M1/M2 macrophage ratio, resulting in resistance to anti-PD-1/PD-L1 therapy. Inhibition of TYRO3 promoted tumor ferroptosis and sensitized resistant tumors to anti-PD-1 therapy. Collectively, our findings suggest that TYRO3 could serve as a predictive biomarker for patient selection and a promising therapeutic target to overcome anti-PD-1/PD-L1 resistance.",
    "journal": "The Journal of clinical investigation",
    "pub_date": "2021-Apr",
    "doi": "10.1172/JCI139434",
    "pmid": "33855973",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Animals",
      "B7-H1 Antigen",
      "Drug Resistance, Neoplasm",
      "Ferroptosis",
      "Humans",
      "Immune Checkpoint Inhibitors",
      "Immunity, Innate",
      "Mice",
      "Neoplasm Proteins",
      "Neoplasms",
      "Programmed Cell Death 1 Receptor",
      "Receptor Protein-Tyrosine Kinases",
      "THP-1 Cells"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/33855973/",
    "summary_ja": "免疫チェックポイント阻害（抗PD-1/PD-L1）治療は有効例がある一方、抵抗性の出現と適切なバイオマーカー不足が課題である。著者らは、TYRO3高発現腫瘍が同系マウスモデルおよび抗PD-1/PD-L1治療を受けた患者において治療抵抗性と関連することを示した。機序として、TYRO3が治療誘導性の腫瘍細胞フェロトーシスを抑制し、M1/M2マクロファージ比の低下など免疫抑制的微小環境を促して抵抗性に寄与するとした。さらにTYRO3阻害によりフェロトーシスが促進され、抵抗性腫瘍が抗PD-1治療に感受性化する可能性が示唆された。",
    "evidence_level": "2b"
  },
  {
    "paper_id": "pubmed:33606996",
    "source": "pubmed",
    "source_id": "33606996",
    "title": "Interferon-γ induces tumor resistance to anti-PD-1 immunotherapy by promoting YAP phase separation.",
    "year": 2021,
    "authors": [
      "Yu Man",
      "Peng Zhengxin",
      "Qin Min",
      "Liu Yang",
      "Wang Jingning",
      "Zhang Cai",
      "Lin Jiaming",
      "Dong Tianqi",
      "Wang Lulu",
      "Li Shasha",
      "Yang Yongqin",
      "Xu Shan",
      "Guo Wencong",
      "Zhang Xiao",
      "Shi Mingjun",
      "Peng Huiming",
      "Luo Xianwen",
      "Zhang Huixia",
      "Zhang Li",
      "Li Yan",
      "Yang Xiang-Ping",
      "Sun Shuguo"
    ],
    "abstract": "Interferon-γ (IFN-γ)-mediated adaptive resistance is one major barrier to improving immunotherapy in solid tumors. However, the mechanisms are not completely understood. Here, we report that IFN-γ promotes nuclear translocation and phase separation of YAP after anti-PD-1 therapy in tumor cells. Hydrophobic interactions of the YAP coiled-coil domain mediate droplet initiation, and weak interactions of the intrinsically disordered region in the C terminus promote droplet formation. YAP partitions with the transcription factor TEAD4, the histone acetyltransferase EP300, and Mediator1 and forms transcriptional hubs for maximizing target gene transcriptions, independent of the canonical STAT1-IRF1 transcription program. Disruption of YAP phase separation reduced tumor growth, enhanced immune response, and sensitized tumor cells to anti-PD-1 therapy. YAP activity is negatively correlated with patient outcome. Our study indicates that YAP mediates the IFN-γ pro-tumor effect through its nuclear phase separation and suggests that YAP can be used as a predictive biomarker and target of anti-PD-1 combination therapy.",
    "journal": "Molecular cell",
    "pub_date": "2021-Mar",
    "doi": "10.1016/j.molcel.2021.01.010",
    "pmid": "33606996",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "A549 Cells",
      "Adaptor Proteins, Signal Transducing",
      "Animals",
      "Biomarkers, Tumor",
      "Drug Resistance, Neoplasm",
      "HEK293 Cells",
      "Humans",
      "Immune Checkpoint Inhibitors",
      "Immunotherapy",
      "Interferon-gamma",
      "Mice",
      "Mice, Knockout",
      "Neoplasms, Experimental",
      "Programmed Cell Death 1 Receptor",
      "Transcription Factors",
      "YAP-Signaling Proteins"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/33606996/",
    "summary_ja": "本研究は、抗PD-1治療後にIFN-γが腫瘍細胞内でYAPの核内移行と相分離（液滴形成）を促進し、免疫療法に対する適応的抵抗性に寄与することを示した。YAPのコイルドコイル領域の疎水性相互作用が液滴開始を、C末端の天然変性領域の弱い相互作用が液滴形成を支えると報告している。相分離したYAPはTEAD4やEP300、Mediator1とともに転写ハブを形成し、STAT1-IRF1経路とは独立に標的遺伝子転写を増強する。YAP相分離の阻害により腫瘍増殖が抑制され免疫応答が高まり、抗PD-1への感受性が改善し、さらにYAP活性は患者予後不良と負の相関を示した。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:35062949",
    "source": "pubmed",
    "source_id": "35062949",
    "title": "Combination strategies with PD-1/PD-L1 blockade: current advances and future directions.",
    "year": 2022,
    "authors": [
      "Yi Ming",
      "Zheng Xiaoli",
      "Niu Mengke",
      "Zhu Shuangli",
      "Ge Hong",
      "Wu Kongming"
    ],
    "abstract": "Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T cells from exhausted status and revive immune response against cancer cells. Based on the immense success in clinical trials, ten α-PD-1 (nivolumab, pembrolizumab, cemiplimab, sintilimab, camrelizumab, toripalimab, tislelizumab, zimberelimab, prolgolimab, and dostarlimab) and three α-PD-L1 antibodies (atezolizumab, durvalumab, and avelumab) have been approved for various types of cancers. Nevertheless, the low response rate of α-PD-1/PD-L1 therapy remains to be resolved. For most cancer patients, PD-1/PD-L1 pathway is not the sole speed-limiting factor of antitumor immunity, and it is insufficient to motivate effective antitumor immune response by blocking PD-1/PD-L1 axis. It has been validated that some combination therapies, including α-PD-1/PD-L1 plus chemotherapy, radiotherapy, angiogenesis inhibitors, targeted therapy, other immune checkpoint inhibitors, agonists of the co-stimulatory molecule, stimulator of interferon genes agonists, fecal microbiota transplantation, epigenetic modulators, or metabolic modulators, have superior antitumor efficacies and higher response rates. Moreover, bifunctional or bispecific antibodies containing α-PD-1/PD-L1 moiety also elicited more potent antitumor activity. These combination strategies simultaneously boost multiple processes in cancer-immunity cycle, remove immunosuppressive brakes, and orchestrate an immunosupportive tumor microenvironment. In this review, we summarized the synergistic antitumor efficacies and mechanisms of α-PD-1/PD-L1 in combination with other therapies. Moreover, we focused on the advances of α-PD-1/PD-L1-based immunomodulatory strategies in clinical studies. Given the heterogeneity across patients and cancer types, individualized combination selection could improve the effects of α-PD-1/PD-L1-based immunomodulatory strategies and relieve treatment resistance.",
    "journal": "Molecular cancer",
    "pub_date": "2022-Jan",
    "doi": "10.1186/s12943-021-01489-2",
    "pmid": "35062949",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Antineoplastic Combined Chemotherapy Protocols",
      "B7-H1 Antigen",
      "Biomarkers, Tumor",
      "Clinical Studies as Topic",
      "Combined Modality Therapy",
      "Disease Management",
      "Disease Susceptibility",
      "Humans",
      "Immune Checkpoint Inhibitors",
      "Molecular Targeted Therapy",
      "Neoplasms",
      "Prognosis",
      "Programmed Cell Death 1 Receptor",
      "Treatment Outcome"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/35062949/",
    "summary_ja": "PD-1/PD-L1を標的とする抗体は、疲弊したT細胞機能を回復させ抗腫瘍免疫を再活性化するが、単剤では奏効率が低いことが課題である。本レビューは、PD-1/PD-L1阻害と化学療法・放射線療法・血管新生阻害・分子標的薬・他の免疫チェックポイント阻害・共刺激分子アゴニスト・STINGアゴニスト・便微生物移植・エピジェネティック/代謝調節薬などの併用、ならびに二機能/二重特異性抗体による強化戦略を整理する。これらの併用はがん免疫サイクルの複数段階を同時に促進し、免疫抑制環境を緩和することで治療効果と応答率の向上が期待される。患者・がん種の異質性を踏まえ、個別化した併用選択が抵抗性軽減と効果最大化に重要である。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:39303724",
    "source": "pubmed",
    "source_id": "39303724",
    "title": "Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer.",
    "year": 2024,
    "authors": [
      "Wang Xueliang",
      "Fang Yi",
      "Liang Wei",
      "Wong Chi Chun",
      "Qin Huanlong",
      "Gao Yaohui",
      "Liang Meinong",
      "Song Lei",
      "Zhang Yongxin",
      "Fan Miao",
      "Liu Chuanfa",
      "Lau Harry Cheuk-Hay",
      "Xu Lixia",
      "Li Xiaoxing",
      "Song Wu",
      "Wang Junlin",
      "Wang Na",
      "Yang Tao",
      "Mo Mengmiao",
      "Zhang Xiang",
      "Fang Jingyuan",
      "Liao Bing",
      "Sung Joseph J Y",
      "Yu Jun"
    ],
    "abstract": "Microsatellite stable (MSS) colorectal cancers (CRCs) are often resistant to anti-programmed death-1 (PD-1) therapy. Here, we show that a CRC pathogen, Fusobacterium nucleatum (Fn), paradoxically sensitizes MSS CRC to anti-PD-1. Fecal microbiota transplantation (FMT) from patients with Fn-high MSS CRC to germ-free mice bearing MSS CRC confers sensitivity to anti-PD-1 compared to FMT from Fn-low counterparts. Single Fn administration also potentiates anti-PD-1 efficacy in murine allografts and CD34",
    "journal": "Cancer cell",
    "pub_date": "2024-Oct",
    "doi": "10.1016/j.ccell.2024.08.019",
    "pmid": "39303724",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Colorectal Neoplasms",
      "Humans",
      "Animals",
      "Fusobacterium nucleatum",
      "Mice",
      "Fecal Microbiota Transplantation",
      "Programmed Cell Death 1 Receptor",
      "Immune Checkpoint Inhibitors",
      "CD8-Positive T-Lymphocytes",
      "T-Box Domain Proteins",
      "Microsatellite Instability",
      "Butyric Acid",
      "Female",
      "Male",
      "Microsatellite Repeats"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/39303724/",
    "summary_ja": "マイクロサテライト安定型（MSS）の大腸癌は抗PD-1療法に抵抗性であることが多いが、本研究はFusobacterium nucleatum（Fn）が逆説的にMSS大腸癌の抗PD-1感受性を高める可能性を示した。Fn高値のMSS大腸癌患者由来便の糞便微生物叢移植（FMT）を無菌マウスのMSS大腸癌モデルに行うと、Fn低値患者由来FMTに比べ抗PD-1への反応性が向上した。さらにFnの単独投与でも、マウス同種移植腫瘍モデルにおける抗PD-1の有効性が増強された。これらより、腫瘍関連微生物が免疫チェックポイント阻害療法の効果に影響しうることが示唆される。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:39168104",
    "source": "pubmed",
    "source_id": "39168104",
    "title": "Soluble Tim-3 serves as a tumor prognostic marker and therapeutic target for CD8",
    "year": 2024,
    "authors": [
      "Chen Chaojia",
      "Zhao Fangcheng",
      "Peng Jiali",
      "Zhao Di",
      "Xu Liyun",
      "Li Huayu",
      "Ma Shuaiya",
      "Peng Xueqi",
      "Sheng Xue",
      "Sun Yang",
      "Wang Tixiao",
      "Dong Haoqing",
      "Ding Yuming",
      "Wu Zhuanchang",
      "Liang Xiaohong",
      "Gao Lifen",
      "Wang Hongyan",
      "Ma Chunhong",
      "Li Chunyang"
    ],
    "abstract": "Resistance to PD-1 blockade in onco-immunotherapy greatly limits its clinical application. T cell immunoglobulin and mucin domain containing-3 (Tim-3), a promising immune checkpoint target, is cleaved by ADAM10/17 to produce its soluble form (sTim-3) in humans, potentially becoming involved in anti-PD-1 resistance. Herein, serum sTim-3 upregulation was observed in non-small cell lung cancer (NSCLC) and various digestive tumors. Notably, serum sTim-3 is further upregulated in non-responding patients undergoing anti-PD-1 therapy for NSCLC and anti-PD-1-resistant cholangiocarcinoma patients. Furthermore, sTim-3 overexpression facilitates tumor progression and confers anti-PD-1 resistance in multiple tumor mouse models. Mechanistically, sTim-3 induces terminal T cell exhaustion and attenuates CD8",
    "journal": "Cell reports. Medicine",
    "pub_date": "2024-Aug",
    "doi": "10.1016/j.xcrm.2024.101686",
    "pmid": "39168104",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Hepatitis A Virus Cellular Receptor 2",
      "Humans",
      "Animals",
      "CD8-Positive T-Lymphocytes",
      "Drug Resistance, Neoplasm",
      "Mice",
      "Programmed Cell Death 1 Receptor",
      "Prognosis",
      "Biomarkers, Tumor",
      "Immune Checkpoint Inhibitors",
      "Cell Line, Tumor",
      "Female",
      "Male",
      "Lung Neoplasms",
      "Carcinoma, Non-Small-Cell Lung",
      "ADAM10 Protein",
      "Mice, Inbred C57BL",
      "T-Cell Exhaustion"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/39168104/",
    "summary_ja": "本研究は、免疫チェックポイント阻害（抗PD-1）に対する抵抗性に可溶性Tim-3（sTim-3）が関与する可能性を検討した。血清sTim-3はNSCLCや消化器系腫瘍で上昇し、NSCLCの抗PD-1治療で非奏効の患者や、抗PD-1抵抗性の胆管癌患者でさらに高値であった。マウス腫瘍モデルではsTim-3過剰発現が腫瘍進行を促進し、抗PD-1抵抗性を付与した。機序として、sTim-3がCD8 T細胞の終末疲弊を誘導し抗腫瘍免疫を減弱させることが示唆された。",
    "evidence_level": "3b"
  },
  {
    "paper_id": "pubmed:40577442",
    "source": "pubmed",
    "source_id": "40577442",
    "title": "Riplet promotes lipid metabolism changes associated with CD8 T cell exhaustion and anti-PD-1 resistance in hepatocellular carcinoma.",
    "year": 2025,
    "authors": [
      "Liang Junnan",
      "Liao Jingyu",
      "Chang Ruizhi",
      "Jia Wenlong",
      "Li Ganxun",
      "Chen Zeyu",
      "Wu Hang",
      "Zhu Chang",
      "Wen Jingyuan",
      "Huang Qibo",
      "Gao Han",
      "Gui Zichen",
      "Xu Weiqi",
      "Liang Huifang",
      "Liu Qiumeng",
      "Xu Dafeng",
      "Li Zifu",
      "Xia Limin",
      "Chen Xiaoping",
      "Huang Zhao",
      "Zhang Wanguang",
      "Ding Zeyang",
      "Zhang Bixiang"
    ],
    "abstract": "The overall response rate to immunotherapy is modest in hepatocellular carcinoma (HCC), and immunotherapy resistance mechanisms are incompletely understood. We report that the E3 ubiquitin ligase ",
    "journal": "Science immunology",
    "pub_date": "2025-Jun",
    "doi": "10.1126/sciimmunol.ado3485",
    "pmid": "40577442",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Carcinoma, Hepatocellular",
      "CD8-Positive T-Lymphocytes",
      "Liver Neoplasms",
      "Humans",
      "Lipid Metabolism",
      "Drug Resistance, Neoplasm",
      "Programmed Cell Death 1 Receptor",
      "Animals",
      "Mice",
      "Cell Line, Tumor",
      "Immune Checkpoint Inhibitors",
      "Ubiquitin-Protein Ligases",
      "Fatty Acid Synthase, Type I",
      "STAT3 Transcription Factor",
      "T-Cell Exhaustion"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/40577442/",
    "summary_ja": "提示された抄録は途中で切れており詳細は不明ですが、肝細胞癌（HCC）における免疫療法（抗PD-1など）の奏効率が限定的で、抵抗性機序が十分に解明されていないという背景が述べられています。著者らは、E3ユビキチンリガーゼであるRipletが、CD8陽性T細胞の疲弊（exhaustion）と関連する脂質代謝変化を促進し、抗PD-1抵抗性に関与する可能性を報告する内容と読み取れます。全体として、腫瘍免疫の代謝制御という観点から、治療抵抗性の分子機序と介入標的の示唆を目的とした研究であると考えられます。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:39889705",
    "source": "pubmed",
    "source_id": "39889705",
    "title": "Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer.",
    "year": 2025,
    "authors": [
      "Guo Xinyi",
      "Nie Hu",
      "Zhang Wenwen",
      "Li Jiesheng",
      "Ge Jing",
      "Xie Bowen",
      "Hu Wenbo",
      "Zhu Yicheng",
      "Zhong Na",
      "Zhang Xinmei",
      "Zhao Xiaohong",
      "Wang Xiaoshuang",
      "Sun Qinli",
      "Wei Kun",
      "Chen Xiaoyuan",
      "Ni Ling",
      "Zhang Ting",
      "Lu Shichun",
      "Zhang Lei",
      "Dong Chen"
    ],
    "abstract": "Combination of anti-PD-1 with lenvatinib showed clinical efficacy in multiple cancers, yet the underlying immunological mechanisms are unclear. Here, we compared T cells in hepatocellular carcinoma (HCC) patients before and after combination treatment using single-cell transcriptomics and T cell receptor (scTCR) clonotype analyses. We found that tumor-infiltrating GZMK",
    "journal": "Cancer cell",
    "pub_date": "2025-Feb",
    "doi": "10.1016/j.ccell.2025.01.001",
    "pmid": "39889705",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Humans",
      "Quinolines",
      "Phenylurea Compounds",
      "T-Lymphocytes, Regulatory",
      "Carcinoma, Hepatocellular",
      "Liver Neoplasms",
      "Programmed Cell Death 1 Receptor",
      "T-Lymphocytes, Cytotoxic",
      "Immune Checkpoint Inhibitors",
      "Antineoplastic Combined Chemotherapy Protocols",
      "Male",
      "Female",
      "CD8-Positive T-Lymphocytes",
      "Lymphocytes, Tumor-Infiltrating",
      "Treatment Outcome",
      "Middle Aged"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/39889705/",
    "summary_ja": "抗PD-1抗体とレンバチニブの併用療法は複数のがんで有効性が示されている一方、その免疫学的機序は十分に解明されていない。著者らは肝細胞がん（HCC）患者において、併用療法の前後でT細胞を単一細胞トランスクリプトーム解析と単一細胞TCRクロノタイプ解析により比較した。これにより、治療に伴う腫瘍内T細胞応答の変化とクローン動態を捉え、異なる臨床転帰を規定しうる細胞傷害性T細胞と制御性T細胞の応答の違いを検討した（提示されたアブストラクトが途中で途切れているため詳細は限定的）。",
    "evidence_level": "4"
  },
  {
    "paper_id": "pubmed:39059396",
    "source": "pubmed",
    "source_id": "39059396",
    "title": "Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor.",
    "year": 2024,
    "authors": [
      "Kim Yunjae",
      "Kim Gihyeon",
      "Kim Sujeong",
      "Cho Beomki",
      "Kim Sang-Yeob",
      "Do Eun-Ju",
      "Bae Dong-Jun",
      "Kim Seungil",
      "Kweon Mi-Na",
      "Song Joon Seon",
      "Park Sang Hyoung",
      "Hwang Sung Wook",
      "Kim Mi-Na",
      "Kim Yeongmin",
      "Min Kyungchan",
      "Kim Sung-Han",
      "Adams Mark D",
      "Lee Charles",
      "Park Hansoo",
      "Park Sook Ryun"
    ],
    "abstract": "The gut microbiome significantly influences immune responses and the efficacy of immune checkpoint inhibitors. We conducted a clinical trial (NCT04264975) combining an anti-programmed death-1 (PD-1) inhibitor with fecal microbiota transplantation (FMT) from anti-PD-1 responder in 13 patients with anti-PD-1-refractory advanced solid cancers. FMT induced sustained microbiota changes and clinical benefits in 6 of 13 patients, with 1 partial response and 5 stable diseases, achieving an objective response rate of 7.7% and a disease control rate of 46.2%. The clinical response correlates with increased cytotoxic T cells and immune cytokines in blood and tumors. We isolated Prevotella merdae Immunoactis from a responder to FMT, which stimulates T cell activity and suppresses tumor growth in mice by enhancing cytotoxic T cell infiltration. Additionally, we found Lactobacillus salivarius and Bacteroides plebeius may inhibit anti-tumor immunity. Our findings suggest that FMT with beneficial microbiota can overcome resistance to anti-PD-1 inhibitors in advanced solid cancers, especially gastrointestinal cancers.",
    "journal": "Cell host & microbe",
    "pub_date": "2024-Aug",
    "doi": "10.1016/j.chom.2024.06.010",
    "pmid": "39059396",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Animals",
      "Humans",
      "Mice",
      "Cytokines",
      "Fecal Microbiota Transplantation",
      "Feces",
      "Gastrointestinal Microbiome",
      "Immune Checkpoint Inhibitors",
      "Neoplasms",
      "Programmed Cell Death 1 Receptor",
      "Male",
      "Female",
      "Adult",
      "Middle Aged"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/39059396/",
    "summary_ja": "腸内細菌叢が免疫チェックポイント阻害薬の効果に影響することを背景に、抗PD-1抵抗性の進行固形がん患者13例で、奏効者由来の糞便微生物移植（FMT）を抗PD-1阻害薬に併用する臨床試験を行った。FMTにより腸内細菌叢の変化が持続し、13例中6例で臨床的利益（部分奏効1例、安定5例）が得られ、奏効率7.7%、病勢制御率46.2%だった。反応例では末梢血・腫瘍内で細胞傷害性T細胞やサイトカインの増加と関連し、奏効者由来のPrevotella merdae ImmunoactisがマウスでT細胞活性化と腫瘍増殖抑制を示した。一方でLactobacillus salivariusやBacteroides plebeiusが抗腫瘍免疫を阻害する可能性も示唆された。",
    "evidence_level": "4"
  },
  {
    "paper_id": "pubmed:29567705",
    "source": "pubmed",
    "source_id": "29567705",
    "title": "Cancer immunotherapy using checkpoint blockade.",
    "year": 2018,
    "authors": [
      "Ribas Antoni",
      "Wolchok Jedd D"
    ],
    "abstract": "The release of negative regulators of immune activation (immune checkpoints) that limit antitumor responses has resulted in unprecedented rates of long-lasting tumor responses in patients with a variety of cancers. This can be achieved by antibodies blocking the cytotoxic T lymphocyte-associated protein 4 (CTLA-4) or the programmed cell death 1 (PD-1) pathway, either alone or in combination. The main premise for inducing an immune response is the preexistence of antitumor T cells that were limited by specific immune checkpoints. Most patients who have tumor responses maintain long-lasting disease control, yet one-third of patients relapse. Mechanisms of acquired resistance are currently poorly understood, but evidence points to alterations that converge on the antigen presentation and interferon-γ signaling pathways. New-generation combinatorial therapies may overcome resistance mechanisms to immune checkpoint therapy.",
    "journal": "Science (New York, N.Y.)",
    "pub_date": "2018-Mar",
    "doi": "10.1126/science.aar4060",
    "pmid": "29567705",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Antibodies",
      "CTLA-4 Antigen",
      "Humans",
      "Immunotherapy",
      "Neoplasms",
      "Programmed Cell Death 1 Receptor"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/29567705/",
    "summary_ja": "免疫チェックポイント（CTLA-4やPD-1経路）による免疫抑制を抗体で解除することで、多様ながん種で長期に持続する腫瘍反応が得られることが示されている。治療効果の前提として、腫瘍特異的T細胞が既に存在し、特定のチェックポイントにより抑えられていた可能性が強調される。多くの奏効例は長期の病勢制御を維持する一方、約3分の1で再発が起こる。獲得耐性の機序は十分解明されていないが、抗原提示やIFN-γシグナル伝達経路に収束する変化が関与する可能性が示唆され、併用療法などの新規組み合わせ戦略が耐性克服に有望とされる。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:38462037",
    "source": "pubmed",
    "source_id": "38462037",
    "title": "LRP1 induces anti-PD-1 resistance by modulating the DLL4-NOTCH2-CCL2 axis and redirecting M2-like macrophage polarisation in bladder cancer.",
    "year": 2024,
    "authors": [
      "Lin Hansen",
      "Fu Liangmin",
      "Zhou Xinwei",
      "Yu Anze",
      "Chen Yuhang",
      "Liao Wuyuan",
      "Shu Guannan",
      "Zhang Lizhen",
      "Tan Lei",
      "Liang Hui",
      "Wang Zhu",
      "Deng Qiong",
      "Wang Jieyan",
      "Jin Meiyu",
      "Chen Zhenhua",
      "Wei Jinhuan",
      "Cao Jiazheng",
      "Chen Wei",
      "Li Xiaofei",
      "Li Pengju",
      "Lu Jun",
      "Luo Junhang"
    ],
    "abstract": "The tumour microenvironment (TME) drives bladder cancer (BLCA) progression. Targeting the TME has emerged as a promising strategy for BLCA treatment in recent years. Furthermore, checkpoint blockade therapies are only beneficial for a minority of patients with BLCA, and drug resistance is a barrier to achieving significant clinical effects of anti-programmed cell death protein-1 (PD-1)/programmed death protein ligand-1 (PD-L1) therapy. In this study, higher low-density lipoprotein receptor-related protein 1 (LRP1) levels were related to a poorer prognosis for patients with various cancers, including those with higher grades and later stages of BLCA. Enrichment analysis demonstrated that LRP1 plays a role in the epithelial-mesenchymal transition (EMT), NOTCH signalling pathway, and ubiquitination. LRP1 knockdown in BLCA cells delayed BLCA progression both in vivo and in vitro. Furthermore, LRP1 knockdown suppressed EMT, reduced DLL4-NOTCH2 signalling activity, and downregulated M2-like macrophage polarisation. Patients with BLCA and higher LRP1 levels responded weakly to anti-PD-1 therapy in the IMvigor210 cohort. Moreover, LRP1 knockdown enhanced the therapeutic effects of anti-PD-1 in mice. Taken together, our findings suggest that LRP1 is a potential target for improving the efficacy of anti-PD-1/PD-L1 therapy by preventing EMT and M2-like macrophage polarisation by blocking the DLL4-NOTCH2 axis.",
    "journal": "Cancer letters",
    "pub_date": "2024-Jul",
    "doi": "10.1016/j.canlet.2024.216807",
    "pmid": "38462037",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Animals",
      "Female",
      "Humans",
      "Male",
      "Mice",
      "Adaptor Proteins, Signal Transducing",
      "Calcium-Binding Proteins",
      "Cell Line, Tumor",
      "Chemokine CCL2",
      "Drug Resistance, Neoplasm",
      "Epithelial-Mesenchymal Transition",
      "Immune Checkpoint Inhibitors",
      "Low Density Lipoprotein Receptor-Related Protein-1",
      "Macrophages",
      "Programmed Cell Death 1 Receptor",
      "Receptor, Notch2",
      "Signal Transduction",
      "Tumor Microenvironment",
      "Urinary Bladder Neoplasms",
      "Xenograft Model Antitumor Assays"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/38462037/",
    "summary_ja": "膀胱癌の腫瘍微小環境が免疫療法抵抗性に関与するという背景のもと、LRP1高発現が膀胱癌を含む複数癌種で予後不良や高悪性度・進行期と関連することを示した。解析からLRP1はEMT、NOTCHシグナル、ユビキチン化に関与し、膀胱癌細胞でのLRP1ノックダウンはin vitro/in vivoで腫瘍進展を抑制した。機序としてDLL4-NOTCH2経路の低下を介してEMTとM2様マクロファージ分極を抑えることが示唆された。IMvigor210コホートではLRP1高値の患者で抗PD-1反応が弱く、マウスではLRP1ノックダウンが抗PD-1治療効果を増強した。",
    "evidence_level": "2b"
  },
  {
    "paper_id": "pubmed:29443960",
    "source": "pubmed",
    "source_id": "29443960",
    "title": "TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.",
    "year": 2018,
    "authors": [
      "Mariathasan Sanjeev",
      "Turley Shannon J",
      "Nickles Dorothee",
      "Castiglioni Alessandra",
      "Yuen Kobe",
      "Wang Yulei",
      "Kadel Edward E",
      "Koeppen Hartmut",
      "Astarita Jillian L",
      "Cubas Rafael",
      "Jhunjhunwala Suchit",
      "Banchereau Romain",
      "Yang Yagai",
      "Guan Yinghui",
      "Chalouni Cecile",
      "Ziai James",
      "Şenbabaoğlu Yasin",
      "Santoro Stephen",
      "Sheinson Daniel",
      "Hung Jeffrey",
      "Giltnane Jennifer M",
      "Pierce Andrew A",
      "Mesh Kathryn",
      "Lianoglou Steve",
      "Riegler Johannes",
      "Carano Richard A D",
      "Eriksson Pontus",
      "Höglund Mattias",
      "Somarriba Loan",
      "Halligan Daniel L",
      "van der Heijden Michiel S",
      "Loriot Yohann",
      "Rosenberg Jonathan E",
      "Fong Lawrence",
      "Mellman Ira",
      "Chen Daniel S",
      "Green Marjorie",
      "Derleth Christina",
      "Fine Gregg D",
      "Hegde Priti S",
      "Bourgon Richard",
      "Powles Thomas"
    ],
    "abstract": "Therapeutic antibodies that block the programmed death-1 (PD-1)-programmed death-ligand 1 (PD-L1) pathway can induce robust and durable responses in patients with various cancers, including metastatic urothelial cancer. However, these responses only occur in a subset of patients. Elucidating the determinants of response and resistance is key to improving outcomes and developing new treatment strategies. Here we examined tumours from a large cohort of patients with metastatic urothelial cancer who were treated with an anti-PD-L1 agent (atezolizumab) and identified major determinants of clinical outcome. Response to treatment was associated with CD8",
    "journal": "Nature",
    "pub_date": "2018-Feb",
    "doi": "10.1038/nature25501",
    "pmid": "29443960",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Animals",
      "Antibodies",
      "Antibodies, Monoclonal",
      "Antibodies, Monoclonal, Humanized",
      "Antigens, Neoplasm",
      "B7-H1 Antigen",
      "CD8-Positive T-Lymphocytes",
      "Cell Cycle Checkpoints",
      "Cohort Studies",
      "Collagen",
      "Disease Models, Animal",
      "Drug Resistance, Neoplasm",
      "Fibroblasts",
      "Humans",
      "Immunotherapy",
      "Mice",
      "Mutation",
      "Neoplasm Metastasis",
      "Phenotype",
      "Signal Transduction",
      "Transforming Growth Factor beta",
      "Treatment Outcome",
      "Tumor Microenvironment",
      "Urologic Neoplasms",
      "Urothelium"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/29443960/",
    "summary_ja": "PD-1/PD-L1経路を遮断する抗体療法は複数のがんで持続的奏効を示し得る一方、反応する患者は一部に限られます。本研究は、抗PD-L1抗体アテゾリズマブで治療された転移性尿路上皮がん患者の大規模コホートの腫瘍検体を解析し、臨床転帰を規定する主要因を同定することを目的としています。結果として、TGFβが腫瘍内へのT細胞浸潤を排除（T cell exclusion）することに寄与し、PD-L1阻害に対する腫瘍応答を減弱させる可能性が示唆されています。また、治療反応はCD8に関連すると報告されています。",
    "evidence_level": "2b"
  },
  {
    "paper_id": "pubmed:30753825",
    "source": "pubmed",
    "source_id": "30753825",
    "title": "Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.",
    "year": 2019,
    "authors": [
      "Gide Tuba N",
      "Quek Camelia",
      "Menzies Alexander M",
      "Tasker Annie T",
      "Shang Ping",
      "Holst Jeff",
      "Madore Jason",
      "Lim Su Yin",
      "Velickovic Rebecca",
      "Wongchenko Matthew",
      "Yan Yibing",
      "Lo Serigne",
      "Carlino Matteo S",
      "Guminski Alexander",
      "Saw Robyn P M",
      "Pang Angel",
      "McGuire Helen M",
      "Palendira Umaimainthan",
      "Thompson John F",
      "Rizos Helen",
      "Silva Ines Pires da",
      "Batten Marcel",
      "Scolyer Richard A",
      "Long Georgina V",
      "Wilmott James S"
    ],
    "abstract": "Cancer immunotherapies provide survival benefits in responding patients, but many patients fail to respond. Identifying the biology of treatment response and resistance are a priority to optimize drug selection and improve patient outcomes. We performed transcriptomic and immune profiling on 158 tumor biopsies from melanoma patients treated with anti-PD-1 monotherapy (n = 63) or combined anti-PD-1 and anti-CTLA-4 (n = 57). These data identified activated T cell signatures and T cell populations in responders to both treatments. Further mass cytometry analysis identified an EOMES",
    "journal": "Cancer cell",
    "pub_date": "2019-Feb",
    "doi": "10.1016/j.ccell.2019.01.003",
    "pmid": "30753825",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Aged",
      "Antibodies, Monoclonal, Humanized",
      "Antigens, CD",
      "Antigens, Differentiation, T-Lymphocyte",
      "Antineoplastic Agents, Immunological",
      "Antineoplastic Combined Chemotherapy Protocols",
      "CTLA-4 Antigen",
      "Drug Resistance, Neoplasm",
      "Female",
      "Humans",
      "Immunologic Memory",
      "Ipilimumab",
      "Lectins, C-Type",
      "Leukocyte Common Antigens",
      "Lymphocytes, Tumor-Infiltrating",
      "Male",
      "Melanoma",
      "Middle Aged",
      "Nivolumab",
      "Phenotype",
      "Programmed Cell Death 1 Receptor",
      "Retrospective Studies",
      "Signal Transduction",
      "Skin Neoplasms",
      "T-Lymphocytes",
      "Treatment Outcome",
      "Tumor Burden",
      "CD69 Antigens"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/30753825/",
    "summary_ja": "本研究は、メラノーマ患者における抗PD-1単剤療法および抗PD-1/抗CTLA-4併用療法の奏効・不奏効の生物学的背景を明らかにすることを目的とした。治療を受けた患者の腫瘍生検158検体（抗PD-1単剤63例、併用57例）に対してトランスクリプトーム解析と免疫プロファイリングを実施した。その結果、両治療の奏効例で活性化T細胞シグネチャーおよびT細胞集団が同定された。さらに質量サイトメトリー解析により、EOMESに関連する免疫細胞集団が示唆された（抄録が途中で途切れているため詳細は限定的）。",
    "evidence_level": "2c"
  },
  {
    "paper_id": "pubmed:34981670",
    "source": "pubmed",
    "source_id": "34981670",
    "title": "Anti-PD-L1/TGF-βR fusion protein (SHR-1701) overcomes disrupted lymphocyte recovery-induced resistance to PD-1/PD-L1 inhibitors in lung cancer.",
    "year": 2022,
    "authors": [
      "Cheng Bo",
      "Ding Kaikai",
      "Chen Pengxiang",
      "Ji Jianxiong",
      "Luo Tao",
      "Guo Xiaofan",
      "Qiu Wei",
      "Ma Chunhong",
      "Meng Xue",
      "Wang Jian",
      "Yu Jinming",
      "Liu Yuan"
    ],
    "abstract": "BACKGROUND: Second-generation programmed cell death-protein 1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors, such as bintrafusp alfa (M7824), SHR-1701, and YM101, have been developed to simultaneously block PD-1/PD-L1 and transforming growth factor-beta/transforming growth factor-beta receptor (TGF-β/TGF-βR). Consequently, it is necessary to identify predictive factors of lung cancer patients who are not only resistant to PD-1/PD-L1 inhibitors but also sensitive to bifunctional drugs. The purpose of this study was to search for such predictors. METHODS: Multivariable Cox regression was used to study the association between the clinical outcome of treatment with PD-1/PD-L1 inhibitors and lymphocyte recovery after lymphopenia in lung cancer patients. Murine CMT167 lung cancer cells were engineered to express the firefly luciferase gene and implanted orthotopically in the lung of syngeneic mice. Bioluminescence imaging, flow cytometry, and immunohistochemistry were employed to determine response to immunotherapy and function of tumor-infiltrating immune cells. RESULTS: For lung cancer patients treated with anti-PD-1/PD-L1 antibodies, poor lymphocyte recovery was associated with a shorter progression-free survival (PFS; P < 0.001), an accumulation of regulatory T cells (Tregs), and an elimination of CD8 CONCLUSIONS: Lung cancer patients with poor lymphocyte recovery and suffering from persistent lymphopenia after previous chemotherapy are resistant to anti-PD-1/PD-L1 antibodies but might be sensitive to second-generation agents such as SHR-1701.",
    "journal": "Cancer communications (London, England)",
    "pub_date": "2022-Jan",
    "doi": "10.1002/cac2.12244",
    "pmid": "34981670",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Animals",
      "B7-H1 Antigen",
      "CD8-Positive T-Lymphocytes",
      "Humans",
      "Immune Checkpoint Inhibitors",
      "Lung Neoplasms",
      "Mice",
      "Programmed Cell Death 1 Receptor"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/34981670/",
    "summary_ja": "本研究は、肺がんにおいてPD-1/PD-L1阻害薬に抵抗性だがPD-L1/TGF-βR二重阻害（SHR-1701など）に感受性を示し得る患者の予測因子を探索した。PD-1/PD-L1抗体治療を受けた肺がん患者の解析では、リンパ球減少後のリンパ球回復不良が無増悪生存期間（PFS）の短縮と関連し、制御性T細胞の増加やCD8陽性T細胞機能の低下を伴った。さらに同系マウス肺がんモデルで免疫療法反応と腫瘍浸潤免疫細胞の機能を評価し、回復不良に伴う免疫抑制状態がPD-1/PD-L1阻害薬抵抗性に関与することを支持した。結論として、化学療法後に持続するリンパ球減少とリンパ球回復不良を有する患者はPD-1/PD-L1阻害薬には抵抗性だが、SHR-1701のような二重阻害薬の候補となり得る。",
    "evidence_level": "2b"
  },
  {
    "paper_id": "pubmed:26997480",
    "source": "pubmed",
    "source_id": "26997480",
    "title": "Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.",
    "year": 2016,
    "authors": [
      "Hugo Willy",
      "Zaretsky Jesse M",
      "Sun Lu",
      "Song Chunying",
      "Moreno Blanca Homet",
      "Hu-Lieskovan Siwen",
      "Berent-Maoz Beata",
      "Pang Jia",
      "Chmielowski Bartosz",
      "Cherry Grace",
      "Seja Elizabeth",
      "Lomeli Shirley",
      "Kong Xiangju",
      "Kelley Mark C",
      "Sosman Jeffrey A",
      "Johnson Douglas B",
      "Ribas Antoni",
      "Lo Roger S"
    ],
    "abstract": "PD-1 immune checkpoint blockade provides significant clinical benefits for melanoma patients. We analyzed the somatic mutanomes and transcriptomes of pretreatment melanoma biopsies to identify factors that may influence innate sensitivity or resistance to anti-PD-1 therapy. We find that overall high mutational loads associate with improved survival, and tumors from responding patients are enriched for mutations in the DNA repair gene BRCA2. Innately resistant tumors display a transcriptional signature (referred to as the IPRES, or innate anti-PD-1 resistance), indicating concurrent up-expression of genes involved in the regulation of mesenchymal transition, cell adhesion, extracellular matrix remodeling, angiogenesis, and wound healing. Notably, mitogen-activated protein kinase (MAPK)-targeted therapy (MAPK inhibitor) induces similar signatures in melanoma, suggesting that a non-genomic form of MAPK inhibitor resistance mediates cross-resistance to anti-PD-1 therapy. Validation of the IPRES in other independent tumor cohorts defines a transcriptomic subset across distinct types of advanced cancer. These findings suggest that attenuating the biological processes that underlie IPRES may improve anti-PD-1 response in melanoma and other cancer types.",
    "journal": "Cell",
    "pub_date": "2016-Mar",
    "doi": "10.1016/j.cell.2016.02.065",
    "pmid": "26997480",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Antibodies, Monoclonal",
      "Antibodies, Monoclonal, Humanized",
      "Antineoplastic Agents",
      "BRCA2 Protein",
      "Drug Resistance, Neoplasm",
      "Humans",
      "MAP Kinase Signaling System",
      "Melanoma",
      "Neoplasm Metastasis",
      "Nivolumab",
      "Programmed Cell Death 1 Receptor",
      "Transcriptome"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/26997480/",
    "summary_ja": "本研究は、転移性メラノーマに対する抗PD-1療法の奏効/抵抗性に関わる要因を、治療前生検の体細胞変異（mutanome）とトランスクリプトーム解析から探索した。高い変異負荷は生存改善と関連し、奏効例の腫瘍ではDNA修復遺伝子BRCA2の変異が相対的に多かった。先天的抵抗性腫瘍では、間葉系転換、細胞接着、細胞外マトリックス改変、血管新生、創傷治癒に関わる遺伝子群の同時上昇からなるIPRES（innate anti-PD-1 resistance）という転写シグネチャを示した。MAPK阻害薬治療が類似シグネチャを誘導し得ること、またIPRESが独立コホートや他がん種でも検証されることから、IPRES基盤の生物学的過程を抑える介入が抗PD-1反応性改善につながる可能性が示唆された。",
    "evidence_level": "2b"
  },
  {
    "paper_id": "pubmed:40925954",
    "source": "pubmed",
    "source_id": "40925954",
    "title": "CD160 dictates anti-PD-1 immunotherapy resistance by regulating CD8",
    "year": 2025,
    "authors": [
      "Zheng Tongsen",
      "Ding Chujie",
      "Lai Shihui",
      "Gao Yang",
      "Lyu Cheng",
      "Liu Caiqi",
      "Shi Jiaqi",
      "Li Xiaobo",
      "Li Mingwei",
      "Meng Hongxue",
      "Li Mingqi",
      "Liang Yingjian",
      "Tai Sheng",
      "Cheng Liang",
      "Zhang Yan",
      "Li Li",
      "Han Peng",
      "Sun Bin",
      "Liu Te",
      "Geng Feng",
      "Hao Dapeng",
      "Zhang Xue"
    ],
    "abstract": "The colon exhibits higher propensity for tumour development than ileum. However, the role of immune microenvironment differences in driving this disparity remains unclear. Here, by comparing paired ileum and colon samples from patients with colorectal cancer (CRC) and healthy donors, we identified ileum-enriched CD160",
    "journal": "Nature cell biology",
    "pub_date": "2025-Sep",
    "doi": "10.1038/s41556-025-01753-3",
    "pmid": "40925954",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Colorectal Neoplasms",
      "Humans",
      "CD8-Positive T-Lymphocytes",
      "Programmed Cell Death 1 Receptor",
      "Animals",
      "Antigens, CD",
      "Drug Resistance, Neoplasm",
      "Mice",
      "GPI-Linked Proteins",
      "Tumor Microenvironment",
      "Immune Checkpoint Inhibitors",
      "Immunotherapy",
      "Cell Line, Tumor",
      "Mice, Inbred C57BL",
      "Lymphocytes, Tumor-Infiltrating",
      "Female",
      "Signal Transduction",
      "Receptors, Immunologic",
      "Mice, Knockout",
      "Male",
      "T-Cell Exhaustion"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/40925954/",
    "summary_ja": "結腸は回腸より腫瘍が発生しやすいが、その差を生む免疫微小環境の違いは十分に分かっていない。著者らは大腸がん患者および健常ドナーから得た回腸・結腸のペア検体を比較し、回腸で豊富なCD160陽性免疫集団を同定した。本研究は、部位差に関連する免疫環境の特徴を明らかにし、免疫療法抵抗性（抗PD-1抵抗性）に関与し得る分子としてCD160に着目している（ただし抄録が途中であり結論の詳細は不明）。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:39842432",
    "source": "pubmed",
    "source_id": "39842432",
    "title": "MFGE8 induces anti-PD-1 therapy resistance by promoting extracellular vesicle sorting of PD-L1.",
    "year": 2025,
    "authors": [
      "Wang Wenhui",
      "Chen Jiming",
      "Wang Shibo",
      "Sun Xinhai",
      "Yang Jie",
      "Yu Pengfei",
      "Hu Guinv",
      "Wang Jiang",
      "Zhang Jing",
      "Qiao Shuya",
      "Wang Jianli",
      "Zhang Gensheng",
      "He Yuzhou",
      "Feng Huajun",
      "Cai Zhijian"
    ],
    "abstract": "Anti-PD-1 therapy, effective in patients with various advanced tumors, still encounters the challenge of insensitivity in most patients. Here, we demonstrate that PD-L1 on tumor cell-derived extracellular vesicles (TEVs) is critical for anti-PD-1 therapy resistance. Reducing endogenous and transferring exogenous TEVs abrogates and induces anti-PD-1 therapy resistance, respectively. Notably, PD-L1 is sorted onto TEVs via the endosomal sorting complex required for transport after ubiquitination by UBE4A and gradually upregulated on TEVs with tumor progression. During progression, increased MFGE8 from tumor cells promotes self α",
    "journal": "Cell reports. Medicine",
    "pub_date": "2025-Feb",
    "doi": "10.1016/j.xcrm.2024.101922",
    "pmid": "39842432",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Humans",
      "B7-H1 Antigen",
      "Extracellular Vesicles",
      "Drug Resistance, Neoplasm",
      "Cell Line, Tumor",
      "Programmed Cell Death 1 Receptor",
      "Animals",
      "Mice",
      "Ubiquitination",
      "Female",
      "Neoplasms",
      "Immune Checkpoint Inhibitors",
      "Endosomal Sorting Complexes Required for Transport",
      "Male"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/39842432/",
    "summary_ja": "本研究は、腫瘍細胞由来の細胞外小胞（TEVs）上に存在するPD-L1が、抗PD-1療法抵抗性の形成に重要であることを示した。内因性TEVsを減らすと抵抗性が低下し、外因性TEVsを移入すると抵抗性が誘導されることから、TEVsが抵抗性を媒介する因果的役割を持つ可能性が示唆される。PD-L1はUBE4Aによるユビキチン化後、ESCRT機構を介してTEVsへ選別され、腫瘍進行に伴いTEVs上のPD-L1が段階的に増加する。さらに腫瘍細胞由来MFGE8の増加がこの過程を促進し、抗PD-1療法抵抗性に寄与することが示される。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:38900877",
    "source": "pubmed",
    "source_id": "38900877",
    "title": "Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients.",
    "year": 2024,
    "authors": [
      "Mathew Divij",
      "Marmarelis Melina E",
      "Foley Caitlin",
      "Bauml Joshua M",
      "Ye Darwin",
      "Ghinnagow Reem",
      "Ngiow Shin Foong",
      "Klapholz Max",
      "Jun Soyeong",
      "Zhang Zhaojun",
      "Zorc Robert",
      "Davis Christiana W",
      "Diehn Maximillian",
      "Giles Josephine R",
      "Huang Alexander C",
      "Hwang Wei-Ting",
      "Zhang Nancy R",
      "Schoenfeld Adam J",
      "Carpenter Erica L",
      "Langer Corey J",
      "Wherry E John",
      "Minn Andy J"
    ],
    "abstract": "Persistent inflammation driven by cytokines such as type-one interferon (IFN-I) can cause immunosuppression. We show that administration of the Janus kinase 1 (JAK1) inhibitor itacitinib after anti-PD-1 (programmed cell death protein 1) immunotherapy improves immune function and antitumor responses in mice and results in high response rates (67%) in a phase 2 clinical trial for metastatic non-small cell lung cancer. Patients who failed to respond to initial anti-PD-1 immunotherapy but responded after addition of itacitinib had multiple features of poor immune function to anti-PD-1 alone that improved after JAK inhibition. Itacitinib promoted CD8 T cell plasticity and therapeutic responses of exhausted and effector memory-like T cell clonotypes. Patients with persistent inflammation refractory to itacitinib showed progressive CD8 T cell terminal differentiation and progressive disease. Thus, JAK inhibition may improve the efficacy of anti-PD-1 immunotherapy by pivoting T cell differentiation dynamics.",
    "journal": "Science (New York, N.Y.)",
    "pub_date": "2024-Jun",
    "doi": "10.1126/science.adf1329",
    "pmid": "38900877",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Animals",
      "Female",
      "Humans",
      "Mice",
      "Carcinoma, Non-Small-Cell Lung",
      "CD8-Positive T-Lymphocytes",
      "Immune Checkpoint Inhibitors",
      "Immunotherapy",
      "Janus Kinase 1",
      "Janus Kinase Inhibitors",
      "Lung Neoplasms",
      "Programmed Cell Death 1 Receptor"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/38900877/",
    "summary_ja": "持続的なサイトカイン炎症（特にI型IFN）による免疫抑制に着目し、抗PD-1療法後にJAK1阻害薬イタシチニブを追加すると、マウスで免疫機能と抗腫瘍効果が改善することを示した。転移性非小細胞肺癌の第2相試験では、イタシチニブ追加により高い奏効率（67%）が報告された。抗PD-1単独で無効だったが追加後に奏効した患者では、免疫機能低下の特徴がJAK阻害で改善し、CD8 T細胞の可塑性や疲弊/エフェクターメモリー様クローンの治療反応が促進された。一方、炎症がイタシチニブに抵抗性の患者ではCD8 T細胞の終末分化が進み、病勢進行と関連した。",
    "evidence_level": "4"
  },
  {
    "paper_id": "pubmed:40563015",
    "source": "pubmed",
    "source_id": "40563015",
    "title": "Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial.",
    "year": 2025,
    "authors": [
      "Wu Song-Yang",
      "Jin Xi",
      "Liu Yin",
      "Wang Zi-Yu",
      "Zuo Wen-Jia",
      "Ma Ding",
      "Xiao Yi",
      "Fu Tong",
      "Xiao Yu-Ling",
      "Chen Li",
      "Liu Xi-Yu",
      "Fan Lei",
      "Wang Zhong-Hua",
      "Shen Minhong",
      "Liu Ronghua",
      "Chai Wen-Jun",
      "Shao Zhi-Ming",
      "Jiang Yi-Zhou"
    ],
    "abstract": "The central challenge in triple-negative breast cancer (TNBC) immunotherapy is to identify novel mechanism-derived strategies for anti-programmed death-1 (PD-1) resistance and efficiently assess their efficacy and safety in humans. Understanding the intricate heterogeneity of the tumor microenvironment and its impact on treatment could guide the initiation of proof-of-concept clinical trials. Here, integrating single-cell transcriptome of 44 treatment-naive patients with TNBC, we unveiled an association between intrapatient mast cell heterogeneity and clinical benefit of PD-1 blockade. Upon independent parallel validation in 484 patients with TNBC, high levels of breast tissue antigen-presenting mast cells (apMCs) were associated with enhanced anti-PD-1 efficacy. Mechanistically, apMCs largely located within tertiary lymphoid structures and were efficient in performing presentation and cross-presentation of antigens and expressed co-stimulatory molecules. Conditional deletion of antigen-presenting machinery in mast cells dampened tumor-reactive T cells. A widely prescribed allergy medication, cromolyn, was identified to mobilize apMC-mediated T cell immunity and sensitize tumors to PD-1 blockade. We subsequently initiated a phase 2 clinical trial in female patients with anti-PD-1-refractory metastatic TNBC. Here we report the results of the cromolyn arm (cromolyn plus anti-PD-1 backbone). The prespecified primary endpoint of this arm was met, with a confirmed objective response rate of 50.0%. Our study defines a crucial role of mast cells in cancer immune control, identifies an apMC-directed approach to overcome anti-PD-1 resistance and highlights a reverse-translational framework that offers conceptual advances in precision immuno-oncology with direct implications for clinical therapy. ClinicalTrials.gov identifier: NCT05076682 .",
    "journal": "Nature medicine",
    "pub_date": "2025-Jul",
    "doi": "10.1038/s41591-025-03776-7",
    "pmid": "40563015",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Humans",
      "Triple Negative Breast Neoplasms",
      "Mast Cells",
      "Female",
      "Programmed Cell Death 1 Receptor",
      "Antigen-Presenting Cells",
      "Tumor Microenvironment",
      "Immune Checkpoint Inhibitors",
      "Middle Aged",
      "Immunotherapy",
      "Drug Resistance, Neoplasm",
      "Mice",
      "T-Lymphocytes",
      "Adult",
      "Animals",
      "Single-Cell Analysis"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/40563015/",
    "summary_ja": "TNBCにおける抗PD-1抵抗性の機序に基づく新規戦略として、腫瘍内の抗原提示能をもつマスト細胞（apMCs）に着目した研究である。治療未施行TNBC患者の単一細胞解析でマスト細胞の不均一性とPD-1阻害の臨床的利益の関連を示し、独立コホートでapMCs高値が抗PD-1効果の増強と関連することを検証した。apMCsは三次リンパ様構造に局在し、抗原提示・交差提示や共刺激分子発現を通じて腫瘍反応性T細胞を支えることが示唆された。抗アレルギー薬クロモグリク酸（cromolyn）がapMCsを介した免疫を動員しPD-1阻害への感受性を高める可能性が示され、抗PD-1不応の転移性TNBC女性を対象とした第2相試験のcromolyn併用アームで主要評価項目を達成し、確認奏効率50%を報告した。",
    "evidence_level": "2b"
  },
  {
    "paper_id": "pubmed:28650338",
    "source": "pubmed",
    "source_id": "28650338",
    "title": "IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.",
    "year": 2017,
    "authors": [
      "Ayers Mark",
      "Lunceford Jared",
      "Nebozhyn Michael",
      "Murphy Erin",
      "Loboda Andrey",
      "Kaufman David R",
      "Albright Andrew",
      "Cheng Jonathan D",
      "Kang S Peter",
      "Shankaran Veena",
      "Piha-Paul Sarina A",
      "Yearley Jennifer",
      "Seiwert Tanguy Y",
      "Ribas Antoni",
      "McClanahan Terrill K"
    ],
    "abstract": "Programmed death-1-directed (PD-1-directed) immune checkpoint blockade results in durable antitumor activity in many advanced malignancies. Recent studies suggest that IFN-γ is a critical driver of programmed death ligand-1 (PD-L1) expression in cancer and host cells, and baseline intratumoral T cell infiltration may improve response likelihood to anti-PD-1 therapies, including pembrolizumab. However, whether quantifying T cell-inflamed microenvironment is a useful pan-tumor determinant of PD-1-directed therapy response has not been rigorously evaluated. Here, we analyzed gene expression profiles (GEPs) using RNA from baseline tumor samples of pembrolizumab-treated patients. We identified immune-related signatures correlating with clinical benefit using a learn-and-confirm paradigm based on data from different clinical studies of pembrolizumab, starting with a small pilot of 19 melanoma patients and eventually defining a pan-tumor T cell-inflamed GEP in 220 patients with 9 cancers. Predictive value was independently confirmed and compared with that of PD-L1 immunohistochemistry in 96 patients with head and neck squamous cell carcinoma. The T cell-inflamed GEP contained IFN-γ-responsive genes related to antigen presentation, chemokine expression, cytotoxic activity, and adaptive immune resistance, and these features were necessary, but not always sufficient, for clinical benefit. The T cell-inflamed GEP has been developed into a clinical-grade assay that is currently being evaluated in ongoing pembrolizumab trials.",
    "journal": "The Journal of clinical investigation",
    "pub_date": "2017-Aug",
    "doi": "10.1172/JCI91190",
    "pmid": "28650338",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Antibodies, Monoclonal, Humanized",
      "Antineoplastic Agents",
      "B7-H1 Antigen",
      "Biopsy",
      "Carcinoma",
      "Carcinoma, Non-Small-Cell Lung",
      "Gene Expression Profiling",
      "Gene Expression Regulation, Neoplastic",
      "Humans",
      "Immune System",
      "Immunohistochemistry",
      "Interferon-gamma",
      "Lung Neoplasms",
      "Melanoma",
      "Pilot Projects",
      "Programmed Cell Death 1 Receptor",
      "ROC Curve",
      "Sequence Analysis, RNA",
      "Signal Transduction",
      "Skin Neoplasms",
      "Stomach Neoplasms",
      "Treatment Outcome",
      "Tumor Microenvironment"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/28650338/",
    "summary_ja": "PD-1阻害（ペムブロリズマブ）治療に対する反応性を、治療前腫瘍の遺伝子発現プロファイルから予測できるかを検討した研究である。19例のメラノーマでの探索から出発し、9がん種220例のデータで腫瘍内T細胞炎症（T cell-inflamed）GEPを定義し、臨床的有益性と相関する免疫関連シグネチャを同定した。頭頸部扁平上皮がん96例で独立検証し、PD-L1免疫染色との比較も行い、IFN-γ応答遺伝子（抗原提示、ケモカイン、細胞傷害、適応免疫抵抗など）を含むGEPが有用な予測指標になり得ることを示した。一方で、これらの特徴は臨床的有益性に必要だが十分条件ではない可能性が示唆され、臨床グレードの検査として試験評価が進められている。",
    "evidence_level": "2b"
  },
  {
    "paper_id": "pubmed:33542131",
    "source": "pubmed",
    "source_id": "33542131",
    "title": "Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients.",
    "year": 2021,
    "authors": [
      "Davar Diwakar",
      "Dzutsev Amiran K",
      "McCulloch John A",
      "Rodrigues Richard R",
      "Chauvin Joe-Marc",
      "Morrison Robert M",
      "Deblasio Richelle N",
      "Menna Carmine",
      "Ding Quanquan",
      "Pagliano Ornella",
      "Zidi Bochra",
      "Zhang Shuowen",
      "Badger Jonathan H",
      "Vetizou Marie",
      "Cole Alicia M",
      "Fernandes Miriam R",
      "Prescott Stephanie",
      "Costa Raquel G F",
      "Balaji Ascharya K",
      "Morgun Andrey",
      "Vujkovic-Cvijin Ivan",
      "Wang Hong",
      "Borhani Amir A",
      "Schwartz Marc B",
      "Dubner Howard M",
      "Ernst Scarlett J",
      "Rose Amy",
      "Najjar Yana G",
      "Belkaid Yasmine",
      "Kirkwood John M",
      "Trinchieri Giorgio",
      "Zarour Hassane M"
    ],
    "abstract": "Anti-programmed cell death protein 1 (PD-1) therapy provides long-term clinical benefits to patients with advanced melanoma. The composition of the gut microbiota correlates with anti-PD-1 efficacy in preclinical models and cancer patients. To investigate whether resistance to anti-PD-1 can be overcome by changing the gut microbiota, this clinical trial evaluated the safety and efficacy of responder-derived fecal microbiota transplantation (FMT) together with anti-PD-1 in patients with PD-1-refractory melanoma. This combination was well tolerated, provided clinical benefit in 6 of 15 patients, and induced rapid and durable microbiota perturbation. Responders exhibited increased abundance of taxa that were previously shown to be associated with response to anti-PD-1, increased CD8",
    "journal": "Science (New York, N.Y.)",
    "pub_date": "2021-Feb",
    "doi": "10.1126/science.abf3363",
    "pmid": "33542131",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Antibodies, Monoclonal, Humanized",
      "Antineoplastic Agents, Immunological",
      "CD8-Positive T-Lymphocytes",
      "Drug Resistance, Neoplasm",
      "Fecal Microbiota Transplantation",
      "Gastrointestinal Microbiome",
      "Humans",
      "Interleukin-8",
      "Lymphocyte Activation",
      "Lymphocytes, Tumor-Infiltrating",
      "Melanoma",
      "Myeloid Cells",
      "Programmed Cell Death 1 Receptor",
      "Skin Neoplasms",
      "Tumor Microenvironment"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/33542131/",
    "summary_ja": "本研究は、抗PD-1療法に抵抗性となった進行メラノーマ患者に対し、奏効者由来の糞便微生物叢移植（FMT）を抗PD-1と併用することで抵抗性を克服できるかを検討した臨床試験である。併用療法は忍容性が良好で、15例中6例で臨床的有益性が認められた。さらに、腸内細菌叢は迅速かつ持続的に変化し、奏効例では抗PD-1反応性と関連するとされる菌群の増加や免疫応答の変化が示唆された。",
    "evidence_level": "2b"
  },
  {
    "paper_id": "pubmed:22658127",
    "source": "pubmed",
    "source_id": "22658127",
    "title": "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.",
    "year": 2012,
    "authors": [
      "Topalian Suzanne L",
      "Hodi F Stephen",
      "Brahmer Julie R",
      "Gettinger Scott N",
      "Smith David C",
      "McDermott David F",
      "Powderly John D",
      "Carvajal Richard D",
      "Sosman Jeffrey A",
      "Atkins Michael B",
      "Leming Philip D",
      "Spigel David R",
      "Antonia Scott J",
      "Horn Leora",
      "Drake Charles G",
      "Pardoll Drew M",
      "Chen Lieping",
      "Sharfman William H",
      "Anders Robert A",
      "Taube Janis M",
      "McMiller Tracee L",
      "Xu Haiying",
      "Korman Alan J",
      "Jure-Kunkel Maria",
      "Agrawal Shruti",
      "McDonald Daniel",
      "Kollia Georgia D",
      "Gupta Ashok",
      "Wigginton Jon M",
      "Sznol Mario"
    ],
    "abstract": "BACKGROUND: Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance. We assessed the antitumor activity and safety of BMS-936558, an antibody that specifically blocks PD-1. METHODS: We enrolled patients with advanced melanoma, non-small-cell lung cancer, castration-resistant prostate cancer, or renal-cell or colorectal cancer to receive anti-PD-1 antibody at a dose of 0.1 to 10.0 mg per kilogram of body weight every 2 weeks. Response was assessed after each 8-week treatment cycle. Patients received up to 12 cycles until disease progression or a complete response occurred. RESULTS: A total of 296 patients received treatment through February 24, 2012. Grade 3 or 4 drug-related adverse events occurred in 14% of patients; there were three deaths from pulmonary toxicity. No maximum tolerated dose was defined. Adverse events consistent with immune-related causes were observed. Among 236 patients in whom response could be evaluated, objective responses (complete or partial responses) were observed in those with non-small-cell lung cancer, melanoma, or renal-cell cancer. Cumulative response rates (all doses) were 18% among patients with non-small-cell lung cancer (14 of 76 patients), 28% among patients with melanoma (26 of 94 patients), and 27% among patients with renal-cell cancer (9 of 33 patients). Responses were durable; 20 of 31 responses lasted 1 year or more in patients with 1 year or more of follow-up. To assess the role of intratumoral PD-1 ligand (PD-L1) expression in the modulation of the PD-1-PD-L1 pathway, immunohistochemical analysis was performed on pretreatment tumor specimens obtained from 42 patients. Of 17 patients with PD-L1-negative tumors, none had an objective response; 9 of 25 patients (36%) with PD-L1-positive tumors had an objective response (P=0.006). CONCLUSIONS: Anti-PD-1 antibody produced objective responses in approximately one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse-event profile does not appear to preclude its use. Preliminary data suggest a relationship between PD-L1 expression on tumor cells and objective response. (Funded by Bristol-Myers Squibb and others; ClinicalTrials.gov number, NCT00730639.).",
    "journal": "The New England journal of medicine",
    "pub_date": "2012-Jun",
    "doi": "10.1056/NEJMoa1200690",
    "pmid": "22658127",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Adult",
      "Antibodies, Monoclonal",
      "Antineoplastic Agents",
      "Carcinoma, Non-Small-Cell Lung",
      "Carcinoma, Renal Cell",
      "Colorectal Neoplasms",
      "Dose-Response Relationship, Drug",
      "Female",
      "Humans",
      "Ligands",
      "Male",
      "Melanoma",
      "Neoplasms",
      "Nivolumab",
      "Programmed Cell Death 1 Receptor",
      "Prostatic Neoplasms"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/22658127/",
    "summary_ja": "本研究は、進行固形がん患者（悪性黒色腫、非小細胞肺がん、腎細胞がんなど）に対して抗PD-1抗体BMS-936558を2週ごとに投与し、安全性と抗腫瘍活性を評価した単群試験である。296例でGrade 3/4の薬剤関連有害事象は14%に認められ、免疫関連有害事象や肺毒性による死亡が3例報告された。評価可能な236例中、非小細胞肺がん18%、悪性黒色腫28%、腎細胞がん27%で客観的奏効がみられ、奏効は長期に持続する例があった。さらに前治療腫瘍のPD-L1発現は奏効と関連し、PD-L1陰性では奏効0%、陽性では36%が奏効した。",
    "evidence_level": "4"
  },
  {
    "paper_id": "pubmed:38969879",
    "source": "pubmed",
    "source_id": "38969879",
    "title": "Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial.",
    "year": 2024,
    "authors": [
      "Mo Hongnan",
      "Yu Yongpei",
      "Sun Xiaoying",
      "Ge Hewei",
      "Yu Lanlan",
      "Guan Xiuwen",
      "Zhai Jingtong",
      "Zhu Aihua",
      "Wei Yuhan",
      "Wang Jinjing",
      "Yan Xiaoyan",
      "Qian Haili",
      "Xu Binghe",
      "Ma Fei"
    ],
    "abstract": "It remains unclear whether metronomic chemotherapy is superior to conventional chemotherapy when combined with immune checkpoint blockade. Here we performed a phase 2 clinical trial of metronomic chemotherapy combined with PD-1 blockade to compare the efficacy of combined conventional chemotherapy and PD-1 blockade using Bayesian adaptive randomization and efficacy monitoring. Eligible patients had metastatic HER2-negative breast cancer and had not received more than one prior line of standard chemotherapy. Patients (total n = 97) were randomized to receive (1) metronomic vinorelbine (NVB) monotherapy (n = 11), (2) NVB plus anti-PD-1 toripalimab (n = 7), (3) anti-angiogenic bevacizumab, NVB and toripalimab (n = 27), (4) conventional cisplatin, NVB and toripalimab (n = 26), or (5) metronomic cyclophosphamide, capecitabine, NVB and toripalimab (the VEX cohort) (n = 26). The primary endpoint was disease control rate (DCR). Secondary objectives included progression-free survival (PFS) and safety. The study met the primary endpoint. The VEX (69.7%) and cisplatin (73.7%) cohorts had the highest DCR. The median PFS of patients in the VEX cohort was the longest, reaching 6.6 months, followed by the bevacizumab (4.0 months) and cisplatin (3.5 months) cohorts. In general, the five regimens were well tolerated, with nausea and neutropenia being the most common adverse events. An exploratory mass cytometry analysis indicated that metronomic VEX chemotherapy reprograms the systemic immune response. Together, the clinical and translational data of this study indicate that metronomic VEX chemotherapy combined with PD-1 blockade can be a treatment option in patients with breast cancer. ClinicalTrials.gov Identifier: NCT04389073 .",
    "journal": "Nature medicine",
    "pub_date": "2024-Sep",
    "doi": "10.1038/s41591-024-03088-2",
    "pmid": "38969879",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Humans",
      "Female",
      "Breast Neoplasms",
      "Administration, Metronomic",
      "Middle Aged",
      "Bayes Theorem",
      "Programmed Cell Death 1 Receptor",
      "Antineoplastic Combined Chemotherapy Protocols",
      "Adult",
      "Aged",
      "Neoplasm Metastasis",
      "Cyclophosphamide",
      "Immune Checkpoint Inhibitors",
      "Vinorelbine",
      "Bevacizumab"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/38969879/",
    "summary_ja": "転移性HER2陰性乳癌患者を対象に、メトロノミック化学療法＋抗PD-1（トリパリマブ）を、従来型化学療法＋抗PD-1を含む複数レジメンと比較したベイズ適応ランダム化第2相試験（n=97）である。主要評価項目の病勢コントロール率（DCR）は試験として達成され、VEX（メトロノミック：シクロホスファミド＋カペシタビン＋ビノレルビン＋トリパリマブ）とシスプラチン併用群が高いDCRを示した。無増悪生存期間（PFS）はVEX群が最長で中央値6.6か月であった。安全性は概ね許容範囲で、悪心と好中球減少が主な有害事象であり、探索的免疫解析ではVEXが全身免疫応答を再プログラムする可能性が示唆された。",
    "evidence_level": "2b"
  },
  {
    "paper_id": "pubmed:34715028",
    "source": "pubmed",
    "source_id": "34715028",
    "title": "Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma.",
    "year": 2021,
    "authors": [
      "Au Lewis",
      "Hatipoglu Emine",
      "Robert de Massy Marc",
      "Litchfield Kevin",
      "Beattie Gordon",
      "Rowan Andrew",
      "Schnidrig Desiree",
      "Thompson Rachael",
      "Byrne Fiona",
      "Horswell Stuart",
      "Fotiadis Nicos",
      "Hazell Steve",
      "Nicol David",
      "Shepherd Scott T C",
      "Fendler Annika",
      "Mason Robert",
      "Del Rosario Lyra",
      "Edmonds Kim",
      "Lingard Karla",
      "Sarker Sarah",
      "Mangwende Mary",
      "Carlyle Eleanor",
      "Attig Jan",
      "Joshi Kroopa",
      "Uddin Imran",
      "Becker Pablo D",
      "Sunderland Mariana Werner",
      "Akarca Ayse",
      "Puccio Ignazio",
      "Yang William W",
      "Lund Tom",
      "Dhillon Kim",
      "Vasquez Marcos Duran",
      "Ghorani Ehsan",
      "Xu Hang",
      "Spencer Charlotte",
      "López José I",
      "Green Anna",
      "Mahadeva Ula",
      "Borg Elaine",
      "Mitchison Miriam",
      "Moore David A",
      "Proctor Ian",
      "Falzon Mary",
      "Pickering Lisa",
      "Furness Andrew J S",
      "Reading James L",
      "Salgado Roberto",
      "Marafioti Teresa",
      "Jamal-Hanjani Mariam",
      "Kassiotis George",
      "Chain Benny",
      "Larkin James",
      "Swanton Charles",
      "Quezada Sergio A",
      "Turajlic Samra"
    ],
    "abstract": "ADAPTeR is a prospective, phase II study of nivolumab (anti-PD-1) in 15 treatment-naive patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma (ccRCC) aiming to understand the mechanism underpinning therapeutic response. Genomic analyses show no correlation between tumor molecular features and response, whereas ccRCC-specific human endogenous retrovirus expression indirectly correlates with clinical response. T cell receptor (TCR) analysis reveals a significantly higher number of expanded TCR clones pre-treatment in responders suggesting pre-existing immunity. Maintenance of highly similar clusters of TCRs post-treatment predict response, suggesting ongoing antigen engagement and survival of families of T cells likely recognizing the same antigens. In responders, nivolumab-bound CD8",
    "journal": "Cancer cell",
    "pub_date": "2021-Nov",
    "doi": "10.1016/j.ccell.2021.10.001",
    "pmid": "34715028",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "CD8-Positive T-Lymphocytes",
      "Carcinoma, Renal Cell",
      "Clinical Trials, Phase II as Topic",
      "Drug Resistance, Neoplasm",
      "Endogenous Retroviruses",
      "Gene Expression Profiling",
      "Genomics",
      "Humans",
      "Immune Checkpoint Inhibitors",
      "Kidney Neoplasms",
      "Nivolumab",
      "Prospective Studies",
      "Receptors, Antigen, T-Cell",
      "Sequence Analysis, RNA",
      "Single-Cell Analysis",
      "Tumor Escape",
      "Tumor Microenvironment",
      "Exome Sequencing"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/34715028/",
    "summary_ja": "本研究は、転移性淡明細胞型腎細胞癌（ccRCC）の未治療患者15例を対象にニボルマブ（抗PD-1）の反応・抵抗性機序を解析した前向き第II相試験（多領域腫瘍サンプル115検体）である。ゲノム解析では腫瘍の分子特徴と臨床反応の明確な相関は示されなかった一方、ccRCC特異的なヒト内在性レトロウイルス発現が間接的に反応と関連した。TCR解析では、治療前から拡大したTCRクローンが多いことが奏効例で有意に多く、既存免疫の存在が示唆された。さらに治療後も類似したTCRクラスターが維持されることが反応予測に有用で、抗原刺激の継続と同一抗原を認識するT細胞ファミリーの生存が関与する可能性が示された。",
    "evidence_level": "2b"
  },
  {
    "paper_id": "pubmed:33783228",
    "source": "pubmed",
    "source_id": "33783228",
    "title": "Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials.",
    "year": 2021,
    "authors": [
      "Sonpavde Guru P",
      "Grivas Petros",
      "Lin Yushun",
      "Hennessy Daniel",
      "Hunt Jay D"
    ],
    "abstract": "",
    "journal": "Future oncology (London, England)",
    "pub_date": "2021-Jul",
    "doi": "10.2217/fon-2020-1222",
    "pmid": "33783228",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "B7-H1 Antigen",
      "Clinical Trials as Topic",
      "Drug-Related Side Effects and Adverse Reactions",
      "Humans",
      "Immune Checkpoint Inhibitors",
      "Incidence",
      "Neoplasms",
      "Programmed Cell Death 1 Receptor",
      "Risk Assessment",
      "Severity of Illness Index"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/33783228/",
    "summary_ja": "（アブストラクト未取得: Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials.）",
    "evidence_level": "N/A"
  },
  {
    "paper_id": "pubmed:31196207",
    "source": "pubmed",
    "source_id": "31196207",
    "title": "Combination of CTLA-4 and PD-1 blockers for treatment of cancer.",
    "year": 2019,
    "authors": [
      "Rotte Anand"
    ],
    "abstract": "Targeting checkpoints of immune cell activation has been demonstrated to be the most effective approach for activation of anti-tumor immune responses. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1), both inhibitory checkpoints commonly seen on activated T-cells have been found to be the most reliable targets for the treatment of cancer. Six drugs targeting PD-1 or its ligand PD-L1 and one drug targeting CTLA-4 have been approved for treatment of different types of cancers and several others are in advanced stages of development. The drugs when administered as monotherapy had dramatic increase in durable response rates and had manageable safety profile, but more than 50% of patients failed to respond to treatment. Combination of CTLA-4 and PD-1 blockers was then evaluated to increase the response rates in patients, and ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) combination was shown to significantly enhance efficacy in metastatic melanoma patients. Subsequently, ipilimumab plus nivolumab was approved for treatment of metastatic melanoma, advanced renal cell carcinoma and metastatic colorectal cancer with MMR/MSI-H aberrations. The success of combination encouraged multiple clinical studies in other cancer types. Efficacy of the combination has been shown in a number of published studies and is under evaluation in multiple ongoing studies. This review aims to support future research in combination immunotherapy by discussing the basic details of CTLA-4 and PD-1 pathways and the results from clinical studies that evaluated combination of CTLA-4 and PD-1/PD-L1 blockers.",
    "journal": "Journal of experimental & clinical cancer research : CR",
    "pub_date": "2019-Jun",
    "doi": "10.1186/s13046-019-1259-z",
    "pmid": "31196207",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Antineoplastic Agents, Immunological",
      "Antineoplastic Combined Chemotherapy Protocols",
      "CTLA-4 Antigen",
      "Clinical Trials as Topic",
      "Humans",
      "Molecular Targeted Therapy",
      "Neoplasms",
      "Programmed Cell Death 1 Receptor",
      "T-Lymphocytes",
      "Treatment Outcome"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/31196207/",
    "summary_ja": "がんに対する免疫チェックポイント阻害の中でも、CTLA-4とPD-1/PD-L1は有効性が高い標的として位置づけられている。単剤療法は奏効の持続や安全性の点で成果がある一方、半数以上が反応しない課題がある。そこでCTLA-4阻害（イピリムマブ）とPD-1阻害（ニボルマブ）の併用が検討され、転移性悪性黒色腫で有効性が有意に向上し、複数のがん種で承認・研究が進んでいる。本レビューは両経路の基礎と、併用療法を評価した臨床研究結果を概説し、今後の研究を支援することを目的としている。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:33883177",
    "source": "pubmed",
    "source_id": "33883177",
    "title": "Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors.",
    "year": 2021,
    "authors": [
      "Curigliano Giuseppe",
      "Gelderblom Hans",
      "Mach Nicolas",
      "Doi Toshihiko",
      "Tai David",
      "Forde Patrick M",
      "Sarantopoulos John",
      "Bedard Philippe L",
      "Lin Chia-Chi",
      "Hodi F Stephen",
      "Wilgenhof Sofie",
      "Santoro Armando",
      "Sabatos-Peyton Catherine A",
      "Longmire Tyler A",
      "Xyrafas Alexandros",
      "Sun Haiying",
      "Gutzwiller Sabine",
      "Manenti Luigi",
      "Naing Aung"
    ],
    "abstract": "PURPOSE: Sabatolimab (MBG453) and spartalizumab are mAbs that bind T-cell immunoglobulin domain and mucin domain-3 (TIM-3) and programmed death-1 (PD-1), respectively. This phase I/II study evaluated the safety and efficacy of sabatolimab, with or without spartalizumab, in patients with advanced solid tumors. PATIENTS AND METHODS: Primary objectives of the phase I/Ib part were to characterize the safety and estimate recommended phase II dose (RP2D) for future studies. Dose escalation was guided by a Bayesian (hierarchical) logistic regression model. Sabatolimab was administered intravenously, 20 to 1,200 mg, every 2 or 4 weeks (Q2W or Q4W). Spartalizumab was administered intravenously, 80 to 400 mg, Q2W or Q4W. RESULTS: Enrolled patients ( CONCLUSIONS: Sabatolimab plus spartalizumab was well tolerated and showed preliminary signs of antitumor activity. The RP2D for sabatolimab was selected as 800 mg Q4W (alternatively Q3W or Q2W schedules, based on modeling), with or without 400 mg spartalizumab Q4W.",
    "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
    "pub_date": "2021-Jul",
    "doi": "10.1158/1078-0432.CCR-20-4746",
    "pmid": "33883177",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Adult",
      "Aged",
      "Aged, 80 and over",
      "Female",
      "Humans",
      "Male",
      "Middle Aged",
      "Young Adult",
      "Antibodies, Monoclonal",
      "Antibodies, Monoclonal, Humanized",
      "Drug Combinations",
      "Hepatitis A Virus Cellular Receptor 2",
      "Immune Checkpoint Inhibitors",
      "Neoplasm Staging",
      "Neoplasms",
      "Programmed Cell Death 1 Receptor"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/33883177/",
    "summary_ja": "本研究は、進行固形腫瘍患者を対象に、抗TIM-3抗体サバトリマブ単剤または抗PD-1抗体スパルタリズマブとの併用の安全性と有効性を評価した第I/Ib相試験である。第I/Ibパートの主要目的は安全性の特性化と、将来の試験に向けた推奨第II相用量（RP2D）の推定であり、ベイズ型ロジスティック回帰モデルに基づく用量漸増が行われた。治療は静脈内投与で、サバトリマブは20〜1,200 mgを2週または4週ごと、スパルタリズマブは80〜400 mgを2週または4週ごとに投与した。結論として、併用療法は忍容性が良好で予備的な抗腫瘍活性の兆候が示され、サバトリマブのRP2Dは800 mgを4週ごと（モデルにより3週/2週スケジュールも代替案）とし、スパルタリズマブ併用時は400 mgを4週ごととされた。",
    "evidence_level": "4"
  },
  {
    "paper_id": "pubmed:20516446",
    "source": "pubmed",
    "source_id": "20516446",
    "title": "Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.",
    "year": 2010,
    "authors": [
      "Brahmer Julie R",
      "Drake Charles G",
      "Wollner Ira",
      "Powderly John D",
      "Picus Joel",
      "Sharfman William H",
      "Stankevich Elizabeth",
      "Pons Alice",
      "Salay Theresa M",
      "McMiller Tracee L",
      "Gilson Marta M",
      "Wang Changyu",
      "Selby Mark",
      "Taube Janis M",
      "Anders Robert",
      "Chen Lieping",
      "Korman Alan J",
      "Pardoll Drew M",
      "Lowy Israel",
      "Topalian Suzanne L"
    ],
    "abstract": "PURPOSE: Programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, may suppress antitumor immunity. This phase I study sought to determine the safety and tolerability of anti-PD-1 blockade in patients with treatment-refractory solid tumors and to preliminarily assess antitumor activity, pharmacodynamics, and immunologic correlates. PATIENTS AND METHODS: Thirty-nine patients with advanced metastatic melanoma, colorectal cancer (CRC), castrate-resistant prostate cancer, non-small-cell lung cancer (NSCLC), or renal cell carcinoma (RCC) received a single intravenous infusion of anti-PD-1 (MDX-1106) in dose-escalating six-patient cohorts at 0.3, 1, 3, or 10 mg/kg, followed by a 15-patient expansion cohort at 10 mg/kg. Patients with evidence of clinical benefit at 3 months were eligible for repeated therapy. RESULTS: Anti-PD-1 was well tolerated: one serious adverse event, inflammatory colitis, was observed in a patient with melanoma who received five doses at 1 mg/kg. One durable complete response (CRC) and two partial responses (PRs; melanoma, RCC) were seen. Two additional patients (melanoma, NSCLC) had significant lesional tumor regressions not meeting PR criteria. The serum half-life of anti-PD-1 was 12 to 20 days. However, pharmacodynamics indicated a sustained mean occupancy of > 70% of PD-1 molecules on circulating T cells > or = 2 months following infusion, regardless of dose. In nine patients examined, tumor cell surface B7-H1 expression appeared to correlate with the likelihood of response to treatment. CONCLUSION: Blocking the PD-1 immune checkpoint with intermittent antibody dosing is well tolerated and associated with evidence of antitumor activity. Exploration of alternative dosing regimens and combinatorial therapies with vaccines, targeted therapies, and/or other checkpoint inhibitors is warranted.",
    "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
    "pub_date": "2010-Jul",
    "doi": "10.1200/JCO.2009.26.7609",
    "pmid": "20516446",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Adult",
      "Aged",
      "Aged, 80 and over",
      "Antibodies, Monoclonal",
      "Antigens, CD",
      "Apoptosis Regulatory Proteins",
      "Carcinoma, Non-Small-Cell Lung",
      "Carcinoma, Renal Cell",
      "Colorectal Neoplasms",
      "Dose-Response Relationship, Drug",
      "Fatigue",
      "Female",
      "Humans",
      "Kidney Neoplasms",
      "Lung Neoplasms",
      "Lymphopenia",
      "Male",
      "Melanoma",
      "Middle Aged",
      "Neoplasms",
      "Nivolumab",
      "Programmed Cell Death 1 Receptor",
      "Prostatic Neoplasms",
      "Treatment Outcome"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/20516446/",
    "summary_ja": "治療抵抗性の進行固形腫瘍患者に対し、抗PD-1抗体MDX-1106の安全性・忍容性と予備的有効性、薬力学および免疫学的相関を評価した第I相試験である。39例に0.3〜10 mg/kgの単回静注（10 mg/kgで拡大コホートあり）を行い、3か月時点で臨床的利益がある場合は反復投与を許可した。治療は概ね良好に忍容され、重篤な有害事象は炎症性大腸炎1例で、奏効としてCRCの持続的完全奏効1例とメラノーマおよびRCCの部分奏効2例が認められた。血中半減期は12〜20日だった一方、循環T細胞上PD-1占有率は用量にかかわらず2か月以上平均70%以上で、腫瘍細胞表面B7-H1発現が反応性と関連する可能性が示唆された。",
    "evidence_level": "4"
  },
  {
    "paper_id": "pubmed:33303685",
    "source": "pubmed",
    "source_id": "33303685",
    "title": "Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients.",
    "year": 2021,
    "authors": [
      "Baruch Erez N",
      "Youngster Ilan",
      "Ben-Betzalel Guy",
      "Ortenberg Rona",
      "Lahat Adi",
      "Katz Lior",
      "Adler Katerina",
      "Dick-Necula Daniela",
      "Raskin Stephen",
      "Bloch Naamah",
      "Rotin Daniil",
      "Anafi Liat",
      "Avivi Camila",
      "Melnichenko Jenny",
      "Steinberg-Silman Yael",
      "Mamtani Ronac",
      "Harati Hagit",
      "Asher Nethanel",
      "Shapira-Frommer Ronnie",
      "Brosh-Nissimov Tal",
      "Eshet Yael",
      "Ben-Simon Shira",
      "Ziv Oren",
      "Khan Md Abdul Wadud",
      "Amit Moran",
      "Ajami Nadim J",
      "Barshack Iris",
      "Schachter Jacob",
      "Wargo Jennifer A",
      "Koren Omry",
      "Markel Gal",
      "Boursi Ben"
    ],
    "abstract": "The gut microbiome has been shown to influence the response of tumors to anti-PD-1 (programmed cell death-1) immunotherapy in preclinical mouse models and observational patient cohorts. However, modulation of gut microbiota in cancer patients has not been investigated in clinical trials. In this study, we performed a phase 1 clinical trial to assess the safety and feasibility of fecal microbiota transplantation (FMT) and reinduction of anti-PD-1 immunotherapy in 10 patients with anti-PD-1-refractory metastatic melanoma. We observed clinical responses in three patients, including two partial responses and one complete response. Notably, treatment with FMT was associated with favorable changes in immune cell infiltrates and gene expression profiles in both the gut lamina propria and the tumor microenvironment. These early findings have implications for modulating the gut microbiota in cancer treatment.",
    "journal": "Science (New York, N.Y.)",
    "pub_date": "2021-Feb",
    "doi": "10.1126/science.abb5920",
    "pmid": "33303685",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Adult",
      "Antineoplastic Agents, Immunological",
      "CD8-Positive T-Lymphocytes",
      "Fecal Microbiota Transplantation",
      "Female",
      "Gastrointestinal Microbiome",
      "Humans",
      "Immunotherapy",
      "Intestinal Mucosa",
      "Lymphocytes, Tumor-Infiltrating",
      "Male",
      "Melanoma",
      "Middle Aged",
      "Nivolumab",
      "Programmed Cell Death 1 Receptor",
      "Skin Neoplasms",
      "Transcriptome",
      "Tumor Microenvironment"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/33303685/",
    "summary_ja": "腸内細菌叢が抗PD-1免疫療法の奏効に影響し得ることが示唆されているが、がん患者で腸内細菌叢を介入的に改変する臨床試験は限られている。著者らは抗PD-1抵抗性の転移性メラノーマ患者10例を対象に、糞便微生物移植（FMT）後に抗PD-1療法を再導入する第1相試験を行い、安全性と実施可能性を評価した。その結果、3例で臨床反応（部分奏効2例、完全奏効1例）が観察された。FMTは腸管粘膜固有層および腫瘍微小環境における免疫細胞浸潤や遺伝子発現プロファイルの好ましい変化と関連していた。",
    "evidence_level": "4"
  },
  {
    "paper_id": "pubmed:35101942",
    "source": "pubmed",
    "source_id": "35101942",
    "title": "Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy.",
    "year": 2022,
    "authors": [
      "Shi Jiawei",
      "Liu Junwei",
      "Tu Xiaoxuan",
      "Li Bin",
      "Tong Zhou",
      "Wang Tian",
      "Zheng Yi",
      "Shi Hongyu",
      "Zeng Xun",
      "Chen Wei",
      "Yin Weiwei",
      "Fang Weijia"
    ],
    "abstract": "BACKGROUND: The early diagnosis of hepatocellular carcinoma (HCC) can greatly improve patients' 5-year survival rate, and the early efficacy assessment is important for oncologists to harness the anti-programmed cell death protein 1 (PD-1) immunotherapy in patients with advanced HCC. The lack of effective predicting biomarkers not only leads to delayed detection of the disease but also results in ineffective immunotherapy and limited clinical survival benefit. METHODS: We exploited the single-cell approach (cytometry by time of flight (CyTOF)) to analyze peripheral blood mononuclear cells from multicohorts of human samples. Immune signatures for different stages of patients with HCC were systematically profiled and statistically compared. Furthermore, the dynamic changes of peripheral immune compositions for both first-line and second-line patients with HCC after anti-PD-1 monotherapy were also evaluated and systematically compared. RESULTS: We identified stage-specific immune signatures for HCC and constructed a logistic AdaBoost-SVM classifier based on these signatures. The classifier provided superior performance in predicting early-stage HCC over the commonly used serum alpha-fetoprotein level. We also revealed the treatment stage-specific immune signatures from peripheral blood and their dynamical changing patterns, all of which were integrated to achieve early discrimination of patients with non-durable benefit for both first-line and second-line anti-PD-1 monotherapies. CONCLUSIONS: Our newly identified single-cell peripheral immune signatures provide promising non-invasive biomarkers for early detection of HCC and early assessment for anti-PD-1 immunotherapy efficacy in patients with advanced HCC. These new findings can potentially facilitate early diagnosis and novel immunotherapy for patients with HCC in future practice and further guide the utility of CyTOF in clinical translation of cancer research. TRIAL REGISTRATION NUMBERS: NCT02576509 and NCT02989922.",
    "journal": "Journal for immunotherapy of cancer",
    "pub_date": "2022-Jan",
    "doi": "10.1136/jitc-2021-003133",
    "pmid": "35101942",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Adolescent",
      "Adult",
      "Aged",
      "Antibodies, Monoclonal, Humanized",
      "Carcinoma, Hepatocellular",
      "Early Detection of Cancer",
      "Female",
      "Humans",
      "Immune Checkpoint Inhibitors",
      "Immunotherapy",
      "Leukocytes, Mononuclear",
      "Liver Neoplasms",
      "Male",
      "Middle Aged",
      "Neoplasm Staging",
      "Nivolumab",
      "Programmed Cell Death 1 Receptor",
      "Single-Cell Analysis",
      "Treatment Outcome",
      "Young Adult"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/35101942/",
    "summary_ja": "本研究は、末梢血単核球をCyTOFで単一細胞解析し、肝細胞癌（HCC）の病期に応じた末梢免疫シグネチャーを多コホートのヒト検体で同定した。得られたシグネチャーからロジスティックAdaBoost-SVM分類器を構築し、早期HCCの予測において血清AFPより良好な性能を示した。さらに、抗PD-1単剤治療（一次・二次）前後の末梢免疫構成の動的変化を解析し、非持続的ベネフィット例を早期に識別できるシグネチャーを提示した。これらの結果から、末梢血由来の単一細胞免疫指標が早期診断および免疫療法効果の早期評価に有望な非侵襲的バイオマーカーとなり得ると結論づけている。",
    "evidence_level": "2b"
  },
  {
    "paper_id": "pubmed:37730273",
    "source": "pubmed",
    "source_id": "37730273",
    "title": "Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.",
    "year": 2023,
    "authors": [
      "Zhang Wenwen",
      "Tong Shuang",
      "Hu Bingyang",
      "Wan Tao",
      "Tang Haowen",
      "Zhao Feilong",
      "Jiao Tianyu",
      "Li Junfeng",
      "Zhang Ze",
      "Cai Jinping",
      "Ye Huiyi",
      "Wang Zhanbo",
      "Chen Shiqing",
      "Wang Yafei",
      "Li Xuerui",
      "Wang Fangzhou",
      "Cao Junning",
      "Tian Lantian",
      "Zhao Xiaochen",
      "Chen Mingyi",
      "Wang Hongguang",
      "Cai Shouwang",
      "Hu Minggen",
      "Bai Yuezong",
      "Lu Shichun"
    ],
    "abstract": "BACKGROUND: Over 70% of the patients with hepatocellular carcinoma (HCC) are diagnosed at an advanced stage and lose the opportunity for radical surgery. Combination therapy of tyrosine kinase inhibitors (TKIs) and anti-programmed cell death protein-1 (PD-1) antibodies has achieved a high tumor response rate in both the first-line and second-line treatment of advanced HCC. However, few studies have prospectively evaluated whether TKIs plus anti-PD-1 antibodies could convert unresectable intermediate-advanced HCC into resectable disease. METHODS: This single-arm, phase II study enrolled systemic therapy-naïve adult patients with unresectable Barcelona Clinic Liver Cancer stage B or C HCC. Patients received oral lenvatinib one time per day plus intravenous anti-PD-1 agents every 3 weeks (one cycle). Tumor response and resectability were evaluated before the fourth cycle, then every two cycles. The primary endpoint was conversion success rate by investigator assessment. Secondary endpoints included objective response rate (ORR) by independent imaging review (IIR) assessment per modified RECIST (mRECIST) and Response Evaluation Criteria in Solid Tumors, V.1.1 (RECIST 1.1), progression-free survival (PFS) and 12-month recurrence-free survival (RFS) rate by IIR per mRECIST, R0 resection rate, overall survival (OS), and safety. Biomarkers were assessed as exploratory objectives. RESULTS: Of the 56 eligible patients enrolled, 53 (94.6%) had macrovascular invasion, and 16 (28.6%) had extrahepatic metastasis. The median follow-up was 23.5 months. The primary endpoint showed a conversion success rate of 55.4% (31/56). ORR was 53.6% per mRECIST and 44.6% per RECIST 1.1. Median PFS was 8.9 months, and median OS was 23.9 months. Among the 31 successful conversion patients, 21 underwent surgery with an R0 resection rate of 85.7%, a pathological complete response rate of 38.1%, and a 12-month RFS rate of 47.6%. Grade ≥3 treatment-related adverse events were observed in 42.9% of patients. Tumor immune microenvironment analysis of pretreatment samples displayed significant enrichment of CD8 CONCLUSION: Lenvatinib plus anti-PD-1 antibodies demonstrate promising efficacy and tolerable safety as conversion therapy in unresectable HCC. Pre-existing CD8 TRIAL REGISTRATION NUMBER: Chinese Clinical Trial Registry, ChiCTR1900023914.",
    "journal": "Journal for immunotherapy of cancer",
    "pub_date": "2023-Sep",
    "doi": "10.1136/jitc-2023-007366",
    "pmid": "37730273",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Adult",
      "Humans",
      "Carcinoma, Hepatocellular",
      "CD8-Positive T-Lymphocytes",
      "Liver Neoplasms",
      "Phenylurea Compounds",
      "Tumor Microenvironment",
      "Quinolines"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/37730273/",
    "summary_ja": "切除不能な中〜進行期肝細胞癌（BCLC B/C）に対し、レンバチニブと抗PD-1抗体の併用を「コンバージョン治療」として前向き単群第II相で評価した。56例のうちコンバージョン成功率は55.4%で、奏効率はmRECISTで53.6%（RECIST1.1で44.6%）だった。追跡中央値23.5か月で、PFS中央値8.9か月、OS中央値23.9か月を示した。コンバージョン成功31例中21例が手術を受け、R0切除率85.7%・病理学的完全奏効38.1%で、Grade≥3の治療関連有害事象は42.9%だった。",
    "evidence_level": "4"
  },
  {
    "paper_id": "pubmed:33846173",
    "source": "pubmed",
    "source_id": "33846173",
    "title": "Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability-High Gastric Cancer.",
    "year": 2021,
    "authors": [
      "Kwon Minsuk",
      "An Minae",
      "Klempner Samuel J",
      "Lee Hyuk",
      "Kim Kyoung-Mee",
      "Sa Jason K",
      "Cho Hee Jin",
      "Hong Jung Yong",
      "Lee Taehyang",
      "Min Yang Won",
      "Kim Tae Jun",
      "Min Byung-Hoon",
      "Park Woong-Yang",
      "Kang Won Ki",
      "Kim Kyu-Tae",
      "Kim Seung Tae",
      "Lee Jeeyun"
    ],
    "abstract": "Sequence alterations in microsatellites and an elevated mutational burden are observed in 20% of gastric cancers and associated with clinical response to anti-PD-1 antibodies. However, 50% of microsatellite instability-high (MSI-H) cancers are intrinsically resistant to PD-1 therapies. We conducted a phase II trial of pembrolizumab in patients with advanced MSI-H gastric cancer and included serial and multi-region tissue samples in addition to serial peripheral blood analyses. The number of whole-exome sequencing (WES)-derived nonsynonymous mutations correlated with antitumor activity and prolonged progression-free survival (PFS). Coupling WES to single-cell RNA sequencing, we identified dynamic tumor evolution with greater on-treatment collapse of mutational architecture in responders. Diverse T-cell receptor repertoire was associated with longer PFS to pembrolizumab. In addition, an increase in PD-1",
    "journal": "Cancer discovery",
    "pub_date": "2021-Sep",
    "doi": "10.1158/2159-8290.CD-21-0219",
    "pmid": "33846173",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Aged",
      "Aged, 80 and over",
      "Antibodies, Monoclonal, Humanized",
      "Antineoplastic Agents, Immunological",
      "Biomarkers, Tumor",
      "Female",
      "Humans",
      "Male",
      "Microsatellite Instability",
      "Middle Aged",
      "Neoplasm Metastasis",
      "Programmed Cell Death 1 Receptor",
      "Stomach Neoplasms",
      "Treatment Outcome"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/33846173/",
    "summary_ja": "MSI-H胃がんの約半数がPD-1阻害に一次抵抗性を示す背景を解明するため、進行MSI-H胃がん患者を対象にペムブロリズマブの第II相試験を行い、腫瘍の多領域・経時検体と末梢血を解析した。WESで推定した非同義変異数（変異負荷）が抗腫瘍効果および無増悪生存期間（PFS）の延長と相関した。さらに単一細胞RNA-seqと組み合わせることで、奏効例では治療中に腫瘍の変異アーキテクチャがより大きく崩壊するなど、動的な腫瘍進化が示唆された。T細胞受容体（TCR）レパトアの多様性もペムブロリズマブ治療下でのPFS延長と関連した。",
    "evidence_level": "2b"
  },
  {
    "paper_id": "pubmed:40086437",
    "source": "pubmed",
    "source_id": "40086437",
    "title": "Distinct CD8",
    "year": 2025,
    "authors": [
      "Li Housaiyin",
      "Zandberg Dan P",
      "Kulkarni Aditi",
      "Chiosea Simion I",
      "Santos Patricia M",
      "Isett Brian R",
      "Joy Marion",
      "Sica Gabriel L",
      "Contrera Kevin J",
      "Tatsuoka Curtis M",
      "Brand Matthias",
      "Duvvuri Umamaheswar",
      "Kim Seungwon",
      "Kubik Mark",
      "Sridharan Shaum",
      "Tu Fei",
      "Chen Jie",
      "Bruno Tullia C",
      "Vignali Dario A A",
      "Cillo Anthony R",
      "Bao Riyue",
      "Wang Jing Hong",
      "Vujanovic Lazar",
      "Ferris Robert L"
    ],
    "abstract": "We leverage a clinical trial (NCT04080804) that compared neoadjuvant anti-PD-1, anti-PD-1+CTLA-4, and anti-PD-1+LAG-3 therapies in head and neck squamous cell carcinoma patients. Combination therapies promote higher pathologic response rates versus monotherapy, and major pathologic response is associated with better survival. To address whether successful immune checkpoint inhibitor (ICI) regimens act through similar or distinct pathways, we robustly and longitudinally characterize transcriptional and proteomic dynamics of CD8",
    "journal": "Cancer cell",
    "pub_date": "2025-Apr",
    "doi": "10.1016/j.ccell.2025.02.026",
    "pmid": "40086437",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Female",
      "Humans",
      "Male",
      "CD8-Positive T-Lymphocytes",
      "CTLA-4 Antigen",
      "Head and Neck Neoplasms",
      "Immune Checkpoint Inhibitors",
      "Immunologic Memory",
      "Immunotherapy",
      "Lymphocyte Activation Gene 3 Protein",
      "Lymphocytes, Tumor-Infiltrating",
      "Neoadjuvant Therapy",
      "Programmed Cell Death 1 Receptor",
      "Squamous Cell Carcinoma of Head and Neck"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/40086437/",
    "summary_ja": "本研究は、頭頸部扁平上皮癌における術前（ネオアジュバント）免疫チェックポイント阻害療法を、抗PD-1単独、抗PD-1+CTLA-4併用、抗PD-1+LAG-3併用で比較した臨床試験（NCT04080804）を解析した。併用療法は単独療法より病理学的奏効率が高く、主要病理学的奏効はより良い生存と関連していた。さらに、有効なICIレジメンが共通経路か異なる経路で作用するかを検討するため、CD8陽性T細胞の転写・蛋白動態を縦断的に詳細解析した。",
    "evidence_level": "2b"
  },
  {
    "paper_id": "pubmed:37595586",
    "source": "pubmed",
    "source_id": "37595586",
    "title": "Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy.",
    "year": 2023,
    "authors": [
      "Topalian Suzanne L",
      "Forde Patrick M",
      "Emens Leisha A",
      "Yarchoan Mark",
      "Smith Kellie N",
      "Pardoll Drew M"
    ],
    "abstract": "Among new treatment approaches for patients with cancer, few have accelerated as quickly as neoadjuvant immune checkpoint blockade (ICB). Neoadjuvant cancer therapy is administered before curative-intent surgery in treatment-naïve patients. Conventional neoadjuvant chemotherapy and radiotherapy are primarily intended to reduce tumor size, improving surgical resectability. However, recent scientific evidence outlined here suggests that neoadjuvant immunotherapy can expand and transcriptionally modify tumor-specific T cell clones to enhance both intratumoral and systemic anti-tumor immunity. It further offers a unique \"window of opportunity\" to explore mechanisms and identify novel biomarkers of ICB response and resistance, opening possibilities for refining long-term clinical outcome predictions and developing new, more highly effective ICB combination therapies. Here, we examine advances in clinical and scientific knowledge gleaned from studies in select cancers and describe emerging key principles relevant to neoadjuvant ICB across many cancer types.",
    "journal": "Cancer cell",
    "pub_date": "2023-Sep",
    "doi": "10.1016/j.ccell.2023.07.011",
    "pmid": "37595586",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Humans",
      "Neoadjuvant Therapy",
      "Immune Checkpoint Inhibitors",
      "Immunotherapy",
      "Clone Cells",
      "Neoplasms"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/37595586/",
    "summary_ja": "免疫チェックポイント阻害（ICB）を手術前に行うネオアジュバント治療は、がん免疫療法の中でも急速に発展している。従来の術前化学療法・放射線療法が主に腫瘍縮小と切除性向上を目的とするのに対し、術前ICBは腫瘍特異的T細胞クローンを拡大・転写的に変化させ、腫瘍内および全身の抗腫瘍免疫を高め得ることが示唆されている。さらに、治療反応・抵抗性機序の解明やバイオマーカー同定の「機会の窓」として、長期予後予測の精緻化や有効な併用療法開発に資する可能性がある。本稿は、いくつかのがん種で得られた臨床・科学的知見を概説し、幅広いがんに共通する術前ICBの原則を整理する。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:40836096",
    "source": "pubmed",
    "source_id": "40836096",
    "title": "Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy.",
    "year": 2025,
    "authors": [
      "Baruch Erez N",
      "Gleber-Netto Frederico O",
      "Nagarajan Priyadharsini",
      "Rao Xiayu",
      "Akhter Shamima",
      "Eichwald Tuany",
      "Xie Tongxin",
      "Balood Mohammad",
      "Adewale Adebayo",
      "Naara Shorook",
      "Sathishkumar Hinduja N",
      "Islam Shajedul",
      "McCarthy William",
      "Mattson Brandi J",
      "Ferrarotto Renata",
      "Wong Michael K",
      "Davies Michael A",
      "Jindal Sonali",
      "Basu Sreyashi",
      "Roversi Karine",
      "Nikpoor Amin Reza",
      "Ahmadi Maryam",
      "Ahmadi Ali",
      "Harwood Catherine",
      "Leigh Irene",
      "Gong Dennis",
      "Tallón de Lara Paulino",
      "Tao Derrick L",
      "Davidson Tara M",
      "Ajami Nadim J",
      "Futreal Andrew",
      "Rai Kunal",
      "Kochat Veena",
      "Castillo Micah",
      "Gunaratne Preethi",
      "Goepfert Ryan P",
      "Hernandez Sharia D",
      "Khushalani Nikhil I",
      "Wang Jing",
      "Watowich Stephanie S",
      "Calin George A",
      "Migden Michael R",
      "Yuan Mona",
      "Liu Naijiang",
      "Ye Yi",
      "Hwang William L",
      "Vermeer Paola D",
      "D'Silva Nisha J",
      "Bunimovich Yuri L",
      "Yaniv Dan",
      "Burks Jared K",
      "Gomez Javier",
      "Dougherty Patrick M",
      "Tsai Kenneth Y",
      "Allison James P",
      "Sharma Padmanee",
      "Wargo Jennifer A",
      "Myers Jeffrey N",
      "Talbot Sebastien",
      "Gross Neil D",
      "Amit Moran"
    ],
    "abstract": "Perineural invasion (PNI) is a well-established factor of poor prognosis in multiple cancer types",
    "journal": "Nature",
    "pub_date": "2025-Oct",
    "doi": "10.1038/s41586-025-09370-8",
    "pmid": "40836096",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Animals",
      "Programmed Cell Death 1 Receptor",
      "Mice",
      "Humans",
      "Drug Resistance, Neoplasm",
      "Female",
      "Male",
      "Interleukin-6",
      "Melanoma",
      "Interferon Type I",
      "Tumor Microenvironment",
      "Receptor, Interferon alpha-beta",
      "Stomach Neoplasms",
      "Skin Neoplasms",
      "Peripheral Nerve Injuries",
      "Carcinoma, Squamous Cell",
      "Inflammation",
      "Signal Transduction",
      "Immune Checkpoint Inhibitors",
      "Neurons",
      "Neoplasms",
      "Neoplasm Invasiveness"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/40836096/",
    "summary_ja": "提示されたアブストラクトは冒頭部分のみであり、研究デザイン・対象・主要結果の詳細は確認できません。タイトルから、がんによって誘発される神経損傷が抗PD-1療法への抵抗性を促進する可能性を扱い、周囲神経浸潤（PNI）が複数のがん種で予後不良因子である点を背景としていることが示唆されます。全文のアブストラクト（方法・結果・結論）を共有いただければ、根拠に基づいてより正確に要約できます。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:25428505",
    "source": "pubmed",
    "source_id": "25428505",
    "title": "PD-1 blockade induces responses by inhibiting adaptive immune resistance.",
    "year": 2014,
    "authors": [
      "Tumeh Paul C",
      "Harview Christina L",
      "Yearley Jennifer H",
      "Shintaku I Peter",
      "Taylor Emma J M",
      "Robert Lidia",
      "Chmielowski Bartosz",
      "Spasic Marko",
      "Henry Gina",
      "Ciobanu Voicu",
      "West Alisha N",
      "Carmona Manuel",
      "Kivork Christine",
      "Seja Elizabeth",
      "Cherry Grace",
      "Gutierrez Antonio J",
      "Grogan Tristan R",
      "Mateus Christine",
      "Tomasic Gorana",
      "Glaspy John A",
      "Emerson Ryan O",
      "Robins Harlan",
      "Pierce Robert H",
      "Elashoff David A",
      "Robert Caroline",
      "Ribas Antoni"
    ],
    "abstract": "Therapies that target the programmed death-1 (PD-1) receptor have shown unprecedented rates of durable clinical responses in patients with various cancer types. One mechanism by which cancer tissues limit the host immune response is via upregulation of PD-1 ligand (PD-L1) and its ligation to PD-1 on antigen-specific CD8(+) T cells (termed adaptive immune resistance). Here we show that pre-existing CD8(+) T cells distinctly located at the invasive tumour margin are associated with expression of the PD-1/PD-L1 immune inhibitory axis and may predict response to therapy. We analysed samples from 46 patients with metastatic melanoma obtained before and during anti-PD-1 therapy (pembrolizumab) using quantitative immunohistochemistry, quantitative multiplex immunofluorescence, and next-generation sequencing for T-cell antigen receptors (TCRs). In serially sampled tumours, patients responding to treatment showed proliferation of intratumoral CD8(+) T cells that directly correlated with radiographic reduction in tumour size. Pre-treatment samples obtained from responding patients showed higher numbers of CD8-, PD-1- and PD-L1-expressing cells at the invasive tumour margin and inside tumours, with close proximity between PD-1 and PD-L1, and a more clonal TCR repertoire. Using multivariate analysis, we established a predictive model based on CD8 expression at the invasive margin and validated the model in an independent cohort of 15 patients. Our findings indicate that tumour regression after therapeutic PD-1 blockade requires pre-existing CD8(+) T cells that are negatively regulated by PD-1/PD-L1-mediated adaptive immune resistance.",
    "journal": "Nature",
    "pub_date": "2014-Nov",
    "doi": "10.1038/nature13954",
    "pmid": "25428505",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Adaptive Immunity",
      "Aged",
      "Aged, 80 and over",
      "Biomarkers",
      "CD8-Positive T-Lymphocytes",
      "Cell Proliferation",
      "Female",
      "Gene Expression Regulation, Neoplastic",
      "Humans",
      "Immunotherapy",
      "Male",
      "Melanoma",
      "Middle Aged",
      "Models, Biological",
      "Multivariate Analysis",
      "Programmed Cell Death 1 Receptor",
      "Treatment Outcome"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/25428505/",
    "summary_ja": "PD-1阻害療法は多様ながん種で持続的な奏効を示すが、その効果は腫瘍がPD-L1を上げてCD8陽性T細胞をPD-1/PD-L1軸で抑制する「適応免疫抵抗性」に左右されうる。転移性黒色腫46例の治療前後検体を解析し、奏効例では腫瘍内CD8陽性T細胞の増殖が腫瘍縮小と相関した。治療前から浸潤縁や腫瘍内にCD8・PD-1・PD-L1陽性細胞が多く、PD-1とPD-L1が近接し、TCRレパトアがよりクローン性であることが奏効と関連した。さらに浸潤縁のCD8発現に基づく予測モデルを作成し、独立コホート15例で検証した。これらより、PD-1遮断による腫瘍退縮には、もともと存在しPD-1/PD-L1で抑制されているCD8陽性T細胞が必要であることが示唆される。",
    "evidence_level": "2b"
  },
  {
    "paper_id": "pubmed:27903500",
    "source": "pubmed",
    "source_id": "27903500",
    "title": "Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.",
    "year": 2017,
    "authors": [
      "Shin Daniel Sanghoon",
      "Zaretsky Jesse M",
      "Escuin-Ordinas Helena",
      "Garcia-Diaz Angel",
      "Hu-Lieskovan Siwen",
      "Kalbasi Anusha",
      "Grasso Catherine S",
      "Hugo Willy",
      "Sandoval Salemiz",
      "Torrejon Davis Y",
      "Palaskas Nicolaos",
      "Rodriguez Gabriel Abril",
      "Parisi Giulia",
      "Azhdam Ariel",
      "Chmielowski Bartosz",
      "Cherry Grace",
      "Seja Elizabeth",
      "Berent-Maoz Beata",
      "Shintaku I Peter",
      "Le Dung T",
      "Pardoll Drew M",
      "Diaz Luis A",
      "Tumeh Paul C",
      "Graeber Thomas G",
      "Lo Roger S",
      "Comin-Anduix Begoña",
      "Ribas Antoni"
    ],
    "abstract": "UNLABELLED: Loss-of-function mutations in JAK1/2 can lead to acquired resistance to anti-programmed death protein 1 (PD-1) therapy. We reasoned that they may also be involved in primary resistance to anti-PD-1 therapy. JAK1/2-inactivating mutations were noted in tumor biopsies of 1 of 23 patients with melanoma and in 1 of 16 patients with mismatch repair-deficient colon cancer treated with PD-1 blockade. Both cases had a high mutational load but did not respond to anti-PD-1 therapy. Two out of 48 human melanoma cell lines had JAK1/2 mutations, which led to a lack of PD-L1 expression upon interferon gamma exposure mediated by an inability to signal through the interferon gamma receptor pathway. JAK1/2 loss-of-function alterations in The Cancer Genome Atlas confer adverse outcomes in patients. We propose that JAK1/2 loss-of-function mutations are a genetic mechanism of lack of reactive PD-L1 expression and response to interferon gamma, leading to primary resistance to PD-1 blockade therapy. SIGNIFICANCE: A key functional result from somatic JAK1/2 mutations in a cancer cell is the inability to respond to interferon gamma by expressing PD-L1 and many other interferon-stimulated genes. These mutations result in a genetic mechanism for the absence of reactive PD-L1 expression, and patients harboring such tumors would be unlikely to respond to PD-1 blockade therapy. Cancer Discov; 7(2); 188-201. ©2016 AACR.See related commentary by Marabelle et al., p. 128This article is highlighted in the In This Issue feature, p. 115.",
    "journal": "Cancer discovery",
    "pub_date": "2017-Feb",
    "doi": "10.1158/2159-8290.CD-16-1223",
    "pmid": "27903500",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Antibodies, Monoclonal, Humanized",
      "Cell Line, Tumor",
      "Colonic Neoplasms",
      "Drug Resistance, Neoplasm",
      "Gene Expression Regulation, Neoplastic",
      "Humans",
      "Interferon-gamma",
      "Janus Kinase 1",
      "Janus Kinase 2",
      "Melanoma",
      "Mutation",
      "Neoplasms",
      "Programmed Cell Death 1 Receptor",
      "Signal Transduction"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/27903500/",
    "summary_ja": "本研究は、抗PD-1療法に対する一次（治療開始時からの）抵抗性の機序として、腫瘍細胞のJAK1/2不活化変異に着目した。メラノーマ23例中1例、MMR欠損大腸癌16例中1例でJAK1/2変異が腫瘍生検から検出され、いずれも高変異負荷でありながら抗PD-1に不応答だった。さらに、JAK1/2変異を持つヒトメラノーマ細胞株ではIFN-γ受容体経路のシグナル不全により、IFN-γ刺激下でのPD-L1誘導（およびIFN応答遺伝子群の発現）が起こらないことを示した。TCGA解析でもJAK1/2機能喪失が不良転帰と関連し、IFN-γに反応できず反応性PD-L1が誘導されないことがPD-1阻害への一次抵抗性につながる可能性を提案している。",
    "evidence_level": "4"
  },
  {
    "paper_id": "pubmed:37689322",
    "source": "pubmed",
    "source_id": "37689322",
    "title": "Immunosuppressive CD10",
    "year": 2023,
    "authors": [
      "Meng Yan",
      "Ye Fei",
      "Nie Pingping",
      "Zhao Qiudong",
      "An Liwei",
      "Wang Wenjia",
      "Qu Shuping",
      "Shen Zhemin",
      "Cao Zhifa",
      "Zhang Xiaobing",
      "Jiao Shi",
      "Wu Dong",
      "Zhou Zhaocai",
      "Wei Lixin"
    ],
    "abstract": "BACKGROUND & AIMS: Remodeling the tumor microenvironment is a critical strategy for treating advanced hepatocellular carcinoma (HCC). Yet, how distinct cell populations in the microenvironment mediate tumor resistance to immunotherapies, such as anti-PD-1, remains poorly understood. METHODS: We analyzed the transcriptomic profile, at a single-cell resolution, of tumor tissues from patients with HCC scheduled to receive anti-PD-1-based immunotherapy. Our comparative analysis and experimental validation using flow cytometry and histopathological analysis uncovered a discrete subpopulation of cells associated with resistance to anti-PD-1 treatment in patients and a rat model. A TurboID-based proximity labeling approach was deployed to gain mechanistic insights into the reprogramming of the HCC microenvironment. RESULTS: We identified CD10 CONCLUSIONS: Collectively, our results reveal a fundamental mechanism by which CD10 IMPACT AND IMPLICATIONS: Herein, we discovered that tumor cells reprogrammed CD10",
    "journal": "Journal of hepatology",
    "pub_date": "2023-Dec",
    "doi": "10.1016/j.jhep.2023.08.024",
    "pmid": "37689322",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Humans",
      "Rats",
      "Animals",
      "Carcinoma, Hepatocellular",
      "T-Lymphocytes",
      "Liver Neoplasms",
      "Neutrophils",
      "Immunotherapy",
      "Tumor Microenvironment",
      "CD8-Positive T-Lymphocytes",
      "Alkaline Phosphatase"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/37689322/",
    "summary_ja": "進行肝細胞癌（HCC）において、抗PD-1免疫療法への抵抗性を腫瘍微小環境内のどの細胞集団が担うのかを明らかにすることを目的とした研究である。抗PD-1ベース治療を予定するHCC患者の腫瘍組織を単一細胞トランスクリプトーム解析し、比較解析とフローサイトメトリー／病理解析で、治療抵抗性に関連する離散的な細胞サブ集団を患者およびラットモデルで同定・検証した。さらにTurboID近接標識法を用いて、HCC微小環境のリプログラミング機構の手掛かりを探索した。結果・結論部分は提示文中で途中までだが、CD10に関連する免疫抑制的な機序が示唆されている。",
    "evidence_level": "2b"
  },
  {
    "paper_id": "pubmed:36527888",
    "source": "pubmed",
    "source_id": "36527888",
    "title": "Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade.",
    "year": 2023,
    "authors": [
      "Pang Kun",
      "Shi Zhen-Duo",
      "Wei Liu-Ya",
      "Dong Yang",
      "Ma Yu-Yang",
      "Wang Wei",
      "Wang Guang-Yue",
      "Cao Ming-Yang",
      "Dong Jia-Jun",
      "Chen Yu-Ang",
      "Zhang Peng",
      "Hao Lin",
      "Xu Hao",
      "Pan Deng",
      "Chen Zhe-Sheng",
      "Han Cong-Hui"
    ],
    "abstract": "The binding of programmed death-1 (PD-1) on the surface of T cells and PD-1 ligand 1 (PD-L1) on tumor cells can prevent the immune-killing effect of T cells on tumor cells and promote the immune escape of tumor cells. Therefore, immune checkpoint blockade targeting PD-1/PD-L1 is a reliable tumor therapy with remarkable efficacy. However, the main challenges of this therapy are low response rate and acquired resistance, so that the outcomes of this therapy are usually unsatisfactory. This review begins with the description of biological structure of the PD-1/PD-L1 immune checkpoint and its role in a variety of cells. Subsequently, the therapeutic effects of immune checkpoint blockers (PD-1 / PD-L1 inhibitors) in various tumors were introduced and analyzed, and the reasons affecting the function of PD-1/PD-L1 were systematically analyzed. Then, we focused on analyzing, sorting out and introducing the possible underlying mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade including abnormal expression of PD-1/PD-L1 and some factors, immune-related pathways, tumor immune microenvironment, and T cell dysfunction and others. Finally, promising therapeutic strategies to sensitize the resistant patients with PD-1/PD-L1 blockade treatment were described. This review is aimed at providing guidance for the treatment of various tumors, and highlighting the drug resistance mechanisms to offer directions for future tumor treatment and improvement of patient prognosis.",
    "journal": "Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy",
    "pub_date": "2023-Jan",
    "doi": "10.1016/j.drup.2022.100907",
    "pmid": "36527888",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Humans",
      "B7-H1 Antigen",
      "Drug Resistance",
      "Immunotherapy",
      "Neoplasms",
      "Programmed Cell Death 1 Receptor",
      "Tumor Microenvironment",
      "Drug Resistance, Neoplasm"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/36527888/",
    "summary_ja": "PD-1（T細胞）とPD-L1（腫瘍細胞）の結合はT細胞の抗腫瘍免疫を抑制し、腫瘍の免疫逃避を促進するため、PD-1/PD-L1阻害による免疫チェックポイント療法は有効な治療選択肢である。本総説は、PD-1/PD-L1の構造と多様な細胞での役割を概説したうえで、各種腫瘍における阻害薬の治療効果と、その機能に影響する要因を整理している。さらに、PD-1/PD-L1の異常発現、免疫関連経路、腫瘍免疫微小環境、T細胞機能不全などを含む一次・獲得耐性の機序を体系的にまとめ、耐性患者を感作する戦略を提示している。目的は、腫瘍治療の指針となる知見と今後の研究・治療改善の方向性を示すことである。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:38280330",
    "source": "pubmed",
    "source_id": "38280330",
    "title": "Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape.",
    "year": 2024,
    "authors": [
      "Cui Jia-Wen",
      "Li Yao",
      "Yang Yang",
      "Yang Hai-Kui",
      "Dong Jia-Mei",
      "Xiao Zhi-Hua",
      "He Xin",
      "Guo Jia-Hao",
      "Wang Rui-Qi",
      "Dai Bo",
      "Zhou Zhi-Ling"
    ],
    "abstract": "Tumor immunotherapy, an innovative anti-cancer therapy, has showcased encouraging outcomes across diverse tumor types. Among these, the PD-1/PD-L1 signaling pathway is a well-known immunological checkpoint, which is significant in the regulation of immune evasion by tumors. Nevertheless, a considerable number of patients develop resistance to anti-PD-1/PD-L1 immunotherapy, rendering it ineffective in the long run. This research focuses on exploring the factors of PD-1/PD-L1-mediated resistance in tumor immunotherapy. Initially, the PD-1/PD-L1 pathway is characterized by its role in facilitating tumor immune evasion, emphasizing its role in autoimmune homeostasis. Next, the primary mechanisms of resistance to PD-1/PD-L1-based immunotherapy are analyzed, including tumor antigen deletion, T cell dysfunction, increased immunosuppressive cells, and alterations in the expression of PD-L1 within tumor cells. The possible ramifications of altered metabolism, microbiota, and DNA methylation on resistance is also described. Finally, possible resolution strategies for dealing with anti-PD-1/PD-L1 immunotherapy resistance are discussed, placing particular emphasis on personalized therapeutic approaches and the exploration of more potent immunotherapy regimens.",
    "journal": "Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie",
    "pub_date": "2024-Feb",
    "doi": "10.1016/j.biopha.2024.116203",
    "pmid": "38280330",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Humans",
      "Tumor Escape",
      "Programmed Cell Death 1 Receptor",
      "B7-H1 Antigen",
      "Neoplasms",
      "Immunotherapy",
      "Tumor Microenvironment"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/38280330/",
    "summary_ja": "腫瘍免疫療法の中でもPD-1/PD-L1経路は代表的な免疫チェックポイントであり、腫瘍の免疫回避に重要だが、多くの患者で抗PD-1/PD-L1療法への耐性が生じうることを概説している。PD-1/PD-L1が腫瘍免疫逃避を助長する仕組みを自己免疫恒常性との関係も含めて整理したうえで、耐性機序として腫瘍抗原の欠失、T細胞機能不全、免疫抑制性細胞の増加、腫瘍細胞におけるPD-L1発現変化などを挙げる。さらに代謝、腸内細菌叢、DNAメチル化の変化が耐性に与える影響にも触れている。最後に、個別化治療やより強力な免疫療法レジメン探索など、耐性克服に向けた方策を議論している。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:39601129",
    "source": "pubmed",
    "source_id": "39601129",
    "title": "PD-1 blockade treatment in melanoma: Mechanism of response and tumor-intrinsic resistance.",
    "year": 2025,
    "authors": [
      "Wang Tong",
      "Ma Wenjie",
      "Zou Zijian",
      "Zhong Jingqin",
      "Lin Xinyi",
      "Liu Wanlin",
      "Sun Wei",
      "Hu Tu",
      "Xu Yu",
      "Chen Yong"
    ],
    "abstract": "Malignant melanoma is characterized by high immunogenicity, genetic heterogeneity, and diverse pathological manifestations, affecting both skin and mucosa over the body. Pembrolizumab and nivolumab, both anti-PD-1 monoclonal antibodies, were approved by the US FDA for unresectable or metastatic melanoma in 2011 and 2014, respectively, with enduring and transformative outcomes. Despite marked clinical achievements, only a subset of patients manifested a complete response. Approximately 55% of melanoma patients exhibited primary resistance to PD-1 antibodies, with nearly 25% developing secondary resistance within 2 years of treatment. Thus, there is a critical need to comprehensively elucidate the mechanisms underlying the efficacy and resistance to PD-1 blockade. This review discusses the fundamental mechanisms of PD-1 blockade, encompassing insights from T cells and B cells, and presents resistance to anti-PD-1 with a particular focus on tumoral-intrinsic mechanisms in melanoma.",
    "journal": "Cancer science",
    "pub_date": "2025-Feb",
    "doi": "10.1111/cas.16398",
    "pmid": "39601129",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Humans",
      "Melanoma",
      "Drug Resistance, Neoplasm",
      "Programmed Cell Death 1 Receptor",
      "Immune Checkpoint Inhibitors",
      "Antibodies, Monoclonal, Humanized",
      "Nivolumab",
      "Skin Neoplasms",
      "Animals",
      "T-Lymphocytes",
      "B-Lymphocytes"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/39601129/",
    "summary_ja": "悪性黒色腫に対するPD-1阻害（ペムブロリズマブ、ニボルマブ）は転移・切除不能例で大きな臨床的成果をもたらした一方、完全奏効は一部の患者に限られます。黒色腫患者の約55%はPD-1抗体に一次抵抗性を示し、さらに約25%は治療開始後2年以内に二次抵抗性を獲得すると報告されています。そこで本レビューは、PD-1阻害の基本的作用機序をT細胞・B細胞の観点から整理し、特に腫瘍内在性（腫瘍細胞側）要因による抵抗性機序に焦点を当てて概説します。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:33129844",
    "source": "pubmed",
    "source_id": "33129844",
    "title": "PD-1 Signaling Promotes Tumor-Infiltrating Myeloid-Derived Suppressor Cells and Gastric Tumorigenesis in Mice.",
    "year": 2021,
    "authors": [
      "Kim Woosook",
      "Chu Timothy H",
      "Nienhüser Henrik",
      "Jiang Zhengyu",
      "Del Portillo Armando",
      "Remotti Helen E",
      "White Ruth A",
      "Hayakawa Yoku",
      "Tomita Hiroyuki",
      "Fox James G",
      "Drake Charles G",
      "Wang Timothy C"
    ],
    "abstract": "BACKGROUND & AIMS: Immune checkpoint inhibitors have limited efficacy in many tumors. We investigated mechanisms of tumor resistance to inhibitors of programmed cell death-1 (PDCD1, also called PD-1) in mice with gastric cancer, and the role of its ligand, PD-L1. METHODS: Gastrin-deficient mice were given N-methyl-N-nitrosourea (MNU) in drinking water along with Helicobacter felis to induce gastric tumor formation; we also performed studies with H/K-ATPase-hIL1B mice, which develop spontaneous gastric tumors at the antral-corpus junction and have parietal cells that constitutively secrete interleukin 1B. Mice were given injections of an antibody against PD-1 or an isotype control before tumors developed, or anti-PD-1 and 5-fluorouracil and oxaliplatin, or an antibody against lymphocyte antigen 6 complex locus G (also called Gr-1), which depletes myeloid-derived suppressor cells [MDSCs]), after tumors developed. We generated knock-in mice that express PD-L1 specifically in the gastric epithelium or myeloid lineage. RESULTS: When given to gastrin-deficient mice before tumors grew, anti-PD-1 significantly reduced tumor size and increased tumor infiltration by T cells. However, anti-PD-1 alone did not have significant effects on established tumors in these mice. Neither early nor late anti-PD-1 administration reduced tumor growth in the presence of MDSCs in H/K-ATPase-hIL-1β mice. The combination of 5-fluorouracil and oxaliplatin reduced MDSCs, increased numbers of intra-tumor CD8 CONCLUSIONS: In mouse models of gastric cancer, 5-fluorouracil and oxaliplatin reduce numbers of MDSCs to increase the effects of anti-PD-1, which promotes tumor infiltration by CD8",
    "journal": "Gastroenterology",
    "pub_date": "2021-Feb",
    "doi": "10.1053/j.gastro.2020.10.036",
    "pmid": "33129844",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Administration, Oral",
      "Animals",
      "Carcinogenesis",
      "Gastric Mucosa",
      "Gastrins",
      "Helicobacter Infections",
      "Helicobacter felis",
      "Humans",
      "Immune Checkpoint Inhibitors",
      "Methylnitrosourea",
      "Mice",
      "Mice, Knockout",
      "Myeloid-Derived Suppressor Cells",
      "Neoplasms, Experimental",
      "Programmed Cell Death 1 Receptor",
      "Signal Transduction",
      "Stomach Neoplasms",
      "Tumor Microenvironment"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/33129844/",
    "summary_ja": "マウス胃がんモデルにおいて、抗PD-1抗体は腫瘍形成前の投与では腫瘍サイズを減少させ、腫瘍内T細胞浸潤を増加させた一方、成立後腫瘍に対しては単独では有意な効果が乏しかった。骨髄由来免疫抑制細胞（MDSC）が存在する状況では、抗PD-1の早期・後期投与とも腫瘍増殖抑制がみられず、MDSCが治療抵抗性に関与することが示唆された。5-FU＋オキサリプラチンはMDSCを減少させ、腫瘍内CD8+T細胞を増やすことで抗PD-1の効果を増強した。PD-L1を胃上皮または骨髄系に特異的に発現するノックインマウスを用い、PD-1/PD-L1シグナルが腫瘍免疫環境形成に関与する機序を検討した。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:27433843",
    "source": "pubmed",
    "source_id": "27433843",
    "title": "Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.",
    "year": 2016,
    "authors": [
      "Zaretsky Jesse M",
      "Garcia-Diaz Angel",
      "Shin Daniel S",
      "Escuin-Ordinas Helena",
      "Hugo Willy",
      "Hu-Lieskovan Siwen",
      "Torrejon Davis Y",
      "Abril-Rodriguez Gabriel",
      "Sandoval Salemiz",
      "Barthly Lucas",
      "Saco Justin",
      "Homet Moreno Blanca",
      "Mezzadra Riccardo",
      "Chmielowski Bartosz",
      "Ruchalski Kathleen",
      "Shintaku I Peter",
      "Sanchez Phillip J",
      "Puig-Saus Cristina",
      "Cherry Grace",
      "Seja Elizabeth",
      "Kong Xiangju",
      "Pang Jia",
      "Berent-Maoz Beata",
      "Comin-Anduix Begoña",
      "Graeber Thomas G",
      "Tumeh Paul C",
      "Schumacher Ton N M",
      "Lo Roger S",
      "Ribas Antoni"
    ],
    "abstract": "BACKGROUND: Approximately 75% of objective responses to anti-programmed death 1 (PD-1) therapy in patients with melanoma are durable, lasting for years, but delayed relapses have been noted long after initial objective tumor regression despite continuous therapy. Mechanisms of immune escape in this context are unknown. METHODS: We analyzed biopsy samples from paired baseline and relapsing lesions in four patients with metastatic melanoma who had had an initial objective tumor regression in response to anti-PD-1 therapy (pembrolizumab) followed by disease progression months to years later. RESULTS: Whole-exome sequencing detected clonal selection and outgrowth of the acquired resistant tumors and, in two of the four patients, revealed resistance-associated loss-of-function mutations in the genes encoding interferon-receptor-associated Janus kinase 1 (JAK1) or Janus kinase 2 (JAK2), concurrent with deletion of the wild-type allele. A truncating mutation in the gene encoding the antigen-presenting protein beta-2-microglobulin (B2M) was identified in a third patient. JAK1 and JAK2 truncating mutations resulted in a lack of response to interferon gamma, including insensitivity to its antiproliferative effects on cancer cells. The B2M truncating mutation led to loss of surface expression of major histocompatibility complex class I. CONCLUSIONS: In this study, acquired resistance to PD-1 blockade immunotherapy in patients with melanoma was associated with defects in the pathways involved in interferon-receptor signaling and in antigen presentation. (Funded by the National Institutes of Health and others.).",
    "journal": "The New England journal of medicine",
    "pub_date": "2016-Sep",
    "doi": "10.1056/NEJMoa1604958",
    "pmid": "27433843",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Antibodies, Monoclonal, Humanized",
      "Antineoplastic Agents",
      "Biopsy",
      "Drug Resistance, Neoplasm",
      "Exome",
      "Gene Expression Regulation, Neoplastic",
      "Genes, MHC Class I",
      "Humans",
      "Immunotherapy",
      "Interferon-gamma",
      "Janus Kinase 1",
      "Janus Kinase 2",
      "Melanoma",
      "Mutation",
      "Programmed Cell Death 1 Receptor",
      "Recurrence",
      "Sequence Analysis, DNA",
      "Signal Transduction",
      "beta 2-Microglobulin"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/27433843/",
    "summary_ja": "メラノーマに対する抗PD-1抗体（ペムブロリズマブ）で一度は客観的奏効を示した後、数か月〜数年を経て再増悪した転移性メラノーマ4例について、治療前と再発病変のペア生検を解析した。全エクソーム解析により、再発腫瘍ではクローン選択と増殖が示され、2例でJAK1またはJAK2の機能喪失変異（野生型アレル欠失を伴う）が同定された。別の1例ではB2Mの打ち切り変異が見つかり、MHCクラスIの細胞表面発現消失と関連した。これらの所見は、IFN受容体シグナル伝達や抗原提示経路の障害がPD-1阻害療法に対する獲得耐性の一因となりうることを示唆する。",
    "evidence_level": "4"
  },
  {
    "paper_id": "pubmed:35679518",
    "source": "pubmed",
    "source_id": "35679518",
    "title": "In Vivo Syngeneic Tumor Models with Acquired Resistance to Anti-PD-1/PD-L1 Therapies.",
    "year": 2022,
    "authors": [
      "Denis Morgane",
      "Grasselly Chloé",
      "Choffour Pierre-Antoine",
      "Wierinckx Anne",
      "Mathé Doriane",
      "Chettab Kamel",
      "Tourette Anne",
      "Talhi Nolan",
      "Bourguignon Aurore",
      "Birzele Fabian",
      "Kress Elsa",
      "Jordheim Lars Petter",
      "Klein Christian",
      "Matera Eva-Laure",
      "Dumontet Charles"
    ],
    "abstract": "Antibodies targeting PD-1 and PD-L1 have produced durable responses in a subset of patients with cancer. However, a majority of these patients will ultimately relapse due to acquired resistance. To explore the underlying mechanisms of this secondary resistance, we developed five syngeneic murine tumor variants with acquired resistance to anti-PD-1 and/or PD-L1 antibodies in vivo. Resistant in vivo models were obtained by serial treatment/reimplantation cycles of the MC38 colorectal, MB49 and MBT2 bladder, and RENCA kidney and TyrNras melanoma models. Tumor immune infiltrates were characterized for wild type and resistant tumors using spectral cytometry and their molecular alterations analyzed using RNA sequencing analyses. Alterations in the tumor immune microenvironment were strongly heterogeneous among resistant models, involving select lymphoid and/or myeloid subpopulations. Molecular alterations in resistant models included previously identified pathways as well as novel candidate genes found to be deregulated in several resistant models. Among these, Serpinf1, coding for pigment epithelial-derived factor (PEDF) was further explored in the MC38 and the MBT2 models. Overexpression of Serpinf1 induced resistance to anti-PD-1 antibodies in the MC38 model, whereas knockdown of Serpinf1 sensitized this model as well as the primarily resistant MBT2 model. Serpinf1 overexpression was associated with increased production of free fatty acids and reduced activation of CD8+ cells, while orlistat, a compound that reduces the production of free fatty acids, reversed resistance to anti-PD-1 therapy. Our results suggest that a panel of syngeneic resistant models constitutes a useful tool to model the heterogeneity of resistance mechanisms encountered in the clinic.",
    "journal": "Cancer immunology research",
    "pub_date": "2022-Aug",
    "doi": "10.1158/2326-6066.CIR-21-0802",
    "pmid": "35679518",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Animals",
      "B7-H1 Antigen",
      "Cell Line, Tumor",
      "Fatty Acids, Nonesterified",
      "Humans",
      "Mice",
      "Neoplasm Recurrence, Local",
      "Tumor Microenvironment"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/35679518/",
    "summary_ja": "抗PD-1/PD-L1抗体治療後に再燃する「獲得耐性」の機序解明のため、複数の同系マウス腫瘍モデルでin vivoの反復治療・再移植により耐性株を樹立した。スペクトルサイトメトリーとRNA-seqにより、耐性化に伴う腫瘍免疫微小環境と分子変化はモデル間で不均一で、リンパ系・骨髄系サブセットの変化が多様にみられた。候補遺伝子の一つSerpinf1（PEDF）に注目し、MC38では過剰発現が抗PD-1耐性を誘導し、ノックダウンはMC38および一次耐性のMBT2で感受性を高めた。Serpinf1過剰発現は遊離脂肪酸産生増加とCD8+細胞活性低下に関連し、脂肪酸産生を抑えるオルリスタットが耐性を逆転した。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:34215690",
    "source": "pubmed",
    "source_id": "34215690",
    "title": "STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation.",
    "year": 2021,
    "authors": [
      "Nakamura Takashi",
      "Sato Takanori",
      "Endo Rikito",
      "Sasaki Shun",
      "Takahashi Naomichi",
      "Sato Yusuke",
      "Hyodo Mamoru",
      "Hayakawa Yoshihiro",
      "Harashima Hideyoshi"
    ],
    "abstract": "BACKGROUND: Resistance to an immune checkpoint inhibitor (ICI) is a major obstacle in cancer immunotherapy. The causes of ICI resistance include major histocompatibility complex (MHC)/histocompatibility locus antigen (HLA) class I loss, neoantigen loss, and incomplete antigen presentation. Elimination by natural killer (NK) cells would be expected to be an effective strategy for the treatment of these ICI-resistant tumors. We previously demonstrated that a lipid nanoparticle containing a stimulator of an interferon gene (STING) agonist (STING-LNP) efficiently induced antitumor activity via the activation of NK cells. Thus, we evaluated the potential of reducing ICI resistance by STING-LNPs. METHODS: Lung metastasis of a B16-F10 mouse melanoma was used as an anti-programmed cell death 1 (anti-PD-1)-resistant mouse model. The mice were intravenously injected with the STING-LNP and the mechanism responsible for the improvement of anti-PD-1 resistance by the STING-LNPs was analyzed by RT-qPCR and flow cytometry. The dynamics of STING-LNP were also investigated. RESULTS: Although anti-PD-1 monotherapy failed to induce an antitumor effect, the combination of the STING-LNP and anti-PD-1 exerted a synergistic antitumor effect. Our results indicate that the STING-LNP treatment significantly increased the expression of CD3, CD4, NK1.1, PD-1 and interferon (IFN)-γ in lung metastases. This change appears to be initiated by the type I IFN produced by liver macrophages that contain the internalized STING-LNPs, leading to the systemic activation of NK cells that express PD-1. The activated NK cells appeared to produce IFN-γ, resulting in an increase in the expression of the PD ligand 1 (PD-L1) in cancer cells, thus leading to a synergistic antitumor effect when anti-PD-1 is administered. CONCLUSIONS: We provide a demonstration to show that a STING-LNP treatment can overcome PD-1 resistance in a B16-F10 lung metastasis model. The mechanism responsible for this indicates that NK cells are activated by stimulating the STING pathway which, in turn, induced the expression of PD-L1 on cancer cells. Based on the findings reported herein, the STING-LNP represents a promising candidate for use in combination therapy with anti-PD-1-resistant tumors.",
    "journal": "Journal for immunotherapy of cancer",
    "pub_date": "2021-Jul",
    "doi": "10.1136/jitc-2021-002852",
    "pmid": "34215690",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Animals",
      "Female",
      "Humans",
      "Killer Cells, Natural",
      "Liposomes",
      "Lung Neoplasms",
      "Melanoma, Experimental",
      "Membrane Proteins",
      "Mice",
      "Nanoparticles",
      "Neoplasm Metastasis",
      "STING Protein"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/34215690/",
    "summary_ja": "免疫チェックポイント阻害薬（抗PD-1）への耐性は腫瘍免疫療法の大きな課題であり、NK細胞による排除が有効になり得るという背景のもと、STINGアゴニスト搭載脂質ナノ粒子（STING-LNP）の有用性を検討した。抗PD-1抵抗性モデルとしてB16-F10メラノーマの肺転移マウスを用い、STING-LNP単独および抗PD-1との併用効果と機序をRT-qPCRとフローサイトメトリーで解析した。抗PD-1単独では効果が乏しい一方、STING-LNP併用で相乗的な抗腫瘍効果が得られ、肝マクロファージ由来のI型IFNを起点とした全身性NK細胞活性化とIFN-γ産生、腫瘍細胞のPD-L1発現増加が関与すると示唆された。これらより、STING-LNPは抗PD-1耐性腫瘍に対する併用療法候補となり得ることが示された。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:38703767",
    "source": "pubmed",
    "source_id": "38703767",
    "title": "Assessing personalized responses to anti-PD-1 treatment using patient-derived lung tumor-on-chip.",
    "year": 2024,
    "authors": [
      "Veith Irina",
      "Nurmik Martin",
      "Mencattini Arianna",
      "Damei Isabelle",
      "Lansche Christine",
      "Brosseau Solenn",
      "Gropplero Giacomo",
      "Corgnac Stéphanie",
      "Filippi Joanna",
      "Poté Nicolas",
      "Guenzi Edouard",
      "Chassac Anaïs",
      "Mordant Pierre",
      "Tosello Jimena",
      "Sedlik Christine",
      "Piaggio Eliane",
      "Girard Nicolas",
      "Camonis Jacques",
      "Shirvani Hamasseh",
      "Mami-Chouaib Fathia",
      "Mechta-Grigoriou Fatima",
      "Descroix Stéphanie",
      "Martinelli Eugenio",
      "Zalcman Gérard",
      "Parrini Maria Carla"
    ],
    "abstract": "There is a compelling need for approaches to predict the efficacy of immunotherapy drugs. Tumor-on-chip technology exploits microfluidics to generate 3D cell co-cultures embedded in hydrogels that recapitulate simplified tumor ecosystems. Here, we present the development and validation of lung tumor-on-chip platforms to quickly and precisely measure ex vivo the effects of immune checkpoint inhibitors on T cell-mediated cancer cell death by exploiting the power of live imaging and advanced image analysis algorithms. The integration of autologous immunosuppressive FAP",
    "journal": "Cell reports. Medicine",
    "pub_date": "2024-May",
    "doi": "10.1016/j.xcrm.2024.101549",
    "pmid": "38703767",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Humans",
      "Lung Neoplasms",
      "Precision Medicine",
      "Programmed Cell Death 1 Receptor",
      "Immune Checkpoint Inhibitors",
      "Carcinoma, Non-Small-Cell Lung",
      "Lab-On-A-Chip Devices",
      "Immunotherapy",
      "Tumor Microenvironment",
      "Cell Line, Tumor"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/38703767/",
    "summary_ja": "免疫療法薬の効果を事前に予測する手法が求められる中、マイクロ流体技術を用いたtumor-on-chipで、腫瘍生態系を簡略化して再現する3D共培養系を構築した。著者らは患者由来の肺腫瘍tumor-on-chipプラットフォームを開発・検証し、免疫チェックポイント阻害薬（抗PD-1など）がT細胞介在性のがん細胞死に与える影響をex vivoで迅速かつ精密に測定できることを示した。ライブイメージングと高度な画像解析アルゴリズムを組み合わせ、薬剤反応を定量評価することを目的としている。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:36630914",
    "source": "pubmed",
    "source_id": "36630914",
    "title": "Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8",
    "year": 2023,
    "authors": [
      "Tichet Mélanie",
      "Wullschleger Stephan",
      "Chryplewicz Agnieszka",
      "Fournier Nadine",
      "Marcone Rachel",
      "Kauzlaric Annamaria",
      "Homicsko Krisztian",
      "Deak Laura Codarri",
      "Umaña Pablo",
      "Klein Christian",
      "Hanahan Douglas"
    ],
    "abstract": "Immunotherapies have shown remarkable, albeit tumor-selective, therapeutic benefits in the clinic. Most patients respond transiently at best, highlighting the importance of understanding mechanisms underlying resistance. Herein, we evaluated the effects of the engineered immunocytokine PD1-IL2v in a mouse model of de novo pancreatic neuroendocrine cancer that is resistant to checkpoint and other immunotherapies. PD1-IL2v utilizes anti-PD-1 as a targeting moiety fused to an immuno-stimulatory IL-2 cytokine variant (IL2v) to precisely deliver IL2v to PD-1",
    "journal": "Immunity",
    "pub_date": "2023-Jan",
    "doi": "10.1016/j.immuni.2022.12.006",
    "pmid": "36630914",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Animals",
      "Mice",
      "B7-H1 Antigen",
      "CD8-Positive T-Lymphocytes",
      "Disease Models, Animal",
      "Immunotherapy",
      "Macrophages",
      "Neoplasms",
      "Tumor Microenvironment",
      "Antibodies, Bispecific",
      "Interleukin-2",
      "Programmed Cell Death 1 Receptor"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/36630914/",
    "summary_ja": "本研究は、免疫療法に抵抗性を示す腫瘍における抵抗性機序の理解と克服を目的として、工学的免疫サイトカインPD1-IL2vの効果を検討した。抵抗性のデノボ膵神経内分泌腫瘍マウスモデルで、チェックポイント阻害など従来の免疫療法が効きにくい状況下での反応を評価している。PD1-IL2vは抗PD-1抗体を標的化モジュールとしてIL-2変異体（IL2v）を融合し、PD-1陽性細胞へIL2vを選択的に送達する設計である。タイトルが示すように、抗PD-L1との併用により腫瘍免疫抵抗性を打破し、幹細胞様の腫瘍反応性CD8 T細胞の増強に寄与することが示唆される。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:40084746",
    "source": "pubmed",
    "source_id": "40084746",
    "title": "Blocking ITGA5 potentiates the efficacy of anti-PD-1 therapy on glioblastoma by remodeling tumor-associated macrophages.",
    "year": 2025,
    "authors": [
      "Zhao Rongrong",
      "Pan Ziwen",
      "Qiu Jiawei",
      "Li Boyan",
      "Qi Yanhua",
      "Gao Zijie",
      "Qiu Wei",
      "Tang Weijie",
      "Guo Xiaofan",
      "Deng Lin",
      "Li Gang",
      "Xue Hao"
    ],
    "abstract": "BACKGROUND: Glioblastoma (GBM) is largely refractory to antibodies against programmed cell death 1 (anti-PD-1) therapy. Fully understanding the cellular heterogeneity and immune adaptations in response to anti-PD-1 therapy is necessary to design more effective immunotherapies for GBM. This study aimed to dissect the molecular mechanisms of specific immunosuppressive subpopulations to drive anti-PD-1 resistance in GBM. METHODS: We systematically analysed single-cell RNA sequencing and spatial transcriptomics data from GBM tissues receiving anti-PD-1 therapy to characterize the microenvironment alterations. The biological functions of a novel circular RNA (circRNA) were validated both in vitro and in vivo. Mechanically, co-immunoprecipitation, RNA immunoprecipitation and pull-down assays were conducted. RESULTS: Mesenchymal GBM (MES-GBM) cells, which were associated with a poor prognosis, and secreted phosphoprotein 1 (SPP1) CONCLUSIONS: This work elucidated the potential tissue adaptation mechanism of intratumoral dynamic interactions between MES-GBM cells, MDMs and T cells in anti-PD-1 non-responders and identified the therapeutic potential of targeting ITGA5 to reduce anti-PD-1 resistance in GBM.",
    "journal": "Cancer communications (London, England)",
    "pub_date": "2025-Jun",
    "doi": "10.1002/cac2.70016",
    "pmid": "40084746",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Glioblastoma",
      "Humans",
      "Animals",
      "Mice",
      "Tumor-Associated Macrophages",
      "Tumor Microenvironment",
      "Programmed Cell Death 1 Receptor",
      "Immune Checkpoint Inhibitors",
      "Brain Neoplasms",
      "Cell Line, Tumor",
      "RNA, Circular",
      "Drug Resistance, Neoplasm",
      "Xenograft Model Antitumor Assays",
      "Integrins"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/40084746/",
    "summary_ja": "本研究は、膠芽腫（GBM）が抗PD-1療法に抵抗性を示す背景として、腫瘍内の細胞不均一性と免疫微小環境の適応機構を解明することを目的とした。抗PD-1治療を受けたGBM組織の単一細胞RNAシーケンスおよび空間トランスクリプトミクス解析により、腫瘍微小環境の変化と免疫抑制に関与するサブ集団を同定した。さらに、新規circRNAの機能をin vitro/in vivoで検証し、免疫沈降法などを用いて分子機序を解析した。結論として、MES-GBM細胞・腫瘍関連マクロファージ（特に単球由来）・T細胞の相互作用が非奏効に関与し、ITGA5阻害が腫瘍関連マクロファージを再構築して抗PD-1の有効性を高め得る可能性を示した。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:29071761",
    "source": "pubmed",
    "source_id": "29071761",
    "title": "Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy.",
    "year": 2018,
    "authors": [
      "Chowdhury P S",
      "Chamoto K",
      "Honjo T"
    ],
    "abstract": "Programmed death 1 (PD-1) is an immune checkpoint molecule that negatively regulates T-cell immune function through the interaction with its ligand PD-L1. Blockage of this interaction unleashes the immune system to fight cancer. Immunotherapy using PD-1 blockade has led to a paradigm shift in the field of cancer drug discovery, owing to its durable effect against a wide variety of cancers with limited adverse effects. A brief history and development of PD-1 blockade, from the initial discovery of PD-1 to the recent clinical output of this therapy, have been summarized here. Despite its tremendous clinical success rate over other cancer treatments, PD-1 blockade has its own pitfall; a significant fraction of patients remains unresponsive to this therapy. The key to improve the PD-1 blockade therapy is the development of combination therapies. As this approach has garnered worldwide interest, here, we have summarized the recent trends in the development of PD-1 blockade-based combination therapies and the ongoing clinical trials. These include combinations with checkpoint inhibitors, radiation therapy, chemotherapy and several other existing cancer treatments. Importantly, FDA has approved PD-1 blockade agent to be used in combination with either CTLA-4 blockade or chemotherapy. Responsiveness to the PD-1 blockade therapy is affected by tumour and immune system-related factors. The role of the immune system, especially T cells, in determining the responsiveness has been poorly studied compared with those factors related to the tumour side. Energy metabolism has emerged as one of the important regulatory mechanisms for the function and differentiation of T cells. We have documented here the recent results regarding the augmentation of PD-1 blockade efficacy by augmenting mitochondrial energy metabolism of T cell.",
    "journal": "Journal of internal medicine",
    "pub_date": "2018-Feb",
    "doi": "10.1111/joim.12708",
    "pmid": "29071761",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Animals",
      "Antineoplastic Agents",
      "B-Lymphocytes",
      "Combined Modality Therapy",
      "Humans",
      "Immunotherapy",
      "Neoplasms",
      "Programmed Cell Death 1 Receptor",
      "T-Lymphocytes"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/29071761/",
    "summary_ja": "PD-1/PD-L1相互作用を阻害するPD-1阻害療法は、幅広いがんで持続的効果と比較的少ない有害事象を示し、がん免疫療法の潮流を変えた。本稿はPD-1の発見から臨床応用までの経緯を概説しつつ、反応しない患者が一定割合存在するという課題を指摘する。その克服策として、他の免疫チェックポイント阻害、放射線、化学療法などとの併用療法の開発動向と進行中の臨床試験を整理し、FDA承認の併用例にも触れる。さらに、治療反応性に影響する免疫側因子、とくにT細胞のエネルギー代謝（ミトコンドリア代謝）を増強してPD-1阻害効果を高める可能性をまとめている。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:33589525",
    "source": "pubmed",
    "source_id": "33589525",
    "title": "Therapeutic depletion of CCR8",
    "year": 2021,
    "authors": [
      "Van Damme Helena",
      "Dombrecht Bruno",
      "Kiss Máté",
      "Roose Heleen",
      "Allen Elizabeth",
      "Van Overmeire Eva",
      "Kancheva Daliya",
      "Martens Liesbet",
      "Murgaski Aleksandar",
      "Bardet Pauline Madeleine Rachel",
      "Blancke Gillian",
      "Jans Maude",
      "Bolli Evangelia",
      "Martins Maria Solange",
      "Elkrim Yvon",
      "Dooley James",
      "Boon Louis",
      "Schwarze Julia Katharina",
      "Tacke Frank",
      "Movahedi Kiavash",
      "Vandamme Niels",
      "Neyns Bart",
      "Ocak Sebahat",
      "Scheyltjens Isabelle",
      "Vereecke Lars",
      "Nana Frank Aboubakar",
      "Merchiers Pascal",
      "Laoui Damya",
      "Van Ginderachter Jo Agnes"
    ],
    "abstract": "BACKGROUND: Modulation and depletion strategies of regulatory T cells (Tregs) constitute valid approaches in antitumor immunotherapy but suffer from severe adverse effects due to their lack of selectivity for the tumor-infiltrating (ti-)Treg population, indicating the need for a ti-Treg specific biomarker. METHODS: We employed single-cell RNA-sequencing in a mouse model of non-small cell lung carcinoma (NSCLC) to obtain a comprehensive overview of the tumor-infiltrating T-cell compartment, with a focus on ti-Treg subpopulations. These findings were validated by flow cytometric analysis of both mouse (LLC-OVA, MC38 and B16-OVA) and human (NSCLC and melanoma) tumor samples. We generated two CCR8-specific nanobodies (Nbs) that recognize distinct epitopes on the CCR8 extracellular domain. These Nbs were formulated as tetravalent Nb-Fc fusion proteins for optimal CCR8 binding and blocking, containing either an antibody-dependent cell-mediated cytotoxicity (ADCC)-deficient or an ADCC-prone Fc region. The therapeutic use of these Nb-Fc fusion proteins was evaluated, either as monotherapy or as combination therapy with anti-programmed cell death protein-1 (anti-PD-1), in both the LLC-OVA and MC38 mouse models. RESULTS: We were able to discern two ti-Treg populations, one of which is characterized by the unique expression of  CONCLUSIONS: Collectively, our findings highlight the efficacy and safety of targeting CCR8 for the depletion of tumor-promoting ti-Tregs in combination with anti-PD-1 therapy.",
    "journal": "Journal for immunotherapy of cancer",
    "pub_date": "2021-Feb",
    "doi": "10.1136/jitc-2020-001749",
    "pmid": "33589525",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Animals",
      "Antineoplastic Agents, Immunological",
      "Carcinoma, Lewis Lung",
      "Combined Modality Therapy",
      "Databases, Genetic",
      "Female",
      "Gene Expression Profiling",
      "Humans",
      "Immune Checkpoint Inhibitors",
      "Lung Neoplasms",
      "Lymphocyte Depletion",
      "Lymphocytes, Tumor-Infiltrating",
      "Melanoma, Experimental",
      "Mice, Inbred C57BL",
      "Mice, Knockout",
      "Molecular Targeted Therapy",
      "Phenotype",
      "Programmed Cell Death 1 Receptor",
      "RNA-Seq",
      "Receptors, CCR8",
      "Skin Neoplasms",
      "T-Lymphocytes, Regulatory",
      "Mice"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/33589525/",
    "summary_ja": "本研究は、腫瘍浸潤性Treg（ti-Treg）を選択的に標的化できるバイオマーカーとしてCCR8に着目し、NSCLCマウスモデルの単一細胞RNA-seqで腫瘍内T細胞、とくにti-Treg亜集団を解析した。得られた所見を、複数のマウス腫瘍モデルおよびヒト（NSCLC・メラノーマ）腫瘍検体のフローサイトメトリーで検証した。さらにCCR8特異的ナノボディを作製し、ADCC能の異なるNb-Fc融合タンパクとして単独または抗PD-1併用で治療評価した。総合的に、CCR8標的化は腫瘍促進的ti-Tregの枯渇を介して、特に抗PD-1併用で有効かつ安全である可能性が示唆された。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:39107132",
    "source": "pubmed",
    "source_id": "39107132",
    "title": "Targeting tumor-associated macrophage-derived CD74 improves efficacy of neoadjuvant chemotherapy in combination with PD-1 blockade for cervical cancer.",
    "year": 2024,
    "authors": [
      "Wang Zixiang",
      "Wang Bingyu",
      "Feng Yuan",
      "Ye Jinwen",
      "Mao Zhonghao",
      "Zhang Teng",
      "Xu Meining",
      "Zhang Wenjing",
      "Jiao Xinlin",
      "Zhang Qing",
      "Zhang Youzhong",
      "Cui Baoxia"
    ],
    "abstract": "BACKGROUND: Cervical cancer has the second-highest mortality rate among malignant tumors of the female reproductive system. Immune checkpoint inhibitors such as programmed cell death protein 1 (PD-1) blockade are promising therapeutic agents, but their efficacy when combined with neoadjuvant chemotherapy (NACT) has not been fully tested, and how they alter the tumor microenvironment has not been comprehensively elucidated. METHODS: In this study, we conducted single-cell RNA sequencing using 46,950 cells from nine human cervical cancer tissues representing sequential different stages of NACT and PD-1 blockade combination therapy. We delineated the trajectory of cervical epithelial cells and identified the crucial factors involved in combination therapy. Cell-cell communication analysis was performed between tumor and immune cells. In addition, THP-1-derived and primary monocyte-derived macrophages were cocultured with cervical cancer cells and phagocytosis was detected by flow cytometry. The antitumor activity of blocking CD74 was validated in vivo using a CD74 humanized subcutaneous tumor model. RESULTS: Pathway enrichment analysis indicated that NACT activated cytokine and complement-related immune responses. Cell-cell communication analysis revealed that after NACT therapy, interaction strength between T cells and cancer cells decreased, but intensified between macrophages and cancer cells. We verified that macrophages were necessary for the PD-1 blockade to exert antitumor effects in vitro. Additionally, CD74-positive macrophages frequently interacted with the most immunoreactive epithelial subgroup 3 (Epi3) cancer subgroup during combination NACT. We found that CD74 upregulation limited phagocytosis and stimulated M2 polarization, whereas CD74 blockade enhanced macrophage phagocytosis, decreasing cervical cancer cell viability in vitro and in vivo. CONCLUSIONS: Our study reveals the dynamic cell-cell interaction network in the cervical cancer microenvironment influenced by combining NACT and PD-1 blockade. Furthermore, blocking tumor-associated macrophage-derived CD74 could augment neoadjuvant therapeutic efficacy.",
    "journal": "Journal for immunotherapy of cancer",
    "pub_date": "2024-Aug",
    "doi": "10.1136/jitc-2024-009024",
    "pmid": "39107132",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Uterine Cervical Neoplasms",
      "Humans",
      "Female",
      "Neoadjuvant Therapy",
      "Tumor-Associated Macrophages",
      "Mice",
      "Animals",
      "Immune Checkpoint Inhibitors",
      "Programmed Cell Death 1 Receptor",
      "Tumor Microenvironment",
      "Antigens, Differentiation, B-Lymphocyte",
      "Antineoplastic Combined Chemotherapy Protocols",
      "Histocompatibility Antigens Class II"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/39107132/",
    "summary_ja": "本研究は、子宮頸癌における術前補助化学療法（NACT）とPD-1阻害の併用が腫瘍微小環境をどのように変化させるかを、9検体・46,950細胞の単一細胞RNAシーケンスで解析した。NACT後はT細胞と癌細胞の相互作用が低下する一方、マクロファージと癌細胞の相互作用が増強し、PD-1阻害の抗腫瘍効果にはマクロファージが必要であることをin vitroで示した。特にCD74陽性腫瘍随伴マクロファージが免疫反応性の高い上皮サブグループ（Epi3）と頻繁に相互作用し、CD74上昇が貪食抑制とM2極性化を促すことが示唆された。CD74遮断はマクロファージ貪食を高め、子宮頸癌細胞の生存率をin vitroおよびCD74ヒト化モデルin vivoで低下させ、併用療法の効果増強標的となり得ると結論づけた。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:37956404",
    "source": "pubmed",
    "source_id": "37956404",
    "title": "Combination of Anti-PD-1 and Electroacupuncture Induces a Potent Antitumor Immune Response in Microsatellite-Stable Colorectal Cancer.",
    "year": 2024,
    "authors": [
      "Wang Yuan",
      "Liu Fengyi",
      "Du Xiaoxue",
      "Shi Jiaqi",
      "Yu Rui",
      "Li Shuang",
      "Na Ruisi",
      "Zhao Ying",
      "Zhou Meng",
      "Guo Ying",
      "Cheng Liang",
      "Wang Guangyu",
      "Zheng Tongsen"
    ],
    "abstract": "Programmed death receptor-1 (PD-1) inhibitors are ineffective against microsatellite-stable (MSS) colorectal cancer. Electroacupuncture (EA) has oncosuppressive and immunomodulatory properties. Here, we investigated the antitumor effects of EA and explored the feasibility of EA combined with anti-PD-1 in MSS colorectal cancer. Results showed that EA exerted its antitumor effect in an intensity-specific manner, and moderate-intensity EA (1.0 mA) induced maximal tumor inhibition. EA enhanced antitumor immune responses by increasing lymphocytes and granzyme B (GzmB) levels, as well as activating the stimulator of IFN genes (STING) pathway. EA combined with anti-PD-1 showed superior efficacy compared with either monotherapy in multiple MSS colorectal cancer mouse models. Single-cell RNA sequencing revealed that cotreatment reprogrammed the tumor immune microenvironment (TIME), as characterized by enhancement of cytotoxic functions. Mechanically, we found that the potentiated effect of EA was dependent upon the STING pathway. Collectively, EA reshapes the TIME of MSS colorectal cancer and sensitizes tumors to anti-PD-1 in a STING pathway-dependent manner. These results provide a mechanistic rationale for using EA as an immunomodulatory strategy to improve the clinical efficacy of anti-PD-1 in MSS colorectal cancer. EA is safe, well-tolerated, and feasible for clinical translation as a promising strategy for treating MSS colorectal cancer.",
    "journal": "Cancer immunology research",
    "pub_date": "2024-Jan",
    "doi": "10.1158/2326-6066.CIR-23-0309",
    "pmid": "37956404",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Animals",
      "Mice",
      "Electroacupuncture",
      "Colorectal Neoplasms",
      "Antineoplastic Agents",
      "Microsatellite Repeats",
      "Immunity",
      "Tumor Microenvironment"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/37956404/",
    "summary_ja": "本研究は、PD-1阻害薬が効きにくいマイクロサテライト安定型（MSS）大腸がんに対し、電気鍼（EA）の抗腫瘍効果と抗PD-1併用の有効性をマウスモデルで検討した。EAは刺激強度依存的に腫瘍増殖を抑制し、1.0 mAの中等度刺激で最大の抑制効果を示した。EAはリンパ球増加やグランザイムB上昇など細胞傷害性免疫を高め、STING経路の活性化を介して腫瘍免疫微小環境を再プログラムした。さらに、EAと抗PD-1の併用は単独療法より複数のMSS大腸がんマウスモデルで優れた抗腫瘍効果を示し、この増強効果はSTING経路依存的であることが示唆された。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:38429070",
    "source": "pubmed",
    "source_id": "38429070",
    "title": "Mitochondria-targeted photodynamic therapy triggers GSDME-mediated pyroptosis and sensitizes anti-PD-1 therapy in colorectal cancer.",
    "year": 2024,
    "authors": [
      "Zhou Yun",
      "Zhang Wenyao",
      "Wang Boda",
      "Wang Pei",
      "Li Danxiu",
      "Cao Tianyu",
      "Zhang Dawei",
      "Han Hua",
      "Bai Mingfeng",
      "Wang Xin",
      "Zhao Xiaodi",
      "Lu Yuanyuan"
    ],
    "abstract": "BACKGROUND: The effectiveness of immune checkpoint inhibitors in colorectal cancer (CRC) is limited due to the low tumor neoantigen load and low immune infiltration in most microsatellite-stable (MSS) tumors. This study aimed to develop a mitochondria-targeted photodynamic therapy (PDT) approach to provoke host antitumor immunity of MSS-CRC and elucidate the underlying molecular mechanisms. METHODS: The role and mechanism of mitochondria-targeted PDT in inhibiting CRC progression and inducing pyroptosis were evaluated both in vitro and in vivo. The immune effects of PDT sensitization on PD-1 blockade were also assessed in CT26 and 4T1 tumor-bearing mouse models. RESULTS: Here, we report that PDT using IR700DX-6T, a photosensitizer targeting the mitochondrial translocation protein, may trigger an antitumor immune response initiated by pyroptosis in CRC. Mechanistically, IR700DX-6T-PDT produced reactive oxygen species on light irradiation and promoted downstream p38 phosphorylation and active caspase3 (CASP3)-mediated cleavage of gasdermin E (GSDME), subsequently inducing pyroptosis. Furthermore, IR700DX-6T-PDT enhanced the sensitivity of MSS-CRC cells to PD-1 blockade. Decitabine, a demethylation drug used to treat hematologic neoplasms, disrupted the abnormal methylation pattern of GSDME in tumor cells, enhanced the efficacy of IR700DX-6T-PDT, and elicited a potent antitumor immune response in combination with PD-1 blockade and IR700DX-6T-PDT. CONCLUSION: Our work provides clear a understanding of immunogenic cell death triggered by mitochondria-targeted PDT, offering a new approach for enhancing the efficacy of PD-1 blockade in CRC.",
    "journal": "Journal for immunotherapy of cancer",
    "pub_date": "2024-Mar",
    "doi": "10.1136/jitc-2023-008054",
    "pmid": "38429070",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Animals",
      "Mice",
      "Cell Line, Tumor",
      "Colorectal Neoplasms",
      "Immunotherapy",
      "Mitochondria",
      "Photochemotherapy",
      "Programmed Cell Death 1 Receptor",
      "Pyroptosis",
      "Gasdermins",
      "Immune Checkpoint Inhibitors"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/38429070/",
    "summary_ja": "本研究は、免疫チェックポイント阻害薬が効きにくいMSS型大腸がんに対し、ミトコンドリア標的の光線力学療法（IR700DX-6T-PDT）で抗腫瘍免疫を誘導できるかを検討した。IR700DX-6T-PDTは光照射によりROSを産生し、p38活性化とCASP3によるGSDME切断を介してパイロトーシス（免疫原性細胞死）を誘導することが示された。さらにPDTは抗PD-1療法への感受性を高め、GSDMEのメチル化異常を脱メチル化するデシタビン併用で効果が増強し、マウス腫瘍モデルでより強い抗腫瘍免疫が得られた。これらはPDTを用いてPD-1阻害の有効性を高める新規戦略を提案する。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:38554419",
    "source": "pubmed",
    "source_id": "38554419",
    "title": "Comparing Safety and Efficacy of TACE + Apatinib in Combination with a PD-1 Inhibitor versus a Non-triple Therapy for Treating Advanced Primary Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.",
    "year": 2024,
    "authors": [
      "Pan Di",
      "Liu Haonan",
      "Qu Pengfei",
      "Chen Xiaoxiao",
      "Ma Xiao",
      "Wang Yuqin",
      "Qin Xiaobing",
      "Han Zhengxiang"
    ],
    "abstract": "BACKGROUND AND AIMS: This meta-analysis was performed to compare the efficacy and safety of a triple therapy, involving transcatheter arterial chemoembolization (TACE) + apatinib combined with a programmed-cell death protein-1 (PD-1) inhibitor versus TACE + apatinib, a dual therapy with apatinib and PD-1 inhibitor, and TACE alone for the treatment of advanced primary hepatocellular carcinoma (HCC). METHODS: A computerized systematic search of databases, such as PubMed, Embase, the Cochrane Library, CNKI, Wanfang Data, and VIP e-Journals was performed to retrieve studies comparing TACE + apatinib combined with a PD-1 inhibitor versus a non-triple therapy for the treatment of advanced primary HCC. The literature search, quality assessment, and data extraction were performed independently by two researchers. Stata 16.0 software was employed to analyze the data. Heterogeneity was assessed utilizing the I2 statistic and p-value, followed by conducting sensitivity analysis. RESULTS: A total of 2,352 patients were enrolled from 8 studies, including 900 patients in the triple therapy group of TACE + apatinib combined with a PD-1 inhibitor, 877 patients in the TACE + apatinib group, 52 patients in the apatinib + a PD-1 inhibitor group, and 112 patients in the TACE group. The results revealed that the objective response rate (ORR) was significantly higher in the triple therapy group of TACE + apatinib combined with a PD-1 inhibitor than that in the non-triple therapy group [odds ratio (OR)=2.47, 95% confidence interval (95%CI): 1.61-3.78]. Besides, disease control rate (DCR) was greater in the triple therapy group of TACE + apatinib combined with a PD-1 inhibitor than that in the non-triple therapy group (OR=1.87, 95%CI: 1.44-2.44). Patients in the triple therapy group experienced a significant extension of overall survival (OS) (HR=0.42, 95%CI: 0.36-0.49). In addition, there was no significant difference in the overall rate of adverse events (AEs) between the two groups (OR=1.05, 95%CI: 0.89-1.22). CONCLUSIONS: Compared with the non-triple therapy group, the triple therapy group of TACE + apatinib combined with a PD-1 inhibitor outperformed in terms of tumor response and long-term survival with manageable AEs.",
    "journal": "Journal of gastrointestinal and liver diseases : JGLD",
    "pub_date": "2024-Mar",
    "doi": "10.15403/jgld-5159",
    "pmid": "38554419",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Humans",
      "Antineoplastic Agents",
      "Carcinoma, Hepatocellular",
      "Chemoembolization, Therapeutic",
      "Combined Modality Therapy",
      "Immune Checkpoint Inhibitors",
      "Liver Neoplasms",
      "Pyridines"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/38554419/",
    "summary_ja": "進行原発性肝細胞癌に対し、TACE＋アパチニブ＋PD-1阻害薬の三者併用療法を、非三者併用（TACE＋アパチニブ、アパチニブ＋PD-1阻害薬、TACE単独）と比較した系統的レビュー／メタ解析である。8研究・計2,352例を解析し、三者併用は客観的奏効率（ORR）と病勢制御率（DCR）を有意に改善した。全生存期間（OS）も延長し（HR=0.42）、腫瘍反応と長期予後の面で優れていた。有害事象の全体発生率は群間で有意差がなく、忍容性は概ね良好と結論づけられた。",
    "evidence_level": "2a"
  },
  {
    "paper_id": "pubmed:38566201",
    "source": "pubmed",
    "source_id": "38566201",
    "title": "Single-cell profiling of response to neoadjuvant chemo-immunotherapy in surgically resectable esophageal squamous cell carcinoma.",
    "year": 2024,
    "authors": [
      "Ji Gang",
      "Yang Qi",
      "Wang Song",
      "Yan Xiaolong",
      "Ou Qiuxiang",
      "Gong Li",
      "Zhao Jinbo",
      "Zhou Yongan",
      "Tian Feng",
      "Lei Jie",
      "Mu Xiaorong",
      "Wang Jian",
      "Wang Tao",
      "Wang Xiaoping",
      "Sun Jianyong",
      "Zhang Jipeng",
      "Jia Chenghui",
      "Jiang Tao",
      "Zhao Ming-Gao",
      "Lu Qiang"
    ],
    "abstract": "BACKGROUND: The efficacy of neoadjuvant chemo-immunotherapy (NAT) in esophageal squamous cell carcinoma (ESCC) is challenged by the intricate interplay within the tumor microenvironment (TME). Unveiling the immune landscape of ESCC in the context of NAT could shed light on heterogeneity and optimize therapeutic strategies for patients. METHODS: We analyzed single cells from 22 baseline and 24 post-NAT treatment samples of stage II/III ESCC patients to explore the association between the immune landscape and pathological response to neoadjuvant anti-PD-1 combination therapy, including pathological complete response (pCR), major pathological response (MPR), and incomplete pathological response (IPR). RESULTS: Single-cell profiling identified 14 major cell subsets of cancer, immune, and stromal cells. Trajectory analysis unveiled an interesting link between cancer cell differentiation and pathological response to NAT. ESCC tumors enriched with less differentiated cancer cells exhibited a potentially favorable pathological response to NAT, while tumors enriched with clusters of more differentiated cancer cells may resist treatment. Deconvolution of transcriptomes in pre-treatment tumors identified gene signatures in response to NAT contributed by specific immune cell populations. Upregulated genes associated with better pathological responses in CD8 + effector T cells primarily involved interferon-gamma (IFNγ) signaling, neutrophil degranulation, and negative regulation of the T cell apoptotic process, whereas downregulated genes were dominated by those in the immune response-activating cell surface receptor signaling pathway. Natural killer cells in pre-treatment tumors from pCR patients showed a similar upregulation of gene expression in response to IFNγ but a downregulation of genes in the neutrophil-mediated immunity pathways. A decreased cellular contexture of regulatory T cells in ESCC TME indicated a potentially favorable pathological response to NAT. Cell-cell communication analysis revealed extensive interactions between CCL5 and its receptor CCR5 in various immune cells of baseline pCR tumors. Immune checkpoint interaction pairs, including CTLA4-CD86, TIGIT-PVR, LGALS9-HAVCR2, and TNFSF4-TNFRSF4, might serve as additional therapeutic targets for ICI therapy in ESCC. CONCLUSIONS: This pioneering study unveiled an intriguing association between cancer cell differentiation and pathological response in esophageal cancer patients, revealing distinct subgroups of tumors for which neoadjuvant chemo-immunotherapy might be effective. We also delineated the immune landscape of ESCC tumors in the context of clinical response to NAT, which provides clinical insights for better understanding how patients respond to the treatment and further identifying novel therapeutic targets for ESCC patients in the future.",
    "journal": "Genome medicine",
    "pub_date": "2024-Apr",
    "doi": "10.1186/s13073-024-01320-9",
    "pmid": "38566201",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Humans",
      "Esophageal Squamous Cell Carcinoma",
      "Neoadjuvant Therapy",
      "Esophageal Neoplasms",
      "Immunotherapy",
      "Combined Modality Therapy",
      "Tumor Microenvironment",
      "OX40 Ligand"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/38566201/",
    "summary_ja": "切除可能な食道扁平上皮癌（ESCC）患者における術前化学免疫療法（抗PD-1併用）の病理学的奏効と腫瘍微小環境（TME）の関係を、治療前22例・治療後24例の単一細胞解析で検討した。単一細胞プロファイリングにより癌・免疫・間質を含む主要14細胞サブセットを同定し、癌細胞の分化状態が奏効（pCR/MPR/IPR）と関連する可能性が示された。治療前腫瘍では、CD8+エフェクターT細胞のIFNγ関連経路の亢進や制御性T細胞の減少、CCL5-CCR5などの細胞間相互作用が良好奏効と結び付く所見が得られ、追加の免疫チェックポイント標的候補も提示された。これらの結果は、奏効しやすい腫瘍サブグループの層別化と新規標的探索に資する免疫景観の特徴を示唆する。",
    "evidence_level": "2b"
  },
  {
    "paper_id": "pubmed:37291608",
    "source": "pubmed",
    "source_id": "37291608",
    "title": "Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials.",
    "year": 2023,
    "authors": [
      "Chu Xianjing",
      "Tian Wentao",
      "Wang Ziqi",
      "Zhang Jing",
      "Zhou Rongrong"
    ],
    "abstract": "Over the past decade, immune checkpoint inhibitors (ICIs) have emerged as a revolutionary cancer treatment modality, offering long-lasting responses and survival benefits for a substantial number of cancer patients. However, the response rates to ICIs vary significantly among individuals and cancer types, with a notable proportion of patients exhibiting resistance or showing no response. Therefore, dual ICI combination therapy has been proposed as a potential strategy to address these challenges. One of the targets is TIGIT, an inhibitory receptor associated with T-cell exhaustion. TIGIT has diverse immunosuppressive effects on the cancer immunity cycle, including the inhibition of natural killer cell effector function, suppression of dendritic cell maturation, promotion of macrophage polarization to the M2 phenotype, and differentiation of T cells to regulatory T cells. Furthermore, TIGIT is linked with PD-1 expression, and it can synergize with PD-1/PD-L1 blockade to enhance tumor rejection. Preclinical studies have demonstrated the potential benefits of co-inhibition of TIGIT and PD-1/PD-L1 in enhancing anti-tumor immunity and improving treatment outcomes in several cancer types. Several clinical trials are underway to evaluate the safety and efficacy of TIGIT and PD-1/PD-L1 co-inhibition in various cancer types, and the results are awaited. This review provides an overview of the mechanisms of TIGIT and PD-1/PD-L1 co-inhibition in anti-tumor treatment, summarizes the latest clinical trials investigating this combination therapy, and discusses its prospects. Overall, co-inhibition of TIGIT and PD-1/PD-L1 represents a promising therapeutic approach for cancer treatment that has the potential to improve the outcomes of cancer patients treated with ICIs.",
    "journal": "Molecular cancer",
    "pub_date": "2023-Jun",
    "doi": "10.1186/s12943-023-01800-3",
    "pmid": "37291608",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Humans",
      "Programmed Cell Death 1 Receptor",
      "B7-H1 Antigen",
      "Neoplasms",
      "Immunotherapy",
      "Combined Modality Therapy",
      "Receptors, Immunologic"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/37291608/",
    "summary_ja": "免疫チェックポイント阻害薬は有効例がある一方で、がん種や個人差により無効・抵抗性が多いことから、二重阻害などの併用戦略が検討されている。TIGITはT細胞疲弊に関わる抑制性受容体で、NK細胞機能低下、樹状細胞成熟抑制、マクロファージのM2極性化促進、制御性T細胞誘導など多面的に抗腫瘍免疫を抑える。TIGITはPD-1発現と関連し、TIGITとPD-1/PD-L1の同時阻害は相乗的に腫瘍拒絶を高めうることが前臨床で示されている。現在、安全性・有効性を検証する臨床試験が進行中であり、本レビューは作用機序と臨床試験動向、今後の展望を概説している。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:36872527",
    "source": "pubmed",
    "source_id": "36872527",
    "title": "Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity.",
    "year": 2023,
    "authors": [
      "Pang Xinghua",
      "Huang Zhaoliang",
      "Zhong Tingting",
      "Zhang Peng",
      "Wang Zhongmin Maxwell",
      "Xia Michelle",
      "Li Baiyong"
    ],
    "abstract": "Clinical studies have shown that combination therapy of antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death-1 (PD-1) significantly improves clinical benefit over PD-1 antibody alone. However, broad application of this combination has been limited by toxicities. Cadonilimab (AK104) is a symmetric tetravalent bispecific antibody with a crystallizable fragment (Fc)-null design. In addition to demonstrating biological activity similar to that of the combination of CTLA-4 and PD-1 antibodies, cadonilimab possess higher binding avidity in a high-density PD-1 and CTLA-4 setting than in a low-density PD-1 setting, while a mono-specific anti-PD-1 antibody does not demonstrate this differential activity. With no binding to Fc receptors, cadonilimab shows minimal antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, and interleukin-6 (IL-6)/IL-8 release. These features all likely contribute to significantly lower toxicities of cadonilimab observed in the clinic. Higher binding avidity of cadonilimab in a tumor-like setting and Fc-null design may lead to better drug retention in tumors and contribute to better safety while achieving anti-tumor efficacy.",
    "journal": "mAbs",
    "pub_date": "2023",
    "doi": "10.1080/19420862.2023.2180794",
    "pmid": "36872527",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "CTLA-4 Antigen",
      "Antibodies, Bispecific",
      "Antibody-Dependent Cell Cytotoxicity",
      "Combined Modality Therapy",
      "Immune Checkpoint Inhibitors"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/36872527/",
    "summary_ja": "PD-1とCTLA-4を同時に標的とする抗体併用療法は有効性が高い一方で毒性が課題となる。Cadonilimab（AK104）はFc機能を無効化した対称性四価の二重特異性抗体で、PD-1/CTLA-4抗体併用に近い生物学的活性を示す。腫瘍環境を模したPD-1/CTLA-4高密度条件で結合アビディティが高まり、腫瘍内滞留の改善が示唆される。Fc受容体に結合しないためADCC/ADCPやIL-6/IL-8放出が最小で、臨床で観察された低毒性に寄与する可能性がある。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:39671272",
    "source": "pubmed",
    "source_id": "39671272",
    "title": "Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial.",
    "year": 2025,
    "authors": [
      "Chen Li",
      "Li Hui",
      "Zhang Hao",
      "Yang Huawei",
      "Qian Jun",
      "Li Zhihua",
      "Ren Yu",
      "Wang Shu",
      "Fu Peifen",
      "Yang Hongjian",
      "Liu Yunjiang",
      "Sun Jing",
      "Nie Jianyun",
      "Lei Ruiwen",
      "Yao Yongzhong",
      "Zhang Anqin",
      "Wang Shouman",
      "Ma Xiaopeng",
      "Ouyang Zhong",
      "Yang Hongwei",
      "Wu Song-Yang",
      "Cao Shuo-Wen",
      "Wang Kun",
      "Jiang Aimei",
      "Ouyang Quchang",
      "Pang Da",
      "Wei Limin",
      "Zha Xiaoming",
      "Shen Yu",
      "Qu Xiangwen",
      "Wu Fei",
      "Zhu Xiaoyu",
      "Wang Zhonghua",
      "Fan Lei",
      "Shao Zhi-Ming"
    ],
    "abstract": "IMPORTANCE: Preferred neoadjuvant strategies for early or locally advanced triple-negative breast cancer include a 4-drug chemotherapy regimen containing anthracyclines, cyclophosphamide, taxanes, and platinum. Blockade of the programmed death receptor 1/ligand-1 (PD-1/PD-L1) pathway may improve efficacy of classic neoadjuvant chemotherapy. Camrelizumab, an anti-PD-1 antibody, has showed antitumor activity in advanced triple-negative breast cancer. OBJECTIVE: To evaluate the efficacy and adverse events of camrelizumab plus chemotherapy vs placebo plus chemotherapy as neoadjuvant therapy for patients with early or locally advanced triple-negative breast cancer. DESIGN, SETTING, AND PARTICIPANTS: This randomized, double-blind, phase 3 trial enrolled patients from 40 hospitals in China between November 25, 2020, and May 12, 2023 (data cutoff: September 30, 2023). A total of 441 eligible patients were enrolled. INTERVENTIONS: Patients were randomized in a 1:1 ratio to receive either camrelizumab 200 mg (n = 222) or placebo (n = 219) combined with chemotherapy every 2 weeks. The chemotherapy included nab-paclitaxel (100 mg/m2) and carboplatin (area under the curve, 1.5) on days 1, 8, and 15 in 28-day cycles for the first 16 weeks followed by epirubicin (90 mg/m2) and cyclophosphamide (500 mg/m2) every 2 weeks for 8 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was pathological complete response (defined as no invasive tumor in breast and lymph nodes [ypT0/Tis ypN0]). RESULTS: Among 441 females randomized (median age, 48 years), the median (range) follow-up duration from randomization was 14.4 (0.0-31.8) months. Pathological complete response was achieved in 126 patients (56.8% [95% CI, 50.0%-63.4%]) in the camrelizumab-chemotherapy group and 98 patients (44.7% [95% CI, 38.0%-51.6%]) in the placebo-chemotherapy group (rate difference, 12.2% [95% CI, 3.3%-21.2%]; 1-sided P = .004). In the neoadjuvant phase, adverse events of grade 3 or higher occurred in 198 patients (89.2%) in the camrelizumab-chemotherapy group and 182 (83.1%) in the placebo-chemotherapy group; serious adverse events occurred in 77 patients (34.7%) in the camrelizumab-chemotherapy group and 50 (22.8%) in the placebo-chemotherapy group, with fatal adverse events occurring in 2 patients (0.9%) in the camrelizumab-chemotherapy group. CONCLUSIONS AND RELEVANCE: Among patients with early or locally advanced triple-negative breast cancer, the addition of camrelizumab to neoadjuvant chemotherapy significantly improved pathological complete response. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04613674.",
    "journal": "JAMA",
    "pub_date": "2025-Feb",
    "doi": "10.1001/jama.2024.23560",
    "pmid": "39671272",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Adult",
      "Aged",
      "Female",
      "Humans",
      "Middle Aged",
      "Antibodies, Monoclonal, Humanized",
      "Antineoplastic Combined Chemotherapy Protocols",
      "Double-Blind Method",
      "Neoadjuvant Therapy",
      "Paclitaxel",
      "Triple Negative Breast Neoplasms",
      "Programmed Cell Death 1 Receptor",
      "Carboplatin",
      "Epirubicin",
      "Cyclophosphamide",
      "Follow-Up Studies",
      "Treatment Outcome",
      "Neoplasm Staging",
      "Disease Progression",
      "Mastectomy",
      "Young Adult",
      "Albumins"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/39671272/",
    "summary_ja": "本試験は、中国40施設で実施された早期または局所進行トリプルネガティブ乳癌を対象とする無作為化二重盲検第3相試験で、術前化学療法にカムレリズマブ（抗PD-1抗体）を上乗せする有効性と安全性を検証した。441人をカムレリズマブ＋化学療法群とプラセボ＋化学療法群に1:1で割り付け、主要評価項目である病理学的完全奏効（pCR）は56.8% vs 44.7%で上乗せ群が有意に高かった（差12.2%、片側P=.004）。一方で、術前期間のGrade≥3有害事象（89.2% vs 83.1%）および重篤な有害事象（34.7% vs 22.8%）は上乗せ群で多く、上乗せ群で致死的有害事象が2例報告された。以上より、カムレリズマブの追加はpCRを改善するが、有害事象増加を伴うことが示唆される。",
    "evidence_level": "1b"
  },
  {
    "paper_id": "pubmed:40402502",
    "source": "pubmed",
    "source_id": "40402502",
    "title": "Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung Cancer.",
    "year": 2025,
    "authors": [
      "Ricciuti Biagio",
      "Fusco Francesca",
      "Cooper Alissa",
      "Garbo Edoardo",
      "Pecci Federica",
      "Aldea Mihaela",
      "Wang Xinan",
      "Mayoral Penalva Maria",
      "Ginsberg Michelle",
      "Sholl Lynette M",
      "Nishino Mizuki",
      "Di Federico Alessandro",
      "Shaverdian Narek",
      "Bott Matthew",
      "Santo Valentina",
      "Rendina Erino",
      "Trisolini Rocco",
      "Ramella Sara",
      "Gallina Filippo",
      "Melis Enrico",
      "Buglioni Simonetta",
      "Minuti Gabriele",
      "Landi Lorenza",
      "Ugalde Figueroa Paula A",
      "Shaw Alice T",
      "Chaft Jamie",
      "Awad Mark M",
      "Cappuzzo Federico"
    ],
    "abstract": "IMPORTANCE: Patients with borderline resectable or unresectable stage III non-small cell lung cancer (NSCLC) with T4 and/or N2-N3 involvement face limited treatment options and poor outcomes. Neoadjuvant chemoimmunotherapy has shown promise in improving resectability and pathological responses. OBJECTIVE: To evaluate the efficacy of neoadjuvant programmed cell death 1 protein (PD-1) or programmed cell death 1 ligand 1 (PD-L1) blockade combined with chemotherapy in enhancing surgical outcomes and pathological responses in patients with T4 and/or N2-N3 stage III NSCLC. DESIGN, SETTING, AND PARTICIPANTS: This multicenter cohort study analyzed data from patients treated between February 2018 and January 2024 with neoadjuvant PD-1/PD-L1 inhibitors plus chemotherapy at academic and tertiary care centers across the US and Italy. Pathological and survival outcomes were assessed. Patients with stage III NSCLC and T4 and/or N2-N3 involvement were included. Data were collected from February 2018 to January 2024. EXPOSURES: Neoadjuvant PD-1/PD-L1 blockade combined with platinum-based chemotherapy. MAIN OUTCOMES AND MEASURES: Pathological complete response (pCR), major pathological response, surgical resectability, and event-free survival (EFS). RESULTS: Of 112 patients, 58 (51.8%) were female, and the median (range) age was 66 (41-84) years. A total of 84(75.0%) underwent surgical resection, achieving a pCR rate of 29.0% (24 of 83 with available final pathology) and a major pathological response rate of 42.2% (35 of 83). Patients with both PD-L1 expression of 50% or more and high tumor mutational burden achieved the highest pCR rate (4 of 9 [44.4%]; P = .03). Conversely, covariants in KRAS/STK11 or KRAS/KEAP1 were associated with lack of pCR. Patients with single-station or multistation N2/N3 disease exhibited comparable pathological outcomes. The median EFS for all resected patients was 52.6 months (95% CI, 27.8 to not reached), and this was significantly longer in patients with pCR (not reached vs 27.8 months [95% CI, 19.5 to not reached]; P < .001). CONCLUSIONS AND RELEVANCE: In this study, neoadjuvant PD-1/PD-L1 blockade combined with chemotherapy resulted in high pathological response rates and surgical resectability in patients with T4 and/or N2-N3 stage III NSCLC. This approach offers a viable treatment option for patients with borderline resectable or unresectable NSCLC but requires further validation through prospective studies.",
    "journal": "JAMA oncology",
    "pub_date": "2025-Jul",
    "doi": "10.1001/jamaoncol.2025.1115",
    "pmid": "40402502",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Humans",
      "Carcinoma, Non-Small-Cell Lung",
      "Female",
      "Male",
      "Lung Neoplasms",
      "Neoadjuvant Therapy",
      "Middle Aged",
      "Aged",
      "Neoplasm Staging",
      "Programmed Cell Death 1 Receptor",
      "Immune Checkpoint Inhibitors",
      "B7-H1 Antigen",
      "Antineoplastic Combined Chemotherapy Protocols",
      "Adult",
      "Aged, 80 and over"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/40402502/",
    "summary_ja": "境界切除可能または切除不能のIII期NSCLC（T4および/またはN2–N3）患者112例を対象に、術前のPD-1/PD-L1阻害薬＋プラチナ製剤ベース化学療法の有効性を多施設コホートで評価した。84例（75%）が手術切除に至り、病理学的完全奏効（pCR）29.0%、主要病理学的奏効42.2%と高い病理学的反応が得られた。PD-L1高発現（≥50%）かつ高TMBでpCRが高く、KRAS/STK11やKRAS/KEAP1共変異はpCR不良と関連した。切除例のEFS中央値は52.6か月で、pCR達成例は未達成例より有意に良好であり、本戦略は有望だが前向き試験での検証が必要と結論づけられた。",
    "evidence_level": "2b"
  },
  {
    "paper_id": "pubmed:28886381",
    "source": "pubmed",
    "source_id": "28886381",
    "title": "Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.",
    "year": 2017,
    "authors": [
      "Ribas Antoni",
      "Dummer Reinhard",
      "Puzanov Igor",
      "VanderWalde Ari",
      "Andtbacka Robert H I",
      "Michielin Olivier",
      "Olszanski Anthony J",
      "Malvehy Josep",
      "Cebon Jonathan",
      "Fernandez Eugenio",
      "Kirkwood John M",
      "Gajewski Thomas F",
      "Chen Lisa",
      "Gorski Kevin S",
      "Anderson Abraham A",
      "Diede Scott J",
      "Lassman Michael E",
      "Gansert Jennifer",
      "Hodi F Stephen",
      "Long Georgina V"
    ],
    "abstract": "Here we report a phase 1b clinical trial testing the impact of oncolytic virotherapy with talimogene laherparepvec on cytotoxic T cell infiltration and therapeutic efficacy of the anti-PD-1 antibody pembrolizumab. Twenty-one patients with advanced melanoma were treated with talimogene laherparepvec followed by combination therapy with pembrolizumab. Therapy was generally well tolerated, with fatigue, fevers, and chills as the most common adverse events. No dose-limiting toxicities occurred. Confirmed objective response rate was 62%, with a complete response rate of 33% per immune-related response criteria. Patients who responded to combination therapy had increased CD8",
    "journal": "Cell",
    "pub_date": "2017-Sep",
    "doi": "10.1016/j.cell.2017.08.027",
    "pmid": "28886381",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Antibodies, Monoclonal, Humanized",
      "Combined Modality Therapy",
      "Herpesviridae",
      "Humans",
      "Immunotherapy",
      "Melanoma",
      "Oncolytic Virotherapy",
      "Programmed Cell Death 1 Receptor",
      "Tumor Microenvironment"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/28886381/",
    "summary_ja": "本研究は、腫瘍溶解ウイルス療法（talimogene laherparepvec）が腫瘍内の細胞傷害性T細胞浸潤を高め、抗PD-1抗体ペムブロリズマブの治療効果を改善し得るかを検討した第1b相臨床試験である。進行メラノーマ21例に対し、talimogene laherparepvec投与後にペムブロリズマブ併用療法を実施した。有害事象は主に倦怠感、発熱、悪寒で、忍容性は概ね良好で用量制限毒性は認めなかった。免疫関連奏効基準で確認客観的奏効率62%、完全奏効率33%を示し、奏効例ではCD8陽性T細胞の増加が示唆された。",
    "evidence_level": "4"
  },
  {
    "paper_id": "pubmed:40615377",
    "source": "pubmed",
    "source_id": "40615377",
    "title": "Tislelizumab (anti-PD-1) plus chemotherapy as neoadjuvant therapy for patients with stage IB3/IIA2 cervical cancer (NATIC): a prospective, single-arm, phase II study.",
    "year": 2025,
    "authors": [
      "Sheng Jindong",
      "Luo Haitao",
      "Liu Xiangyu",
      "Liu Chunyan",
      "Zhou Wenhao",
      "Zhao Yujie",
      "Liu Ruoyan",
      "Li Dan",
      "Xu Changxiao",
      "Yang Bo",
      "Liu Ying",
      "Fu Xin",
      "Bao Lewen",
      "Wang Ke",
      "Hao Jihui",
      "Liu Wenxin"
    ],
    "abstract": "The clinical benefit of neoadjuvant immunochemotherapy in locally advanced cervical cancer (LACC) remains unclear. This single-arm, phase II study (Chinese Clinical Trial Registry, ChiCTR2200065392) aimed to evaluate the efficacy and safety of neoadjuvant anti-programmed cell death protein 1 (PD-1) antibody tislelizumab in combination with chemotherapy in treatment-naïve patients with stage IB3/IIA2 LACC. Enrolled patients received tislelizumab (200 mg, every 3 weeks) plus chemotherapy for 3 cycles before radical surgery. The primary endpoint was the pathological complete response (pCR). Secondary endpoints were objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1, disease-free survival, overall survival, and safety. Exploratory endpoints included tissue-based and blood-based biomarkers to identify the biological drivers behind the clinical outcomes. Between November 2022 and March 2024, 30 patients were enrolled. All patients completed 3 cycles of neoadjuvant immunochemotherapy and underwent radical surgery. The pCR was observed in 20 (66.7%) patients, and 4 (13.3%) patients achieved major pathological response (MPR), with an optimal pathological response rate (OPR) of 80.0%. The ORR was 90.0%, with 17 (56.7%) complete responses. Survival data were immature at the median follow-up of 14.7 months (data cutoff, December 31, 2024). Grade 3 treatment-related adverse events (TRAEs) and immune-related AEs occurred in 26.7% and 3.3% of patients, respectively. No treatment-related death occurred. Patients with pCR had significantly higher expression of PD-L1 CPS at baseline, and a strong relationship with immune-related signature (all p < 0.05). Neoadjuvant tislelizumab plus chemotherapy showed promising antitumor efficacy and a well-tolerated safety profile in patients with stage IB3/IIA2 LACC, and might be a potential option in this population.",
    "journal": "Signal transduction and targeted therapy",
    "pub_date": "2025-Jul",
    "doi": "10.1038/s41392-025-02294-9",
    "pmid": "40615377",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Humans",
      "Female",
      "Neoadjuvant Therapy",
      "Middle Aged",
      "Antibodies, Monoclonal, Humanized",
      "Adult",
      "Uterine Cervical Neoplasms",
      "Neoplasm Staging",
      "Aged",
      "Prospective Studies",
      "Programmed Cell Death 1 Receptor",
      "Antineoplastic Combined Chemotherapy Protocols"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/40615377/",
    "summary_ja": "局所進行子宮頸がん（IB3/IIA2）未治療30例を対象に、術前治療としてチスレリズマブ（抗PD-1）＋化学療法を3サイクル行い、その後に根治手術を実施した前向き単群第II相試験である。主要評価項目の病理学的完全奏効（pCR）は66.7%（20/30）で、主要病理学的奏効（MPR）を含む最適病理学的奏効率は80.0%、画像評価の奏効率（ORR）は90.0%だった。追跡期間中央値14.7か月で生存データは未成熟であったが、Grade 3の治療関連有害事象は26.7%、免疫関連有害事象は3.3%で治療関連死亡はなかった。pCR例ではベースラインのPD-L1 CPS高値や免疫関連シグネチャーとの関連が示され、術前免疫化学療法の有望性が示唆された。",
    "evidence_level": "4"
  },
  {
    "paper_id": "pubmed:38702343",
    "source": "pubmed",
    "source_id": "38702343",
    "title": "Combination therapy with oncolytic virus and T cells or mRNA vaccine amplifies antitumor effects.",
    "year": 2024,
    "authors": [
      "Fu Rao",
      "Qi Ruoyao",
      "Xiong Hualong",
      "Lei Xing",
      "Jiang Yao",
      "He Jinhang",
      "Chen Feng",
      "Zhang Liang",
      "Qiu Dekui",
      "Chen Yiyi",
      "Nie Meifeng",
      "Guo Xueran",
      "Zhu Yuhe",
      "Zhang Jinlei",
      "Yue Mingxi",
      "Cao Jiali",
      "Wang Guosong",
      "Que Yuqiong",
      "Fang Mujing",
      "Wang Yingbin",
      "Chen Yixin",
      "Cheng Tong",
      "Ge Shengxiang",
      "Zhang Jun",
      "Yuan Quan",
      "Zhang Tianying",
      "Xia Ningshao"
    ],
    "abstract": "Antitumor therapies based on adoptively transferred T cells or oncolytic viruses have made significant progress in recent years, but the limited efficiency of their infiltration into solid tumors makes it difficult to achieve desired antitumor effects when used alone. In this study, an oncolytic virus (rVSV-LCMVG) that is not prone to induce virus-neutralizing antibodies was designed and combined with adoptively transferred T cells. By transforming the immunosuppressive tumor microenvironment into an immunosensitive one, in B16 tumor-bearing mice, combination therapy showed superior antitumor effects than monotherapy. This occurred whether the OV was administered intratumorally or intravenously. Combination therapy significantly increased cytokine and chemokine levels within tumors and recruited CD8",
    "journal": "Signal transduction and targeted therapy",
    "pub_date": "2024-May",
    "doi": "10.1038/s41392-024-01824-1",
    "pmid": "38702343",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Animals",
      "Mice",
      "Oncolytic Viruses",
      "Oncolytic Virotherapy",
      "Combined Modality Therapy",
      "mRNA Vaccines",
      "Melanoma, Experimental",
      "Tumor Microenvironment",
      "CD8-Positive T-Lymphocytes",
      "T-Lymphocytes",
      "Humans",
      "Cell Line, Tumor",
      "Cancer Vaccines"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/38702343/",
    "summary_ja": "養子移入T細胞療法や腫瘍溶解ウイルス（OV）は進歩している一方、固形腫瘍への浸潤効率の低さが単独治療の限界となる。著者らは中和抗体を誘導しにくい腫瘍溶解ウイルスrVSV-LCMVGを設計し、養子移入T細胞と併用した。B16担癌マウスにおいて、腫瘍微小環境を免疫抑制的から免疫感受性へ変化させ、単独治療よりも優れた抗腫瘍効果を示した。OVの投与経路が腫瘍内投与でも静脈内投与でも併用効果が認められ、腫瘍内のサイトカイン／ケモカイン増加と免疫細胞（CD8など）の動員が示唆された。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:37635168",
    "source": "pubmed",
    "source_id": "37635168",
    "title": "Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends.",
    "year": 2023,
    "authors": [
      "Sun Qian",
      "Hong Zhenya",
      "Zhang Cong",
      "Wang Liangliang",
      "Han Zhiqiang",
      "Ma Ding"
    ],
    "abstract": "Immune-checkpoint inhibitors (ICBs), in addition to targeting CTLA-4, PD-1, and PD-L1, novel targeting LAG-3 drugs have also been approved in clinical application. With the widespread use of the drug, we must deeply analyze the dilemma of the agents and seek a breakthrough in the treatment prospect. Over the past decades, these agents have demonstrated dramatic efficacy, especially in patients with melanoma and non-small cell lung cancer (NSCLC). Nonetheless, in the field of a broad concept of solid tumours, non-specific indications, inseparable immune response and side effects, unconfirmed progressive disease, and complex regulatory networks of immune resistance are four barriers that limit its widespread application. Fortunately, the successful clinical trials of novel ICB agents and combination therapies, the advent of the era of oncolytic virus gene editing, and the breakthrough of the technical barriers of mRNA vaccines and nano-delivery systems have made remarkable breakthroughs currently. In this review, we enumerate the mechanisms of each immune checkpoint targets, associations between ICB with tumour mutation burden, key immune regulatory or resistance signalling pathways, the specific clinical evidence of the efficacy of classical targets and new targets among different tumour types and put forward dialectical thoughts on drug safety. Finally, we discuss the importance of accurate triage of ICB based on recent advances in predictive biomarkers and diagnostic testing techniques.",
    "journal": "Signal transduction and targeted therapy",
    "pub_date": "2023-Aug",
    "doi": "10.1038/s41392-023-01522-4",
    "pmid": "37635168",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Humans",
      "Carcinoma, Non-Small-Cell Lung",
      "Lung Neoplasms",
      "Melanoma",
      "Combined Modality Therapy",
      "Drug Delivery Systems"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/37635168/",
    "summary_ja": "本総説は、CTLA-4/PD-1/PD-L1に加えてLAG-3など新規標的も含む免疫チェックポイント阻害薬（ICB）の固形腫瘍における現状と課題を整理している。メラノーマや非小細胞肺癌での顕著な有効性がある一方、適応の非特異性、有害事象と免疫反応の不可分性、進行判定の不確実性、免疫抵抗性の複雑な制御ネットワークが普及の障壁として挙げられる。新規ICBや併用療法、腫瘍溶解ウイルスや遺伝子編集、mRNAワクチンやナノデリバリーなどの技術進展が打開策として論じられる。さらに、腫瘍変異量（TMB）や抵抗性シグナル経路、腫瘍種別の臨床エビデンスを踏まえ、予測バイオマーカーと診断技術による適切な患者選択（トリアージ）の重要性を強調している。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:32246277",
    "source": "pubmed",
    "source_id": "32246277",
    "title": "Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment.",
    "year": 2020,
    "authors": [
      "Sato Hiro",
      "Okonogi Noriyuki",
      "Nakano Takashi"
    ],
    "abstract": "Significant technological advances in radiotherapy have been made in the past few decades. High-precision radiotherapy has recently become popular and is contributing to improvements in the local control of the irradiated target lesions and the reduction of adverse effects. Accordingly, for long-term survival, the importance of systemic cancer control, including at non-irradiated sites, is growing. Toward this challenge, the treatment methods in which anti-PD-1/PD-L1 antibodies that exert systemic effects by restoring anti-tumour immunity are combined with radiotherapy has attracted attention in recent years. Previous studies have reported the activation of anti-tumour immunity by radiotherapy, which simultaneously elevates PD-L1 expression, suggesting a potential for combination therapy. Radiotherapy induces so-called 'immunogenic cell death', which involves cell surface translocation of calreticulin and extracellular release of high-mobility group protein box 1 (HMGB-1) and adenosine-5'-triphosphate (ATP). Furthermore, radiotherapy causes immune activation via MHC class I upregulation and cGAS-STING pathway. In contrast, induction of immunosuppressive lymphocytes and the release of immunosuppressive cytokines and chemokines by radiotherapy contribute to immunosuppressive reactions. In this article, we review immune responses induced by radiotherapy as well as previous reports to support the rationale of combination of radiotherapy and anti-PD-1/PD-L1 antibodies. A number of preclinical and clinical studies have shown the efficacy of radiotherapy combined with immune checkpoint inhibition, hence combination therapy is considered to be an important future strategy for cancer treatment.",
    "journal": "International journal of clinical oncology",
    "pub_date": "2020-May",
    "doi": "10.1007/s10147-020-01666-1",
    "pmid": "32246277",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Animals",
      "Antibodies",
      "B7-H1 Antigen",
      "Combined Modality Therapy",
      "Humans",
      "Immunosuppression Therapy",
      "Immunotherapy",
      "Neoplasms",
      "Programmed Cell Death 1 Receptor",
      "Translational Research, Biomedical",
      "Treatment Outcome"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/32246277/",
    "summary_ja": "近年の高精度放射線治療は局所制御と有害事象低減を進めた一方、非照射部位を含む全身制御の重要性が増している。放射線は免疫原性細胞死（カルレチクリン露出、HMGB1・ATP放出）やMHCクラスI上昇、cGAS-STING経路活性化などを介して抗腫瘍免疫を促進するが、同時にPD-L1発現上昇や免疫抑制性細胞・サイトカイン誘導といった抑制的反応も引き起こし得る。これらの知見を踏まえ、全身性に抗腫瘍免疫を回復させる抗PD-1/PD-L1抗体と放射線の併用には合理性があり、前臨床・臨床研究で有効性が示されつつある。著者らは、併用療法が将来の重要な治療戦略になり得ると結論づけている。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:34688374",
    "source": "pubmed",
    "source_id": "34688374",
    "title": "Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial.",
    "year": 2022,
    "authors": [
      "Hu Huabin",
      "Kang Liang",
      "Zhang Jianwei",
      "Wu Zehua",
      "Wang Hui",
      "Huang Meijin",
      "Lan Ping",
      "Wu Xiaojian",
      "Wang Chao",
      "Cao Wuteng",
      "Hu Jiancong",
      "Huang Yan",
      "Huang Liang",
      "Wang Huaiming",
      "Shi Lishuo",
      "Cai Yue",
      "Shen Cailu",
      "Ling Jiayu",
      "Xie Xiaoyu",
      "Cai Yonghua",
      "He Xiaowen",
      "Dou Ruoxu",
      "Zhou Jiaming",
      "Ma Tenghui",
      "Zhang Xingwei",
      "Luo Shuangling",
      "Deng Weihao",
      "Ling Li",
      "Liu Hao",
      "Deng Yanhong"
    ],
    "abstract": "BACKGROUND: PD-1 blockade is highly effective in patients with mismatch repair-deficient or microsatellite instability-high metastatic colorectal cancer. The role of single-agent PD-1 blockade in the neoadjuvant setting for resectable mismatch repair-deficient or microsatellite instability-high colorectal cancer remains unclear. We investigated the efficacy and safety of PD-1 blockade with toripalimab, with or without the COX-2 inhibitor celecoxib, as neoadjuvant treatment for mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancers. METHODS: The PD-1 Inhibitor in Microsatellite Instability Colorectal Cancer (PICC) trial was a single-centre, open-label, parallel-group, non-comparative, randomised, phase 2 study undertaken at the Sixth Affiliated Hospital of Sun Yat-sen University (Guangzhou, China). Eligible patients were aged 18-75 years, had histologically confirmed mismatch repair-deficient or microsatellite instability-high colorectal cancer, had clinical stage T3-T4 or any T with lymph node positivity (N+), Eastern Cooperative Oncology Group performance score of 0 or 1, and adequate haematological, hepatic, and renal function. Participants were randomly assigned (1:1), without any stratification or balanced blocking, to receive toripalimab 3 mg/kg intravenously on day 1, with or without celecoxib 200 mg orally twice daily from day 1 to 14 of each 14-day cycle, for six cycles before surgical resection. Adjuvant treatment with toripalimab with or without celecoxib was permitted at the investigators' discretion. The primary endpoint was the proportion of patients with pathological complete response, defined as tumours without any viable tumour cells in the resected primary tumour sample and all sampled regional lymph nodes. All efficacy and safety analyses were assessed in the modified intention-to-treat population, which included all patients who were randomly assigned to treatment and who received at least one dose of toripalimab. This trial is registered with ClinicalTrials.gov, NCT03926338, and is ongoing. FINDINGS: Between May 1, 2019, and April 1, 2021, 53 patients were screened, of whom 34 were randomly assigned to either the toripalimab plus celecoxib group (n=17) or the toripalimab monotherapy group (n=17). As of data cutoff (Aug 10, 2021), median follow-up was 14·9 months (IQR 8·8-17·0). All patients received study treatment and underwent surgical resection; there were no treatment-related surgical delays. All 34 patients had an R0 resection (>1 mm resection margin). 15 of 17 patients (88% [95% CI 64-99]) in the toripalimab plus celecoxib group and 11 of 17 patients (65% [38-86]) in the toripalimab monotherapy group had a pathological complete response. All patients continued to receive adjuvant toripalimab with or without celecoxib for a total perioperative duration of 6 months and were alive and free of recurrence at data cutoff. During neoadjuvant treatment, ten (59%) patients in the toripalimab plus celecoxib group and ten (59%) in the toripalimab monotherapy group had grade 1-2 treatment-related adverse events. Only one (3%) of 34 patients, who was in the toripalimab plus celecoxib group, had a grade 3 or higher treatment-related adverse event during the neoadjuvant phase, which was grade 3 increased aspartate aminotransferase levels. In the adjuvant phase, only one (3%) of 34 patients, who was in the toripalimab monotherapy group, had a grade 3 or higher treatment-related adverse events, which was grade 3 increased aspartate aminotransferase and alanine aminotransferase levels. INTERPRETATION: Neoadjuvant toripalimab with or without celecoxib could be a potential therapeutic option for patients with mismatch repair deficient or microsatellite instability-high, locally advanced, colorectal cancer. This treatment was associated with a high pathological complete response rate and an acceptable safety profile, which did not compromise surgery. Longer term follow-up is needed to assess effects on survival-related endpoints. FUNDING: The National Key R&D Program of China, the National Natural Science Foundation of China, and the Chinese Society of Clinical Oncology-Junshi Biosciences Oncology Immunity Research. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.",
    "journal": "The lancet. Gastroenterology & hepatology",
    "pub_date": "2022-Jan",
    "doi": "10.1016/S2468-1253(21)00348-4",
    "pmid": "34688374",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Adult",
      "Aged",
      "Antibodies, Monoclonal, Humanized",
      "Antineoplastic Combined Chemotherapy Protocols",
      "Celecoxib",
      "Chemotherapy, Adjuvant",
      "Colectomy",
      "Colorectal Neoplasms",
      "DNA Mismatch Repair",
      "DNA-Binding Proteins",
      "Female",
      "Humans",
      "Lymph Node Excision",
      "Lymphatic Metastasis",
      "Male",
      "Microsatellite Instability",
      "Middle Aged",
      "Mismatch Repair Endonuclease PMS2",
      "MutL Protein Homolog 1",
      "MutS Homolog 2 Protein",
      "Neoadjuvant Therapy",
      "Programmed Cell Death 1 Receptor",
      "Young Adult"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/34688374/",
    "summary_ja": "本研究は、切除可能なdMMR/MSI-H局所進行大腸癌に対する術前治療として、PD-1阻害薬トリパリマブ単剤またはセレコキシブ併用の有効性と安全性を検討した単施設・非盲検・第2相無比較ランダム化試験である。34例が2群（各17例）に割り付けられ、6サイクルの術前治療後に全例が手術を受け、治療による手術遅延はなかった。病理学的完全奏効（pCR）は併用群88%、単剤群65%と高率で、全例R0切除でデータカットオフ時点で再発なく生存していた。有害事象は主にグレード1–2で、術前・術後ともにグレード3以上は各1例（3%）にとどまった。",
    "evidence_level": "2b"
  },
  {
    "paper_id": "pubmed:36171008",
    "source": "pubmed",
    "source_id": "36171008",
    "title": "Combination of a novel heat shock protein 90-targeted photodynamic therapy with PD-1/PD-L1 blockade induces potent systemic antitumor efficacy and abscopal effect against breast cancers.",
    "year": 2022,
    "authors": [
      "Kaneko Kensuke",
      "Acharya Chaitanya R",
      "Nagata Hiroshi",
      "Yang Xiao",
      "Hartman Zachary Conrad",
      "Hobeika Amy",
      "Hughes Philip F",
      "Haystead Timothy A J",
      "Morse Michael A",
      "Lyerly Herbert Kim",
      "Osada Takuya"
    ],
    "abstract": "BACKGROUND: We previously demonstrated potent antitumor activity against human breast cancer xenografts using photodynamic therapy (PDT) targeting a novel tumor-specific photosensitizer (HS201), which binds heat shock protein 90 (HS201-PDT). However, induction of systemic antitumor immunity by HS201-PDT alone or by the combination strategy with immune checkpoint blockade has yet to be determined. METHODS: Using unilateral and bilateral implantation models of syngeneic breast tumors (E0771, MM3MG-HER2, and JC-HER3) in mice, we assessed whether HS201-PDT could induce local and systemic antitumor immunity. In an attempt to achieve a stronger abscopal effect for distant tumors, the combination strategy with anti-PD-L1 antibody was tested. Tumor-infiltrating leukocytes were analyzed by single cell RNA-sequencing and receptor-ligand interactome analysis to characterize in more detailed the mechanisms of action of the treatment and key signaling pathways involved. RESULTS: HS201-PDT demonstrated greater tumor control and survival in immune competent mice than in immunocompromised mice, suggesting the role of induced antitumor immunity; however, survival was modest and an abscopal effect on distant implanted tumor was weak. A combination of HS201-PDT with anti-PD-L1 antibody demonstrated the greatest antigen-specific immune response, tumor growth suppression, prolonged mouse survival time and abscopal effect. The most significant increase of intratumoral, activated CD8+T cells and decrease of exhausted CD8+T cells occurred following combination treatment compared with HS201-PDT monotherapy. Receptor-ligand interactome analysis showed marked enhancement of several pathways, such as CXCL, GALECTIN, GITRL, PECAM1 and NOTCH, associated with CD8+T cell activation in the combination group. Notably, the expression of the CXCR3 gene signature was the highest in the combination group, possibly explaining the enhanced tumor infiltration by T cells. CONCLUSIONS: The increased antitumor activity and upregulated CXCR3 gene signature induced by the combination of anti-PD-L1 antibody with HS201-PDT warrants the clinical testing of HS201-PDT combined with PD-1/PD-L1 blockade in patients with breast cancer, and the use of the CXCR3 gene signature as a biomarker.",
    "journal": "Journal for immunotherapy of cancer",
    "pub_date": "2022-Sep",
    "doi": "10.1136/jitc-2022-004793",
    "pmid": "36171008",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Animals",
      "Breast Neoplasms",
      "Cell Line, Tumor",
      "Female",
      "Galectins",
      "Heat-Shock Proteins",
      "Humans",
      "Immune Checkpoint Inhibitors",
      "Ligands",
      "Mice",
      "Photochemotherapy",
      "Photosensitizing Agents",
      "Programmed Cell Death 1 Receptor",
      "RNA"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/36171008/",
    "summary_ja": "本研究は、HSP90に結合する腫瘍特異的光感受性物質HS201を用いた光線力学療法（HS201-PDT）が、乳がん同系マウスモデルで局所および全身の抗腫瘍免疫を誘導できるかを検証した。HS201-PDT単独は免疫健常マウスで腫瘍制御と生存を改善したが、効果は限定的で遠隔腫瘍へのアブスコパル効果は弱かった。抗PD-L1抗体との併用により、抗原特異的免疫応答、腫瘍増殖抑制、生存延長、アブスコパル効果が最も強くなり、腫瘍内の活性化CD8+T細胞増加と疲弊CD8+T細胞減少が顕著だった。単一細胞RNA-seqと受容体—リガンド解析から、CXCLなど複数経路の活性化とCXCR3遺伝子シグネチャーの上昇が示され、T細胞浸潤増強の機序が示唆された。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:37304303",
    "source": "pubmed",
    "source_id": "37304303",
    "title": "PD-1 inhibitors-based second-line therapy for metastatic gastric cancer.",
    "year": 2023,
    "authors": [
      "Gou Miaomiao",
      "Zhang Yong",
      "Wang Zhikuan",
      "Dai Guanghai"
    ],
    "abstract": "BACKGROUND: Metastatic gastric cancer (MGC) patients with progression on first-line treatment still have poor outcomes on chemotherapy. The KEYNOTE-061 study demonstrated that pembrolizumab, a PD-1inhibitor, was not better than paclitaxel as second-line therapy for MGC. Herein, we explored the efficacy and safety of PD-1inhibitor based treatment for MGC patients in the second line. METHODS: In this observational, retrospective study, we enrolled MGC patients treated with anti-PD-1 based therapy as second-line in our hospital. We primarily assessed the treatment's efficacy and safety. We also evaluated the relationship between clinical features and outcomes using univariate and multivariate analyses. RESULTS: We enrolled 129 patients with an objective response rate (ORR) of 16.3% and a disease control rate (DCR) of 79.1%. Patients treated with PD-1inhibitor combined with chemotherapy and anti-angiogenic agents had ORR of 19.6% and higher DCR of 94.1%. The median progression-free survival (PFS) was 4.10 months, and the median overall survival (OS) was 7.60 months. In univariate analysis, patients treated with PD-1inhibitor combined with chemotherapy and anti-angiogenic agents and with prior anti-PD-1 history were significantly associated with favorable PFS and OS. In the multivariate analysis, different combination therapy and prior anti-PD-1 history were independent prognosis biomarkers for PFS and OS. Grade 3 or 4 treatment-related adverse events (TRAEs) occurred in 28 (21.7%) patients. Common adverse events (AEs) included fatigue, hyper/hypothyroidism, neutrophil decrease, anemia, skin reactions, proteinuria, and hypertension. We did not observe treatment-related deaths. CONCLUSION: Our current results indicated that PD-1-inhibitor and chemo-anti-angiogenic agents combination therapy and prior PD-1 treatment history might improve clinical activity for GC immunotherapy as second-line treatment with acceptable safety profiles. Further studies are needed to verify those outcomes for MGC in other centers.",
    "journal": "Frontiers in immunology",
    "pub_date": "2023",
    "doi": "10.3389/fimmu.2023.1136437",
    "pmid": "37304303",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Humans",
      "Immune Checkpoint Inhibitors",
      "Retrospective Studies",
      "Stomach Neoplasms",
      "Combined Modality Therapy",
      "Immunotherapy",
      "Angiogenesis Inhibitors"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/37304303/",
    "summary_ja": "本研究は、一次治療後に進行した転移性胃癌患者を対象に、二次治療としての抗PD-1抗体ベース治療の有効性と安全性を単施設後ろ向きに評価した観察研究である。129例においてORRは16.3%、DCRは79.1%で、化学療法＋抗血管新生薬との併用群ではORR 19.6%、DCR 94.1%と高かった。全体の中央値PFSは4.10か月、OSは7.60か月で、併用療法の種類や既治療としての抗PD-1使用歴が予後（PFS/OS）と関連した。Grade 3/4の治療関連有害事象は21.7%で、治療関連死亡は認めず、忍容性は概ね許容範囲とされた。",
    "evidence_level": "4"
  },
  {
    "paper_id": "pubmed:25695955",
    "source": "pubmed",
    "source_id": "25695955",
    "title": "PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.",
    "year": 2015,
    "authors": [
      "Patel Sandip Pravin",
      "Kurzrock Razelle"
    ],
    "abstract": "The resurgence of cancer immunotherapy stems from an improved understanding of the tumor microenvironment. The PD-1/PD-L1 axis is of particular interest, in light of promising data demonstrating a restoration of host immunity against tumors, with the prospect of durable remissions. Indeed, remarkable clinical responses have been seen in several different malignancies including, but not limited to, melanoma, lung, kidney, and bladder cancers. Even so, determining which patients derive benefit from PD-1/PD-L1-directed immunotherapy remains an important clinical question, particularly in light of the autoimmune toxicity of these agents. The use of PD-L1 (B7-H1) immunohistochemistry (IHC) as a predictive biomarker is confounded by multiple unresolved issues: variable detection antibodies, differing IHC cutoffs, tissue preparation, processing variability, primary versus metastatic biopsies, oncogenic versus induced PD-L1 expression, and staining of tumor versus immune cells. Emerging data suggest that patients whose tumors overexpress PD-L1 by IHC have improved clinical outcomes with anti-PD-1-directed therapy, but the presence of robust responses in some patients with low levels of expression of these markers complicates the issue of PD-L1 as an exclusionary predictive biomarker. An improved understanding of the host immune system and tumor microenvironment will better elucidate which patients derive benefit from these promising agents.",
    "journal": "Molecular cancer therapeutics",
    "pub_date": "2015-Apr",
    "doi": "10.1158/1535-7163.MCT-14-0983",
    "pmid": "25695955",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Animals",
      "B7-H1 Antigen",
      "Biomarkers",
      "Gene Expression",
      "Humans",
      "Immunohistochemistry",
      "Immunophenotyping",
      "Immunotherapy",
      "Neoplasms",
      "Phenotype",
      "Prognosis"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/25695955/",
    "summary_ja": "がん免疫療法の進展により、PD-1/PD-L1経路を標的とする治療で複数のがん種において顕著かつ持続的な奏効が報告されている。 一方で自己免疫毒性もあり、誰が治療利益を得るかの予測が重要である。PD-L1免疫染色（IHC）を予測バイオマーカーとして用いる試みは、抗体やカットオフ、検体処理、原発/転移、腫瘍細胞/免疫細胞の染色など多くの未解決要因により解釈が難しい。PD-L1高発現例で奏効が良い可能性は示唆されるが、低発現でも強い反応が起こり得るため、除外基準としては不十分であり、腫瘍微小環境と宿主免疫の理解深化が必要だと述べている。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:27117833",
    "source": "pubmed",
    "source_id": "27117833",
    "title": "PD-L1 Expression in Lung Cancer.",
    "year": 2016,
    "authors": [
      "Yu Hui",
      "Boyle Theresa A",
      "Zhou Caicun",
      "Rimm David L",
      "Hirsch Fred R"
    ],
    "abstract": "Immunotherapies targeted against programmed death ligand 1 (PD-L1) and its receptor (PD-1) have improved survival in a subset of patients with advanced lung cancer. PD-L1 protein expression has emerged as a biomarker that predicts which patients are more likely to respond to immunotherapy. The understanding of PD-L1 as a biomarker is complicated by the history of use of different immunohistochemistry platforms with different PD-L1 antibodies, scoring systems, and positivity cut-offs for immunotherapy clinical trials with different anti-PD-L1 and anti-PD-1 drugs. Herein, we summarize the brief history of PD-L1 as a biomarker and describe the challenges remaining to harmonize PD-L1 detection and interpretation for best patient care.",
    "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
    "pub_date": "2016-Jul",
    "doi": "10.1016/j.jtho.2016.04.014",
    "pmid": "27117833",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Animals",
      "B7-H1 Antigen",
      "Biomarkers",
      "Humans",
      "Immunohistochemistry",
      "Immunotherapy",
      "Lung Neoplasms",
      "Mice"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/27117833/",
    "summary_ja": "進行肺癌の一部患者では、PD-1/PD-L1を標的とする免疫療法が生存を改善している。PD-L1タンパク発現は、免疫療法に反応しやすい患者を予測するバイオマーカーとして用いられている。一方で、異なる免疫組織化学プラットフォーム、抗体、スコアリング法、陽性カットオフが臨床試験ごとに混在してきた経緯があり、解釈は複雑である。本稿はPD-L1バイオマーカーの経緯を概説し、検出法と判定の標準化（ハーモナイゼーション）に残る課題を整理している。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:31668929",
    "source": "pubmed",
    "source_id": "31668929",
    "title": "Mechanisms Controlling PD-L1 Expression in Cancer.",
    "year": 2019,
    "authors": [
      "Cha Jong-Ho",
      "Chan Li-Chuan",
      "Li Chia-Wei",
      "Hsu Jennifer L",
      "Hung Mien-Chie"
    ],
    "abstract": "The engagement of programmed cell death protein 1 (PD-1; encoded by the PDCD1 gene) receptor expressed on activated T cells and its ligand, programmed death-ligand 1 (PD-L1; encoded by the CD274 gene), is a major co-inhibitory checkpoint signaling that controls T cell activities. Various types of cancers express high levels of PD-L1 and exploit PD-L1/PD-1 signaling to evade T cell immunity. Blocking the PD-L1/PD-1 pathway has consistently shown remarkable anti-tumor effects in patients with advanced cancers and is recognized as the gold standard for developing new immune checkpoint blockade (ICB) and combination therapies. However, the response rates of anti-PD-L1 have been limited in several solid tumors. Therefore, furthering our understanding of the regulatory mechanisms of PD-L1 can bring substantial benefits to patients with cancer by improving the efficacy of current PD-L1/PD-1 blockade or other ICBs. In this review, we provide current knowledge of PD-L1 regulatory mechanisms at the transcriptional, posttranscriptional, post-translational, and extracellular levels, and discuss the implications of these findings in cancer diagnosis and immunotherapy.",
    "journal": "Molecular cell",
    "pub_date": "2019-Nov",
    "doi": "10.1016/j.molcel.2019.09.030",
    "pmid": "31668929",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Animals",
      "Antineoplastic Agents, Immunological",
      "B7-H1 Antigen",
      "Biomarkers, Tumor",
      "Gene Expression Regulation, Neoplastic",
      "Humans",
      "Molecular Targeted Therapy",
      "Neoplasms",
      "Protein Processing, Post-Translational",
      "RNA Processing, Post-Transcriptional",
      "Signal Transduction",
      "Transcription, Genetic",
      "Tumor Escape"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/31668929/",
    "summary_ja": "PD-1/PD-L1経路は活性化T細胞の免疫応答を抑制する主要な免疫チェックポイントであり、多くのがんはPD-L1高発現を利用してT細胞免疫から逃避する。PD-1/PD-L1阻害は進行がんで顕著な抗腫瘍効果を示し、免疫チェックポイント阻害療法開発の基盤となっている。一方で固形腫瘍の一部では抗PD-L1の奏効率が限定的であり、PD-L1発現制御機構の理解深化が治療効果向上に重要である。本総説は、転写・転写後・翻訳後・細胞外レベルにおけるPD-L1制御機構の最新知見を整理し、診断や免疫療法への示唆を論じる。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:39164705",
    "source": "pubmed",
    "source_id": "39164705",
    "title": "Implications of PD-L1 expression on the immune microenvironment in HER2-positive gastric cancer.",
    "year": 2024,
    "authors": [
      "Chen Yang",
      "Jia Keren",
      "Chong Xiaoyi",
      "Xie Yi",
      "Jiang Lei",
      "Peng Haoxin",
      "Liu Dan",
      "Yuan Jiajia",
      "Li Yanyan",
      "Feng Xujiao",
      "Sun Yu",
      "Li Jian",
      "Zhang Xiaotian",
      "Shen Lin"
    ],
    "abstract": "In the KEYNOTE-811 study, anti-HER2 and immunotherapy treatments resulted in longer survival in HER2-positive gastric cancer patients with CPS ≥ 1, whereas CPS < 1 patients lacked notable benefits. We studied this in a real-world cohort of 106 HER2-positive, CPS < 1 patients and found no survival differences between those treated with anti-HER2 therapy alone or with added immunotherapy. Thus, we investigate the tumor microenvironment variations in 160 HER2-positive patients, CPS ≥ 1 cases exhibited elevated spatial effective scores of immune cells, including CD4, CD8 subtypes, and NK cells, compared to CPS < 1. Furthermore, through single-cell sequencing in eight HER2-positive individuals, gene expressions revealed regulation of T-cell co-stimulation in CPS ≥ 1 and IL-1 binding in CPS < 1 cases. Notably, we discovered a CPS < 1 subtype marked by CXCR4",
    "journal": "Molecular cancer",
    "pub_date": "2024-Aug",
    "doi": "10.1186/s12943-024-02085-w",
    "pmid": "39164705",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Humans",
      "Tumor Microenvironment",
      "Stomach Neoplasms",
      "B7-H1 Antigen",
      "Erb-b2 Receptor Tyrosine Kinases",
      "Prognosis",
      "Biomarkers, Tumor",
      "Gene Expression Regulation, Neoplastic",
      "Female",
      "Immunotherapy"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/39164705/",
    "summary_ja": "KEYNOTE-811ではHER2陽性胃がんのうちPD-L1 CPS≥1で抗HER2療法＋免疫療法の生存利益が示唆された一方、CPS<1では利益が乏しいことが報告されている。著者らは実臨床のHER2陽性・CPS<1の106例で、抗HER2単独と免疫療法追加の間に生存差がないことを確認した。さらに160例の腫瘍微小環境解析では、CPS≥1でCD4/CD8 T細胞やNK細胞などの免疫細胞の空間的有効スコアが高いことを示した。8例の単一細胞解析では、CPS≥1でT細胞共刺激の制御、CPS<1でIL-1結合に関連する発現傾向が示され、CPS<1内にもCXCR4で特徴づけられるサブタイプの存在が示唆された。",
    "evidence_level": "2b"
  },
  {
    "paper_id": "pubmed:30120041",
    "source": "pubmed",
    "source_id": "30120041",
    "title": "A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.",
    "year": 2018,
    "authors": [
      "Sun Roger",
      "Limkin Elaine Johanna",
      "Vakalopoulou Maria",
      "Dercle Laurent",
      "Champiat Stéphane",
      "Han Shan Rong",
      "Verlingue Loïc",
      "Brandao David",
      "Lancia Andrea",
      "Ammari Samy",
      "Hollebecque Antoine",
      "Scoazec Jean-Yves",
      "Marabelle Aurélien",
      "Massard Christophe",
      "Soria Jean-Charles",
      "Robert Charlotte",
      "Paragios Nikos",
      "Deutsch Eric",
      "Ferté Charles"
    ],
    "abstract": "BACKGROUND: Because responses of patients with cancer to immunotherapy can vary in success, innovative predictors of response to treatment are urgently needed to improve treatment outcomes. We aimed to develop and independently validate a radiomics-based biomarker of tumour-infiltrating CD8 cells in patients included in phase 1 trials of anti-programmed cell death protein (PD)-1 or anti-programmed cell death ligand 1 (PD-L1) monotherapy. We also aimed to evaluate the association between the biomarker, and tumour immune phenotype and clinical outcomes of these patients. METHODS: In this retrospective multicohort study, we used four independent cohorts of patients with advanced solid tumours to develop and validate a radiomic signature predictive of immunotherapy response by combining contrast-enhanced CT images and RNA-seq genomic data from tumour biopsies to assess CD8 cell tumour infiltration. To develop the radiomic signature of CD8 cells, we used the CT images and RNA sequencing data of 135 patients with advanced solid malignant tumours who had been enrolled into the MOSCATO trial between May 1, 2012, and March 31, 2016, in France (training set). The genomic data, which are based on the CD8B gene, were used to estimate the abundance of CD8 cells in the samples and data were then aligned with the images to generate the radiomic signatures. The concordance of the radiomic signature (primary endpoint) was validated in a Cancer Genome Atlas [TGCA] database dataset including 119 patients who had available baseline preoperative imaging data and corresponding transcriptomic data on June 30, 2017. From 84 input variables used for the machine-learning method (78 radiomic features, five location variables, and one technical variable), a radiomics-based predictor of the CD8 cell expression signature was built by use of machine learning (elastic-net regularised regression method). Two other independent cohorts of patients with advanced solid tumours were used to evaluate this predictor. The immune phenotype internal cohort (n=100), were randomly selected from the Gustave Roussy Cancer Campus database of patient medical records based on previously described, extreme tumour-immune phenotypes: immune-inflamed (with dense CD8 cell infiltration) or immune-desert (with low CD8 cell infiltration), irrespective of treatment delivered; these data were used to analyse the correlation of the immune phenotype with this biomarker. Finally, the immunotherapy-treated dataset (n=137) of patients recruited from Dec 1, 2011, to Jan 31, 2014, at the Gustave Roussy Cancer Campus, who had been treated with anti-PD-1 and anti-PD-L1 monotherapy in phase 1 trials, was used to assess the predictive value of this biomarker in terms of clinical outcome. FINDINGS: We developed a radiomic signature for CD8 cells that included eight variables, which was validated with the gene expression signature of CD8 cells in the TCGA dataset (area under the curve [AUC]=0·67; 95% CI 0·57-0·77; p=0·0019). In the cohort with assumed immune phenotypes, the signature was also able to discriminate inflamed tumours from immune-desert tumours (0·76; 0·66-0·86; p<0·0001). In patients treated with anti-PD-1 and PD-L1, a high baseline radiomic score (relative to the median) was associated with a higher proportion of patients who achieved an objective response at 3 months (vs those with progressive disease or stable disease; p=0·049) and a higher proportion of patients who had an objective response (vs those with progressive disease or stable disease; p=0·025) or stable disease (vs those with progressive disease; p=0·013) at 6 months. A high baseline radiomic score was also associated with improved overall survival in univariate (median overall survival 24·3 months in the high radiomic score group, 95% CI 18·63-42·1; vs 11·5 months in the low radiomic score group, 7·98-15·6; hazard ratio 0·58, 95% CI 0·39-0·87; p=0·0081) and multivariate analyses (0·52, 0·35-0·79; p=0·0022). INTERPRETATION: The radiomic signature of CD8 cells was validated in three independent cohorts. This imaging predictor provided a promising way to predict the immune phenotype of tumours and to infer clinical outcomes for patients with cancer who had been treated with anti-PD-1 and PD-L1. Our imaging biomarker could be useful in estimating CD8 cell count and predicting clinical outcomes of patients treated with immunotherapy, when validated by further prospective randomised trials. FUNDING: Fondation pour la Recherche Médicale, and SIRIC-SOCRATE 2.0, French Society of Radiation Oncology.",
    "journal": "The Lancet. Oncology",
    "pub_date": "2018-Sep",
    "doi": "10.1016/S1470-2045(18)30413-3",
    "pmid": "30120041",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Adult",
      "Aged",
      "Antineoplastic Agents, Immunological",
      "B7-H1 Antigen",
      "Biomarkers, Tumor",
      "CD8-Positive T-Lymphocytes",
      "Female",
      "Gene Expression Profiling",
      "Humans",
      "Lymphocytes, Tumor-Infiltrating",
      "Male",
      "Middle Aged",
      "Molecular Imaging",
      "Neoplasms",
      "Phenotype",
      "Predictive Value of Tests",
      "Programmed Cell Death 1 Receptor",
      "RNA, Neoplasm",
      "Reproducibility of Results",
      "Retrospective Studies",
      "Sequence Analysis, RNA",
      "Time Factors",
      "Tomography, X-Ray Computed",
      "Transcriptome",
      "Treatment Outcome"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/30120041/",
    "summary_ja": "本研究は、造影CT画像と腫瘍生検RNA-seq（CD8B発現）を統合し、腫瘍内CD8細胞浸潤を推定する放射線画像（ラジオミクス）署名を機械学習で開発した後ろ向き多コホート研究である。MOSCATO試験由来の135例で署名を構築し、TCGAの119例および2つの独立コホートで検証し、CD8遺伝子署名や免疫表現型（inflamed vs desert）の識別に一定の性能を示した。免疫療法（抗PD-1/抗PD-L1）治療例では、高いベースライン放射線スコアが客観的奏効や全生存期間の改善と関連した。画像バイオマーカーとして有望だが、臨床実装には前向き無作為化試験での追加検証が必要と結論づけている。",
    "evidence_level": "2b"
  },
  {
    "paper_id": "pubmed:39694700",
    "source": "pubmed",
    "source_id": "39694700",
    "title": "LKB1 dictates sensitivity to immunotherapy through Skp2-mediated ubiquitination of PD-L1 protein in non-small cell lung cancer.",
    "year": 2024,
    "authors": [
      "Lv Liting",
      "Miao Qing",
      "Zhan Sutong",
      "Chen Peilin",
      "Liu Wei",
      "Lv Jiawen",
      "Yan Wenjie",
      "Wang Dong",
      "Liu Hongbing",
      "Yin Jie",
      "Feng Jian",
      "Song Yong",
      "Ye Mingxiang",
      "Lv Tangfeng"
    ],
    "abstract": "BACKGROUND: Loss-of-function mutations of  METHODS: We investigated the mutational landscape of  RESULTS: By using NGS data sets and histological approaches, we demonstrated that LKB1 status was positively associated with PD-L1 protein expression and conferred a T cell-enriched \"hot\" TME in NSCLC. Patients with good responses to anti-PD-1/PD-L1 immunotherapy possessed a high level of LKB1 and PD-L1. Skp2 emerged as the molecular hub connecting LKB1 and PD-L1, by which Skp2 catalyzed K63-linked polyubiquitination on K136 and K280 residues to stabilize PD-L1 protein. Inhibition of Skp2 expression by short hairpin RNA or its E3 ligase activity by compound #25 abrogated intact expression of PD-L1 in vitro and generated a T cell-excluded \"cold\" TME in vivo. Thus, the LKB1-Skp2-PD-L1 regulatory loop was crucial for retaining PD-L1 protein expression and manipulation of this pathway would be a feasible approach for TME remodeling. CONCLUSION: LKB1 and Skp2 are required for intact PD-L1 protein expression and TME remodeling in NSCLC. Inhibition of Skp2 resulted in a conversion from \"hot\" TME to \"cold\" TME and abrogated therapeutic outcomes of immunotherapy. Screening LKB1 and Skp2 status would be helpful to select recipients who may benefit from anti-PD-1/PD-L1 immunotherapy.",
    "journal": "Journal for immunotherapy of cancer",
    "pub_date": "2024-Dec",
    "doi": "10.1136/jitc-2024-009444",
    "pmid": "39694700",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Humans",
      "AMP-Activated Protein Kinase Kinases",
      "S-Phase Kinase-Associated Proteins",
      "B7-H1 Antigen",
      "Ubiquitination",
      "Loss of Function Mutation",
      "Carcinoma, Non-Small-Cell Lung",
      "Lung Neoplasms",
      "Immunotherapy",
      "Drug Resistance, Neoplasm",
      "Immune Checkpoint Inhibitors",
      "Gene Expression Regulation, Neoplastic",
      "Tumor Microenvironment",
      "Biomarkers, Tumor",
      "Cell Line, Tumor",
      "Specific Pathogen-Free Organisms",
      "Mice, Inbred C57BL",
      "Male",
      "Animals",
      "Mice",
      "Xenograft Model Antitumor Assays",
      "Female",
      "Middle Aged",
      "Antineoplastic Combined Chemotherapy Protocols",
      "Ubiquitin-Protein Ligases",
      "Cohort Studies"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/39694700/",
    "summary_ja": "本研究は非小細胞肺癌（NSCLC）において、LKB1の状態がPD-L1タンパク発現と関連し、T細胞浸潤の多い「hot」な腫瘍微小環境（TME）を形成することをNGSデータと組織学的解析で示した。抗PD-1/PD-L1免疫療法で良好な奏効を示した患者ではLKB1およびPD-L1が高い傾向があった。機序としてSkp2がLKB1とPD-L1をつなぐ要となり、PD-L1のK63結合型ポリユビキチン化（K136/K280）を介してPD-L1を安定化することが示唆された。Skp2の抑制はPD-L1発現低下と「cold」TME化を引き起こし、免疫療法効果を減弱させ得るため、LKB1/Skp2の評価が治療選択に有用である可能性がある。",
    "evidence_level": "2c"
  },
  {
    "paper_id": "pubmed:35140113",
    "source": "pubmed",
    "source_id": "35140113",
    "title": "Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.",
    "year": 2022,
    "authors": [
      "Yang Lei",
      "He Yun-Ting",
      "Dong Song",
      "Wei Xue-Wu",
      "Chen Zhi-Hong",
      "Zhang Bo",
      "Chen Wei-Dong",
      "Yang Xiao-Rong",
      "Wang Fen",
      "Shang Xue-Meng",
      "Zhong Wen-Zhao",
      "Wu Yi-Long",
      "Zhou Qing"
    ],
    "abstract": "BACKGROUNDS: Immunotherapy is less effective in patients with epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer (NSCLC). Lower programmed cell death-ligand 1 (PD-L1) expression and tumor mutation burden (TMB) are reported to be the underlying mechanism. Being another important factor to affect the efficacy of immunotherapy, tumor microenvironment (TME) characteristics of this subgroup of NSCLC are not comprehensively understood up to date. Hence, we initiated this study to describe the specific TME of EGFR-mutant lung adenocarcinoma (LUAD) from cellular compositional and functional perspectives to better understand the immune landscape of this most common subtype of NSCLC. METHODS: We used single-cell transcriptome sequencing and multiplex immunohistochemistry to investigate the immune microenvironment of EGFR-mutant and EGFR wild-type LUADs and determined the efficacy of immunotherapy. We analyzed single cells from nine treatment-naïve samples and compared them to three post-immunotherapy samples previously reported from single cell perspective using bioinformatics methods. RESULTS: We found that EGFR-mutant malignant epithelial cells had similar characteristics to the epithelial cells in non-responders. EGFR-mutant LUAD lacked CD8 CONCLUSIONS: Our findings provide a comprehensive understanding of the immune landscape of EGFR-mutant LUAD at the single-cell level. Based on the results, many cellular components might have negative impact on the specific TME of EGFR-mutant LUAD through influencing CD8",
    "journal": "Journal for immunotherapy of cancer",
    "pub_date": "2022-Jan",
    "doi": "10.1136/jitc-2021-003534",
    "pmid": "35140113",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Adenocarcinoma of Lung",
      "Biomarkers, Tumor",
      "ErbB Receptors",
      "Female",
      "Humans",
      "Immune Checkpoint Inhibitors",
      "Immunotherapy",
      "Lung Neoplasms",
      "Male",
      "Mutation",
      "Prognosis",
      "Single-Cell Analysis",
      "Transcriptome",
      "Tumor Microenvironment"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/35140113/",
    "summary_ja": "EGFR変異を有する肺腺癌では免疫療法が効きにくい背景として、腫瘍微小環境（TME）の免疫学的特徴が十分に解明されていない。著者らは治療前検体9例の単一細胞トランスクリプトーム解析と多重免疫組織化学により、EGFR変異例と野生型の免疫細胞組成・機能を比較し、既報の免疫療法後検体3例の単一細胞データとも対比した。EGFR変異腫瘍の悪性上皮細胞は免疫療法非奏効例の上皮細胞に近い特徴を示し、免疫抑制的なTME（特にCD8関連の抗腫瘍免疫の乏しさを示唆）が観察された。これらの所見から、EGFR変異肺腺癌に特有の免疫抑制的TMEの全体像を単一細胞レベルで提示している。",
    "evidence_level": "4"
  },
  {
    "paper_id": "pubmed:37217086",
    "source": "pubmed",
    "source_id": "37217086",
    "title": "Correlation between immunotherapy biomarker PD-L1 expression and genetic alteration in patients with non-small cell lung cancer.",
    "year": 2023,
    "authors": [
      "Chen Hefeng",
      "Ge Mengxi",
      "Zhang Fuchuang",
      "Xing Yishi",
      "Yu Shicheng",
      "Chen Chunzhu",
      "Zhang Hougang",
      "Wang Xiaoyong",
      "Gao Xing",
      "Chen Fangtao",
      "Chen Peilin",
      "Zhang Dadong",
      "Zhan Qiong",
      "Zhu Youcai"
    ],
    "abstract": "Programmed death-ligand 1 (PD-L1) has been widely used in immunotherapy evaluation of patients with non-small cell lung cancer (NSCLC). However, the effect is not particularly ideal, and the association between PD-L1 and genetic alterations requires more exploration. Here, we performed targeted next-generation sequencing and PD-L1 immunohistochemistry (IHC) testing for PD-L1 expression on both tumor cells (TCs) and tumor-infiltrating immune cells (ICs) in 1549 patients. Our studies showed that surgical method of resection was positively correlated with IC+, and a low tumor mutation burden (TMB) was negatively correlated with TC+. Furthermore, we found that EGFR was mutually exclusive with both ALK and STK11. In addition, the features between PD-L1 expression status and genomic alterations were characterized. These results suggest that clinical characteristics and molecular phenotypes are associated with PD-L1 expression signatures, which may provide novel insights for improving the efficiency of immune checkpoint inhibitors (ICIs) in immunotherapy.",
    "journal": "Genomics",
    "pub_date": "2023-Jul",
    "doi": "10.1016/j.ygeno.2023.110648",
    "pmid": "37217086",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Humans",
      "Carcinoma, Non-Small-Cell Lung",
      "Lung Neoplasms",
      "B7-H1 Antigen",
      "Biomarkers, Tumor",
      "Mutation",
      "Immunotherapy"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/37217086/",
    "summary_ja": "本研究は、非小細胞肺癌（NSCLC）1549例を対象に、標的NGSとPD-L1免疫染色（腫瘍細胞TCおよび腫瘍浸潤免疫細胞IC）を用いて、PD-L1発現と遺伝子変化・臨床因子の関連を解析した。切除術式はICのPD-L1陽性と正の相関を示し、低腫瘍変異量（TMB）はTCのPD-L1陽性と負の相関を示した。さらにEGFR変異はALKおよびSTK11と相互排他的であり、PD-L1発現状態とゲノム異常の特徴が整理された。これらの所見は、臨床的特徴と分子表現型がPD-L1発現シグネチャと関連し、免疫チェックポイント阻害薬の適用最適化に資する可能性を示唆する。",
    "evidence_level": "2c"
  },
  {
    "paper_id": "pubmed:25428504",
    "source": "pubmed",
    "source_id": "25428504",
    "title": "Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.",
    "year": 2014,
    "authors": [
      "Herbst Roy S",
      "Soria Jean-Charles",
      "Kowanetz Marcin",
      "Fine Gregg D",
      "Hamid Omid",
      "Gordon Michael S",
      "Sosman Jeffery A",
      "McDermott David F",
      "Powderly John D",
      "Gettinger Scott N",
      "Kohrt Holbrook E K",
      "Horn Leora",
      "Lawrence Donald P",
      "Rost Sandra",
      "Leabman Maya",
      "Xiao Yuanyuan",
      "Mokatrin Ahmad",
      "Koeppen Hartmut",
      "Hegde Priti S",
      "Mellman Ira",
      "Chen Daniel S",
      "Hodi F Stephen"
    ],
    "abstract": "The development of human cancer is a multistep process characterized by the accumulation of genetic and epigenetic alterations that drive or reflect tumour progression. These changes distinguish cancer cells from their normal counterparts, allowing tumours to be recognized as foreign by the immune system. However, tumours are rarely rejected spontaneously, reflecting their ability to maintain an immunosuppressive microenvironment. Programmed death-ligand 1 (PD-L1; also called B7-H1 or CD274), which is expressed on many cancer and immune cells, plays an important part in blocking the 'cancer immunity cycle' by binding programmed death-1 (PD-1) and B7.1 (CD80), both of which are negative regulators of T-lymphocyte activation. Binding of PD-L1 to its receptors suppresses T-cell migration, proliferation and secretion of cytotoxic mediators, and restricts tumour cell killing. The PD-L1-PD-1 axis protects the host from overactive T-effector cells not only in cancer but also during microbial infections. Blocking PD-L1 should therefore enhance anticancer immunity, but little is known about predictive factors of efficacy. This study was designed to evaluate the safety, activity and biomarkers of PD-L1 inhibition using the engineered humanized antibody MPDL3280A. Here we show that across multiple cancer types, responses (as evaluated by Response Evaluation Criteria in Solid Tumours, version 1.1) were observed in patients with tumours expressing high levels of PD-L1, especially when PD-L1 was expressed by tumour-infiltrating immune cells. Furthermore, responses were associated with T-helper type 1 (TH1) gene expression, CTLA4 expression and the absence of fractalkine (CX3CL1) in baseline tumour specimens. Together, these data suggest that MPDL3280A is most effective in patients in which pre-existing immunity is suppressed by PD-L1, and is re-invigorated on antibody treatment.",
    "journal": "Nature",
    "pub_date": "2014-Nov",
    "doi": "10.1038/nature14011",
    "pmid": "25428504",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Adult",
      "Aged",
      "Aged, 80 and over",
      "Antibodies, Monoclonal",
      "Antibodies, Monoclonal, Humanized",
      "B7-H1 Antigen",
      "Biomarkers",
      "CTLA-4 Antigen",
      "Chemokine CX3CL1",
      "Clinical Protocols",
      "Disease-Free Survival",
      "Female",
      "Gene Expression Regulation, Neoplastic",
      "Humans",
      "Immunotherapy",
      "Lymphocytes, Tumor-Infiltrating",
      "Male",
      "Middle Aged",
      "Neoplasms",
      "Treatment Outcome",
      "Young Adult"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/25428504/",
    "summary_ja": "本研究は、抗PD-L1抗体MPDL3280A（アテゾリズマブ）の安全性・抗腫瘍活性と、有効性を予測しうるバイオマーカーを複数のがん種で評価した。RECIST 1.1での奏効は、腫瘍でPD-L1高発現の患者、とくに腫瘍浸潤免疫細胞でPD-L1が高い場合に多く認められた。さらに奏効は、ベースライン腫瘍におけるTH1関連遺伝子発現やCTLA4発現と関連し、CX3CL1（フラクタルカイン）の欠如とも関連した。これらより、PD-L1により既存免疫が抑制されている腫瘍で治療により免疫が再活性化されやすい可能性が示唆された。",
    "evidence_level": "2b"
  },
  {
    "paper_id": "pubmed:38744008",
    "source": "pubmed",
    "source_id": "38744008",
    "title": "Proteomic, single-cell and bulk transcriptomic analysis of plasma and tumor tissues unveil core proteins in response to anti-PD-L1 immunotherapy in triple negative breast cancer.",
    "year": 2024,
    "authors": [
      "Li Yingpu",
      "Yue Liang",
      "Zhang Sifan",
      "Wang Xinxuan",
      "Zhu Yu-Nan",
      "Liu Jianyu",
      "Ren He",
      "Jiang Wenhao",
      "Wang Jingxuan",
      "Zhang Zhiren",
      "Liu Tong"
    ],
    "abstract": "BACKGROUND: Anti-PD-1/PD-L1 treatment has achieved durable responses in TNBC patients, whereas a fraction of them showed non-sensitivity to the treatment and the mechanism is still unclear. METHODS: Pre- and post-treatment plasma samples from triple negative breast cancer (TNBC) patients treated with immunotherapy were measured by tandem mass tag (TMT) mass spectrometry. Public proteome data of lung cancer and melanoma treated with immunotherapy were employed to validate the findings. Blood and tissue single-cell RNA sequencing (scRNA-seq) data of TNBC patients treated with or without immunotherapy were analyzed to identify the derivations of plasma proteins. RNA-seq data from IMvigor210 and other cancer types were used to validate plasma proteins in predicting response to immunotherapy. RESULTS: A random forest model constructed by FAP, LRG1, LBP and COMP could well predict the response to immunotherapy. The activation of complement cascade was observed in responders, whereas FAP and COMP showed a higher abundance in non-responders and negative correlated with the activation of complements. scRNA-seq and bulk RNA-seq analysis suggested that FAP, COMP and complements were derived from fibroblasts of tumor tissues. CONCLUSIONS: We constructe an effective plasma proteomic model in predicting response to immunotherapy, and find that FAP",
    "journal": "Computers in biology and medicine",
    "pub_date": "2024-Jun",
    "doi": "10.1016/j.compbiomed.2024.108537",
    "pmid": "38744008",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Humans",
      "Triple Negative Breast Neoplasms",
      "Female",
      "Immunotherapy",
      "Single-Cell Analysis",
      "Proteomics",
      "B7-H1 Antigen",
      "Biomarkers, Tumor",
      "Transcriptome",
      "Immune Checkpoint Inhibitors",
      "Gene Expression Profiling",
      "Proteome"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/38744008/",
    "summary_ja": "トリプルネガティブ乳がん（TNBC）における抗PD-1/PD-L1免疫療法の感受性差の機序解明と、治療反応予測バイオマーカー探索を目的とした解析である。治療前後の血漿をTMT質量分析でプロテオーム解析し、公開データ（肺がん・メラノーマの免疫療法コホート）で所見を検証しつつ、TNBCの血液・腫瘍のscRNA-seqやバルクRNA-seqで血漿タンパクの由来を推定した。FAP、LRG1、LBP、COMPの4因子からなるランダムフォレストモデルが免疫療法反応を予測し、奏効例では補体系カスケード活性化が目立つ一方、非奏効例ではFAPとCOMPが高く補体系活性と負に相関した。これら（FAP、COMP、補体系関連分子）は腫瘍組織の線維芽細胞由来である可能性が示され、血漿プロテオームに基づく反応予測モデルと免疫応答に関わるコア分子が提案された。",
    "evidence_level": "2b"
  },
  {
    "paper_id": "pubmed:27924752",
    "source": "pubmed",
    "source_id": "27924752",
    "title": "Predictive biomarkers for checkpoint inhibitor-based immunotherapy.",
    "year": 2016,
    "authors": [
      "Gibney Geoffrey T",
      "Weiner Louis M",
      "Atkins Michael B"
    ],
    "abstract": "The clinical development of checkpoint inhibitor-based immunotherapy has ushered in an exciting era of anticancer therapy. Durable responses can be seen in patients with melanoma and other malignancies. Although monotherapy with PD-1 or PD-L1 agents are typically well tolerated, the risk of immune-related adverse events increases with combination regimens. The development of predictive biomarkers is needed to optimise patient benefit, minimise risk of toxicities, and guide combination approaches. The greatest focus has been on tumour-cell PD-L1 expression. Although PD-L1 positivity enriches for populations with clinical benefit, PD-L1 testing alone is insufficient for patient selection in most malignancies. In this Review, we discuss the status of PD-L1 testing and explore emerging data on new biomarker strategies with tumour-infiltrating lymphocytes, mutational burden, immune gene signatures, and multiplex immunohistochemistry. Future development of an effective predictive biomarker for checkpoint inhibitor-based immunotherapy will integrate multiple approaches for optimal characterisation of the immune tumour microenvironment.",
    "journal": "The Lancet. Oncology",
    "pub_date": "2016-Dec",
    "doi": "10.1016/S1470-2045(16)30406-5",
    "pmid": "27924752",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "B7-H1 Antigen",
      "Biomarkers",
      "Cell Cycle Checkpoints",
      "Humans",
      "Immunohistochemistry",
      "Immunotherapy",
      "Lymphocytes, Tumor-Infiltrating",
      "Neoplasms",
      "Tumor Microenvironment"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/27924752/",
    "summary_ja": "免疫チェックポイント阻害薬はメラノーマなどで長期奏効が得られる一方、併用療法では免疫関連有害事象のリスクが高まる。患者の利益最大化と毒性最小化、併用戦略の最適化のために予測バイオマーカーの開発が必要である。現在最も注目されている腫瘍細胞PD-L1発現は有効例の集団を濃縮するが、多くのがん種で単独では選択に不十分である。本レビューはPD-L1検査の現状を整理し、腫瘍浸潤リンパ球、変異負荷、免疫遺伝子シグネチャ、マルチプレックス免疫組織化学など新規戦略を概説し、今後は複数手法の統合が重要だと述べる。",
    "evidence_level": "5"
  },
  {
    "paper_id": "pubmed:31455411",
    "source": "pubmed",
    "source_id": "31455411",
    "title": "PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer.",
    "year": 2019,
    "authors": [
      "Zhou Zi-Qi",
      "Zhao Jing-Jing",
      "Pan Qiu-Zhong",
      "Chen Chang-Long",
      "Liu Yuan",
      "Tang Yan",
      "Zhu Qian",
      "Weng De-Sheng",
      "Xia Jian-Chuan"
    ],
    "abstract": "BACKGROUND: A sequential combination of radiochemotherapy/endocrinotherapy and cytokine-induced killer cell (CIK) infusion has been shown to be an effective therapy for post-mastectomy breast cancer based on statistical analysis of the patient population. However, whether an individual could obtain an improved prognosis from CIK cell-based treatment remains unknown. In the present study, we focused on immune microenvironment regulation and specifically investigated the relationship between PD-L1 expression and survival benefit from CIK immunotherapy in breast cancer. METHODS: A total of 310 postoperative breast cancer patients who received comprehensive treatment were enrolled in this retrospective study, including 160 patients in the control group (received chemotherapy/radiotherapy/endocrinotherapy) and 150 patients in the CIK cell treatment group (received chemotherapy/radiotherapy/ endocrinotherapy and subsequent CIK infusion). RESULTS: We found that overall survival (OS) and recurrence-free survival (RFS) were significantly better in the CIK group than that in the control group. PD-L1 expression in tumor tissue sections was showed to be an independent prognostic factor for patients in the CIK treatment group using multivariate survival analysis. Further survival analysis in the CIK group showed that patients with PD-L1 tumor expression exhibited longer OS and RFS. In addition, among all patients who were enrolled in this study, only the patients with PD-L1 expression experienced survival benefits from CIK treatment. CONCLUSIONS: Our study showed the relationship between PD-L1 expression and CIK therapy and revealed that PD-L1 expression in the tumor is as an indicator of adjuvant CIK therapy for postoperative breast cancer.",
    "journal": "Journal for immunotherapy of cancer",
    "pub_date": "2019-Aug",
    "doi": "10.1186/s40425-019-0696-8",
    "pmid": "31455411",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Antineoplastic Agents, Hormonal",
      "B7-H1 Antigen",
      "Biomarkers, Tumor",
      "Breast Neoplasms",
      "Case-Control Studies",
      "Chemoradiotherapy",
      "Combined Modality Therapy",
      "Cytokine-Induced Killer Cells",
      "Female",
      "Follow-Up Studies",
      "Gene Expression Regulation, Neoplastic",
      "Humans",
      "Immunotherapy",
      "Infusions, Intravenous",
      "Middle Aged",
      "Postoperative Care",
      "Prognosis",
      "Retrospective Studies",
      "Survival Rate"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/31455411/",
    "summary_ja": "乳がん術後患者310例を対象に、標準治療のみ（対照160例）と標準治療後にCIK細胞投与を追加（CIK群150例）を比較した後ろ向き研究である。CIK群は対照群より全生存（OS）と無再発生存（RFS）が有意に良好だった。CIK群内の多変量解析で腫瘍PD-L1発現は独立した予後因子で、PD-L1陽性患者ほどOS/RFSが長かった。全体解析でもPD-L1陽性患者のみがCIK治療による生存利益を示し、PD-L1発現がCIK補助療法の予測バイオマーカーになり得ることが示唆された。",
    "evidence_level": "2b"
  },
  {
    "paper_id": "pubmed:28131993",
    "source": "pubmed",
    "source_id": "28131993",
    "title": "PD-L1 Expression in Pancreatic Cancer.",
    "year": 2017,
    "authors": [
      "Zheng Lei"
    ],
    "abstract": "",
    "journal": "Journal of the National Cancer Institute",
    "pub_date": "2017-Jan",
    "doi": "10.1093/jnci/djw304",
    "pmid": "28131993",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Antibodies, Monoclonal",
      "Antineoplastic Agents",
      "B7-H1 Antigen",
      "Biomarkers, Tumor",
      "Humans",
      "Immunotherapy",
      "Pancreatic Neoplasms"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/28131993/",
    "summary_ja": "（アブストラクト未取得: PD-L1 Expression in Pancreatic Cancer.）",
    "evidence_level": "N/A"
  },
  {
    "paper_id": "pubmed:39822174",
    "source": "pubmed",
    "source_id": "39822174",
    "title": "PD-L1 as a Biomarker in Gastric Cancer Immunotherapy.",
    "year": 2025,
    "authors": [
      "Cho Yunjoo",
      "Ahn Soomin",
      "Kim Kyoung-Mee"
    ],
    "abstract": "Combining chemotherapy with immune checkpoint inhibitors (ICIs) that target the programmed death-1 (PD-1) protein has been shown to be a clinically effective first-line treatment for human epidermal growth factor receptor 2 (HER2)-negative and -positive advanced or metastatic gastric cancer (GC). Currently, PD-1 inhibitors combined with chemotherapy are the standard treatment for patients with HER2-negative/positive locally advanced or metastatic GC. Programmed death-ligand 1 (PD-L1) expression, as assessed using immunohistochemistry (IHC), is a crucial biomarker for predicting response to anti-PD-1/PD-L1 agents in various solid tumors, including GC. In GC, the PD-L1 IHC test serves as a companion or complementary diagnostic test for immunotherapy, and an accurate interpretation of PD-L1 status is essential for selecting patients who may benefit from immunotherapy. However, PD-L1 IHC testing presents several challenges that limit its reliability as a biomarker for immunotherapy. In this review, we provide an overview of the current practices of immunotherapy and PD-L1 testing in GC. In addition, we discuss the clinical challenges associated with PD-L1 testing and its future use as a biomarker for immunotherapy. Finally, we present prospective biomarkers currently under investigation as alternative predictors of immunotherapy response in GC.",
    "journal": "Journal of gastric cancer",
    "pub_date": "2025-Jan",
    "doi": "10.5230/jgc.2025.25.e4",
    "pmid": "39822174",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Humans",
      "Stomach Neoplasms",
      "B7-H1 Antigen",
      "Biomarkers, Tumor",
      "Immunotherapy",
      "Immune Checkpoint Inhibitors"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/39822174/",
    "summary_ja": "（要約生成失敗: Codex returned no output）",
    "evidence_level": "N/A"
  },
  {
    "paper_id": "pubmed:33932597",
    "source": "pubmed",
    "source_id": "33932597",
    "title": "The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer.",
    "year": 2021,
    "authors": [
      "Xu Yichi",
      "Song Gendi",
      "Xie Shangdan",
      "Jiang Wenxiao",
      "Chen Xin",
      "Chu Man",
      "Hu Xiaoli",
      "Wang Zhi-Wei"
    ],
    "abstract": "Multiple studies have confirmed that programmed cell death 1/programmed cell death ligand-1 (PD-1/PD-L1) and immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 play pivotal roles in the treatment of numerous tumors. Patients suffering from cancer are provided hope in the form of immunotherapy. In this review, we discuss the finding that high PD-L1 expression is associated with poor clinical outcomes in prostate cancer patients. Some molecules exert their antitumor effects by downregulating PD-L1 expression in prostate cancer. Additionally, we discuss and summarize the important roles played by anti-PD-1/PD-L1 immunotherapy and its combination with other drugs, including chemotherapy and vaccines, in the treatment of prostate cancer.",
    "journal": "Molecular therapy : the journal of the American Society of Gene Therapy",
    "pub_date": "2021-Jun",
    "doi": "10.1016/j.ymthe.2021.04.029",
    "pmid": "33932597",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Antineoplastic Agents, Immunological",
      "B7-H1 Antigen",
      "Biomarkers, Tumor",
      "Combined Modality Therapy",
      "Drug Development",
      "Gene Expression Regulation, Neoplastic",
      "Humans",
      "Immunotherapy",
      "Interleukin-6",
      "Janus Kinases",
      "Male",
      "Molecular Targeted Therapy",
      "Prognosis",
      "Programmed Cell Death 1 Receptor",
      "Prostatic Neoplasms",
      "RNA, Small Interfering",
      "Signal Transduction",
      "Treatment Outcome"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/33932597/",
    "summary_ja": "（要約生成失敗: Codex returned no output）",
    "evidence_level": "N/A"
  },
  {
    "paper_id": "pubmed:32841942",
    "source": "pubmed",
    "source_id": "32841942",
    "title": "Personalized Immuno-Oncology.",
    "year": 2021,
    "authors": [
      "Jain Kewal K"
    ],
    "abstract": "Cancer immunotherapy, which aims to control the immune system to eradicate cancer cells and prevent their spread, needs to be personalized because anticancer immune responses can be inhibited in several ways that vary from patient to patient. Cancer immunotherapy includes pharmaceuticals such as immune checkpoint inhibitors and monoclonal antibodies (MAbs) as well as cell therapy, immunogene therapy, and vaccines. Combination of programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) drugs with other immunotherapy drugs, for example, antibody-drug conjugates, as well as combination of PD-1/PD-L1 drugs with other therapies, for example, chemotherapy and radiation therapy, are being explored. Biomarkers are important for predicting the response to immunotherapy. Molecular diagnostics and sequencing are important technologies for guiding treatment in immuno-oncology. Genomic profiling of tumor mutational burden may enhance the predictive utility of PD-L1 expression and facilitate personalized combination immunotherapy. Optimization of personalized immuno-oncology requires integration of several technologies and selection of those best suited for an individual patient. Advances in immuno-oncology are also attributed to technologies for targeted delivery of anticancer therapeutics such as antigen-capturing nanoparticles for precision targeting and selective delivery. A breakthrough in cell therapy of cancer is a chimeric antigen receptors-T cell, which combines the antigen-binding site of a MAb with the signal activating machinery of a T cell, freeing antigen recognition from major histocompatibility complex restriction. Gene-editing tools such as clustered regularly interspaced short palindromic repeats have a promising application for removing alloreactivity and decreasing immunogenicity of third-party T cells. In conclusion, personalized immuno-oncology is one of the most promising approaches to management of cancer.",
    "journal": "Medical principles and practice : international journal of the Kuwait University, Health Science Centre",
    "pub_date": "2021",
    "doi": "10.1159/000511107",
    "pmid": "32841942",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Adjuvants, Immunologic",
      "Adoptive Transfer",
      "Antineoplastic Agents, Immunological",
      "Biomarkers, Tumor",
      "CTLA-4 Antigen",
      "Cancer Vaccines",
      "Cell Line, Tumor",
      "Combined Modality Therapy",
      "Genomics",
      "Granulocytes",
      "Humans",
      "Immune Checkpoint Inhibitors",
      "Immunotherapy",
      "Immunotherapy, Adoptive",
      "Lab-On-A-Chip Devices",
      "Neoplasms",
      "Precision Medicine",
      "Programmed Cell Death 1 Receptor",
      "Receptors, Chimeric Antigen",
      "T-Lymphocytes, Cytotoxic",
      "Transcriptome"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/32841942/",
    "summary_ja": "（要約生成失敗: Codex returned no output）",
    "evidence_level": "N/A"
  },
  {
    "paper_id": "pubmed:39205582",
    "source": "pubmed",
    "source_id": "39205582",
    "title": "Immunotherapy and PD-L1 Tumor Expression in Moroccan Non-Small Cell Lung Cancer Patients with Various Metastasis.",
    "year": 2024,
    "authors": [
      "Aazzane Oussama",
      "Fathi Sofia",
      "Charkaoui Meryeme",
      "Acharki Abdelkader",
      "Sahraoui Souha",
      "Benchakroun Nadia",
      "Fellah Hassan",
      "Karkouri Mehdi"
    ],
    "abstract": "INRODUCTION: The question of whether tumor expression of PD-L1 and the presence of distant metastasis could influence the efficacy of immunotherapy represents a major challenge and needs to be further elucidated. The aim of this study is to evaluate the predictive significance of tumor expression of PD-L1 as well as the number and site of metastasis in non-small cell lung cancer (NSCLC) among Moroccan patients treated with immunotherapy. MATERIAL AND METHODS: Between January 2019 and February 2023, we recruited Moroccan patients with metastatic NSCLC. All were treated with immunotherapy, either as monotherapy or in combination with chemotherapy. Immunohistochemistry was used to assess PD-L1 (clone 22C3) and ALK (clone D5F3) status. EGFR status was established by qPCR. Tumor PD-L1 expression was classified into 2 levels: TPS <1% (negative expression) and TPS ≥1% (positive expression). Statistical analysis was performed using SPSS Statistics V.21 software. RESULTS: The median age of patients (N=40) was 67 years (39- 92 years) and the sex ratio was 9. Disease dissemination revealed that 22.5% (N=9) of patients had a metastatic burden ≥ 3 (MB≥3). As for the sites of metastasis, the results showed that 20% (N=8), 10% (N=4), 42.5% (N=17), 22.5% (N=9), 27.5% (N=11), 45% (N=18) and 27.5% (N=11) of patients had developed lymph node, liver, bone, brain, pleural, contralateral lung and adrenal metastasis respectively. Positive PD-L1 expression was significantly associated with shorter overall survival (OS = 17.19 vs. 28.85 months, p=0.01). High metastatic burden (MB ≥ 3) was associated with lower objective response rate (ORR), shorter progression-free survival (PFS), and reduced OS, respectively (ORR = 0 vs. 58.06%, p=0.002; PFS = 10.23 vs. 25.27 months, p=0.001; and OS = 11.60 vs. 27.91 months, p=0.003). Only the presence of osseous metastasis was significantly associated with lower ORR, shorter PFS, and OS compared to other metastatic locations (ORR = 5.88 vs. 73.9%, p=0.000; PFS = 10.72 vs. 31.33 months, p=0.000; and OS = 11.39 vs. 36.17 months, p=0.000). Finally, the presence of hepatic metastasis was significantly associated with shorter PFS (10.75 months) compared to those without hepatic metastasis (22.53 months) (p=0.046). Finally, the results of the multivariate analysis revealed that the presence of bone metastasis was strongly correlated with a significant decrease in progression-free survival (p=0.001) as well as overall survival (p=0.002). CONCLUSION: Our results suggest that tumor expression of PD-L1 and metastatic burden should play a significant role in predicting the response to immunotherapy. Furthermore, it is important to note that the presence of osseous and hepatic metastasis could negatively influence the clinical outcomes of immunotherapy.",
    "journal": "Asian Pacific journal of cancer prevention : APJCP",
    "pub_date": "2024-Aug",
    "doi": "10.31557/APJCP.2024.25.8.2841",
    "pmid": "39205582",
    "pmc_id": null,
    "keywords": [],
    "mesh_terms": [
      "Humans",
      "Carcinoma, Non-Small-Cell Lung",
      "Male",
      "Female",
      "B7-H1 Antigen",
      "Lung Neoplasms",
      "Middle Aged",
      "Aged",
      "Adult",
      "Morocco",
      "Aged, 80 and over",
      "Immunotherapy",
      "Biomarkers, Tumor",
      "Prognosis",
      "Follow-Up Studies",
      "Neoplasm Metastasis",
      "Survival Rate"
    ],
    "url": "https://pubmed.ncbi.nlm.nih.gov/39205582/",
    "summary_ja": "（要約生成失敗: Codex returned no output）",
    "evidence_level": "N/A"
  }
]